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Abstract
In 2001 mutations in WNK1 (With-No-K, lysine) and WNK4 were linked to the
dominant, hypertensive, hyperkalemic disorder, Gordon syndrome. Although a
mystery for many years, the basis of this unusual disorder, having concurrent Na+
and K+ retention, promised to yield valuable insights into the causes of essential
hypertension (thiazide diuretics are first-line treatments for both). The association of
mutations in WNK1 and WNK4 with Gordon syndrome was a major breakthrough
also implicating these novel serine/threonine kinases in the regulation of electrolyte
balance and blood pressure (BP). Thus, elucidation of the novel pathway in which
these WNK kinases participate should lead to fundamental advances in our
understanding of these phenomena.
When the studies of this thesis began only very limited findings were reported about
WNK1 and WNK4, and so to begin to understand how this pathway might function,
particularly in vivo, it was important to examine the expression of the genes
involved. In situ hybridization and PCR studies revealed tissue-specific splicing for
WNK1 and widespread, intricate regulation ofWNK1 and WNK4 expression during
development involving both epithelial and non-epithelial tissues. The importance of
this expression is highlighted by the WNK1-/- mouse which is embryonic lethal by
mid-gestation. A survey of the distribution ofWNK1 and WNK4 across adult mouse
tissues by Northern blot strikingly highlighted the unique qualities of how the WNK
pathway is expressed in kidney. Thus, kidney has by far the strongest expression of
WNK4 of any major organ. Moreover, whilst WNK1 is widely expressed, the kidney
has an additional kidney-specific smaller WNK1 transcript. Thus, the high levels of
WNK4 and this smaller WNK1 transcript seemed likely to be linked to how
mutations in this pathway have crucial consequences in kidney altering electrolyte
handling and BP. Accordingly, detailed studies of the nature and expression of these
WNK gene transcripts were undertaken. These showed that rather than merely being
a polyA-tail variant the short kidney-specific WNK1 transcript (WNK1-S) actually
differed from the longer widely distributed transcript (WNK1-L) in a much more
functionally significant way. It lacked the first four coding exons yielding a predicted
protein missing the kinase domain. Establishing that in kidney, transcription of the
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WNK1 gene differed from elsewhere and a kinase deficient WNK1 product would
predominate, demanded a revision of ideas as to how mutations of this gene might
cause autosomal dominant disease. Thus, it became apparent that the WNK pathway
at least in kidney may involve features beyond a simple kinase cascade, shifting the
focus of research on this pathway.
Reports of in vitro interactions between WNK4 and/or WNK1 and a number of renal
electrolyte transporters have been flooding into the literature implying a surprising
diversity of possible regulatory roles of these genes in electrolyte balance. Detailed
localization studies, undertaken as part of this thesis, show that WNK1-S and WNK4
are highly expressed in distal convoluted tubule (DCT) and connecting tubule
(CNT), adjacent distal nephron segments known to play key roles in electrolyte
balance and BP control. Additional novel domains of substantial WNK4 expression
were found in thick ascending limb (TAL; including macula densa), while WNK1-L
was uniformly expressed at low-level throughout kidney. These findings indicate that
the spectrum ofWNK interacting partners may be determined largely by their local
renal distributions, a factor which is frequently overlooked at present.
Having established the steady-state expression of this pathway in kidney, work then
extended to investigating how the WNK pathway, and genes likely linked to it,
respond to dynamic changes in renal K+, Na+ and Cf load and aldosterone level. This
work has revealed key dietary electrolyte and aldosterone driven transcriptional
regulation of elements of the WNK pathway and the renal outer medullary K+
channel (ROMK), leading to better understanding of how this pathway may
participate in the in vivo regulation of electrolyte balance and BP. Specifically,
upregulation of WNK1-S and WNK4 was found with high K+ intake, which via
inhibition of the thiazide sensitive NaCl cotransporter (NCC) and enhanced distal
Na+ delivery would facilitate enhanced K+-excretion needed in response to high K+
intake. As K+ intake drops, the WNK pathway modulation of K+ balance coordinates
with H+/K+-ATPase and striking reciprocal ROMK isoform-specific expression
changes in a way which would allow fine regulation of K+ and acid-base balance. As
chronic NaCl intake drops to low levels there may be regulation of WNK gene
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expression limiting NaCl excretion. These in vivo findings, in conjunction with clues
from reported in vitro functional studies, allow the development of a model of how
the WNK pathway may function in an integrated way which fits well with normal
renal electrolyte handling and also how this is altered in treatment with thiazide
diuretics or when mutated in Gordon syndrome.
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1.1 Electrolyte Balance and BP Control
1.1.1 Epithelial Transport: Transcellular and Paracellular Pathways
The primary function of epithelial cells in all organs of higher organisms is to
partition extracellular compartments of different composition. The flux of
electrolytes across a polarised epithelium is a highly regulated process (Figure
1.1(a)), with permeating species traversing by either the transcellular route through
cells or the paracellular route between cells (reviewed in130). Transcellular transport
is mediated by specialised channels, exchangers, cotransporters and pumps typically
found differentially expressed between the apical and basolateral surfaces of
polarised epithelial cells (Figure 1.1(b)). Transport between cells is more obscure but
it is well established that tight junctions between epithelial cells form the major
barriers regulating diffusion through the paracellular pathway. The tight junction also
prevents the lateral diffusion of integral membrane proteins, including those involved
in the transcellular pathway, thereby functionally dividing the apical and basolateral
membrane domains. Tight junctions of different epithelia vary in tightness and show
charge and size selectivity in their permeability. Recent work has demonstrated the
key role of the Claudin family of tight junction proteins in determining paracellular
permeability (reviewed in120'136). Transepithelial transport is particularly important in
the kidney where it regulates whole body fluid, electrolyte homeostasis and BP.
1.1.2 BP Control in Kidney
High BP or hypertension affects 20-25% of the adult population in industrialized
countries, contributing to morbidity and mortality from stroke, myocardial infarction,
QO ... *
congestive heart failure, and renal failure . Despite its major importance, very little
is understood about the causes of essential hypertension. Over 30 years ago, Guyton
hypothesised that control of BP in the steady-state and on a long-term basis is
critically dependent on renal mechanisms44,45. It is now well established that the
normal regulation of electrolyte handling in the distal nephron of kidney (importantly
Na+, CF and K+ ions) is required for normal long-term BP control.
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(i) (ii) (iii) (iv)
Figure 1.1: Schematic representation of transepithelial transport. (a)Epithelial cells
establish apical contacts with neighbouring epithelial cells through a tripartite junctional complex
to form an epithelium. This tripartite junctional complex consists of the tight junction, the adherens
junction, and the desmosome. Electrolyte transport across a polarised epithelium occurs by
either the transcellular route through cells or the paracellular route between cells. The tight
junction forms the major barrier to the paracellular transport of electrolytes. (b)Transcellular
transport is mediated by (i)specialised channels, (ii)cotransporters, (iii)exchangers, and
(iv)energy-coupled pumps found on the apical and basolateral surfaces of epithelial cells.
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1.1.3 Electrolyte Balance in Distal Nephron
The kidney filters -170 litres of plasma daily containing -23 mol salt. More than
99.5% of this filtered salt must be reabsorbed to maintain homeostasis. The bulk
(-60%) of the filtered Na+ is reabsorbed in the proximal tubule and a further 30% is
reabsorbed in TAL. The remainder is recovered in DCT, CNT and the collecting duct
(CD; Figure 1.2). NaCl reabsorption in DCT-CD is driven by basolateral Na+/K+-
ATPase in conjunction with two major apical pathways. Firstly, electroneutral
cotransport by NCC (encoded by SLC12A3; Figure 1.3(a)), a member of the cation-
chloride cotransporter gene family (SLC12), which mediates the reabsorption of 3-
7% of the total filtered NaCl across the apical surface of epithelial cells ofDCT. The
second pathway involves electrogenic Na+ reabsorption in the late DCT (DCT2),
CNT and CD through the amiloride-sensitive epithelial Na+ channel (ENaC; a
tetrameric (o^Py) channel composed of a, p, and y subunits encoded by SCNN1A,
SCNN1B, and SCNN1G, respectively) accompanied by largely paracellular CF flux
(Figure 1.3(b))95.
Figure 1.2: Schematic depiction of kidney and nephron structure, (a) Saggital section
through the kidney illustrating the cortical, outer medullary (subdivided into outer stripe and
inner stripe) and inner medullary regions, (b) The nephron (functional unit of the kidney) is
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Figure 1.3: Schematic depiction of electroneutral and electrogenic transport.
(a)(i)Electroneutral transport occurs in DCT whereby NaCI is reabsorbed from the tubular
lumen via NCC. (ii)Overactivity of NCC would create a transcellular shunt in DCT, resulting
in excess NaCI reabsorption in this segment and reduced distal Na+ delivery.
(b)(i)Electrogenic reabsorption occurs in DCT2-CD, whereby Na+ is reabsorbed via ENaC, in
association with a paracellular CI" flux. This generates a lumen negative charge which
facilitates K+ and H+ excretion. (ii)Excessive or "leaky" paracellular CI" transport ("paracellular
CI" shunt") would deplete the lumen negative charge, thereby diminishing the
electrochemical driving force for K+ and H+ excretion.
Maintenance of the body's unequal distribution of K+ between the intra- and
extracellular compartments is essential for many fundamental cellular functions and
is critical to normal electrical polarization of the cell. Mechanisms regulating the
transport of K+ (and NaCI) between intracellular and extracellular compartments play
an important role at times in smoothing and damping short-term swings in electrolyte
and fluid balance which naturally occur on occasions such as after ingesting a meal.
However these mechanisms are of relatively short-term importance and it is the
kidney which is principally responsible for determining K+ balance over hours, days
and in the longer-term. In the kidney the bulk of filtered K+ is reabsorbed in proximal
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nephron segments, with tightly regulated K+ secretion, occurring in DCT2-CD
• • • • • "I- Qa #
(principally in the CNT and CCD), largely determining K balance . Electrogenic
Na+ reabsorption by ENaC provides a "lumen negative" driving force for K+
secretion (Figure 1.3(b)), occurring primarily via the inwardly rectifying ROMK
channel (Kir1.1; encoded by KCNJ1). Remarkably, during K+ depletion, the CNT-
CD switches from a largely K+ secreting segment to a site of K+ reabsorption. In
severe K+ restriction several attendant processes assist in renal function with minimal
K+, including the production and recycling of NH4+, an ion which can substitute for
K+ to maintain key transport of NaCl by NKCC2 (Na+/K+/2C1" cotransporter-2) and
Na+/K+-ATPase41'141. The role of NH4+ in electrolyte homeostasis, particularly K+
and acid-base balance, is discussed in greater detail in Chapter 9.
Although in quantitative terms the DCT-CD distal nephron segments make a
minority contribution to renal NaCl reabsorption (<10%), they nonetheless normally
have the primary role in determining net NaCl and K+ balance as Na+ reabsorption
and K+ secretion are closely regulated in the distal nephron and this is the major
determinant of the final excretion of these electrolytes from the body.
1.1.3.1 Renin Angiotensin Aldosterone System (RAAS)
In health, the renin-angiotensin-aldosterone system (RAAS; Figure 1.4) powerfully
assists in the maintenance of circulatory homeostasis with key effects on vascular
tone and in determining renal NaCl and K+ handling, with a major influence on distal
nephron. Lower circulatory filling and pressure are sensed through: higher autonomic
(baroreceptor) reflex stimulation; reduced renal afferent arteriolar stretch and/or
altered NaCl delivery to the macula densa. These specific physiological stimuli
signal to trigger secretion of the aspartyl protease renin from specialised afferent
arteriole cells forming part of the juxtaglomerular apparatus. Renin cleaves
circulating angiotensinogen releasing a decapeptide, angiotensin I. This is converted
to an octapeptide, angiotensin II, in the lung by angiotensin converting enzyme
(ACE). This potent short peptide has several important actions including binding to
its receptor in the zona glomerulosa of the adrenal cortex and inducing the secretion
of the mineralocorticoid hormone, aldosterone. Binding of aldosterone to the
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mineralocorticoid receptor (MR), a nuclear hormone receptor found in principal cells
of the distal nephron, initiates a sequence of events leading to increased activity of












Figure 1.4: Overview of the Renin-Angiotensin-Aldosterone System.
The aspartyl protease renin is released from the juxtaglomerular apparatus (cells of the
afferent and efferent arterioles of the glomerulus) in response to specific signals. Renin
cleaves circulating angiotensinogen releasing a decapeptide, angiotensin I. This is converted
to an octapeptide, angiotensin II, in the lung by ACE. This short peptide hormone binds to its
AT1 receptor in the zona glomerulosa of the adrenal cortex and induces the secretion of the
mineralocorticoid hormone, aldosterone. Binding of aldosterone to MR, found in particular in
late DCT, CNT and principal cells of the distal nephron, initiates a sequence of events
leading to increased activity of ENaC, thereby upregulating salt reabsorption.
Aldosterone secretion is stimulated in two different physiological states:
hypovolemia, triggering increased renin secretion and angiotensin II action as just
described; and hyperkalaemia, directly stimulating adrenal aldosterone secretion,
thereby promoting increased K+ secretion. How the kidney differentiates between
these two high aldosterone states so that in the first there is powerful stimulation
principally of NaCl reabsorption, but in the second potassium secretion is strongly
augmented remains poorly understood14.
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Figure 1.5: Mechanism of aldosterone action. Aldosterone (ALDO) traverses the plasma
membrane and binds to its cytosolic receptor, MR. The receptor-hormone complex
translocates to the nucleus, where it interacts with steroid response elements (SREs) within
the promoter region of target genes activating or repressing their transcriptional activity.
Aldosterone-induced or -repressed proteins (AlPs or ARPs) mediate an increase in
transepithelial sodium transport by increasing the activity and/or number of transport proteins
(e.g. ENaC, Na/K-ATPase) in the plasma membrane. 1 ip-Hydroxysteroid Dehydrogenase 2
(11P-HSD2) converts Cortisol to cortisone, thus preventing occupancy of MR by Cortisol.
1.1.4 Single gene disorders of electrolyte balance and BP
Inappropriate transepithelial transport can lead to disease and this is particularly
evident in kidney disorders. Molecular genetic studies have recently identified a
number of rare Mendelian disorders of both electrolyte balance and BP, in which
single gene mutations alter normal transepithelial transport in the distal nephron67'77.
Although rare these disorders have been disproportionately valuable in our
understanding of electrolyte balance and hypertension. Most of these disorders have
a related phenotype, having either hypertension with hypokalaemia or the opposite,
hypotension with hyperkalaemia. The gradual cloning and characterisation of the
genes associated with these disorders revealed they function in a common pathway in
kidney, the RAAS pathway, explaining the related phenotype in these disorders
(Figure 1.6 and Table 1.1) and highlighting the importance of the nephron segments
in which they are expressed in Na+ and K+ balance.
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Figure 1.6: Single gene disorders of BP associated with the distal nephron. Loss-of-
function mutations in NCC in DCT cause Gitelman's syndrome128; loss-of-function mutations
in either NKCC2126, ROMK127, or CLCkb125 in TAL cause Bartter syndrome; gain of function
mutations in p or yENaC in DCT2-CD cause Liddle syndrome46'123, while loss-of-function
mutations in a, p, or yENaC cause Pseudohypoaldosteronism Type 1 (PHA 1, recessive);
loss-of-function mutations in 11P-HSD2 in DCT2-CD cause Apparent Mineralocorticoid
Excess (AME)99; loss-of-function mutations in MR in DCT2-CD cause PHA1 (autosomal
dominant)39, while gain-of-function mutations in MR cause Hypertension Exacerbated in
Pregnancy38.
A number of these genes have also been modified in transgenic mouse models,
reproducing the human disease phenotype and further highlighting the importance of
79 "1 1 S ■ 199 •
these distal nephron segments in electrolyte balance ' ' .In addition, some of the
most powerful and effective BP treatments target these nephron segments, for
example, loop and thiazide diuretics act in TAL and DCT, respectively;
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spironalactone and amiloride act in DCT2-CCD (cortical collecting duct). A study by
Majid et al. also identified regulation of Na+ reabsorption by NCC in DCT, as the
• 81
major contributor to BP . Thus, the adjacent distal nephron segments, TAL-CD,
play a powerful role in long-term regulation of electrolyte balance, extracellular fluid
(ECF) volume and BP.
Table 1.1: Single gene disorders of electrolyte balance and BP.
DISORDER PHENOTYPE SITE CAUSE
grh Tbp Tk+ cd Aldo Synthase
Liddle syndrome Tbp Tk+ CD ENaC
ame Tbp Tk+ CD 11pHSD2
Gordon syndrome Tbp Tk+ ?DCT? wnk1, wnk4
PHA I Tbp Tk+ CD ENaC
1.2 Gordon syndrome
1.2.1 Features of Gordon syndrome
The study of such rare inherited diseases has led to the identification of novel
components of important regulatory networks maintaining normal electrolyte balance
and BP. Gordon syndrome (pseudohypoaldosteronism type II (PHA II); familial
hyperkalaemia and hypertension (FHHt); Online Mendelian Inheritance in Man,
OMIM, #145260), one such rare disorder, is an autosomal dominant disease
featuring hypertension (attributed to increased renal NaCl reabsorption) with
hyperkalaemia (due to impaired renal K+ excretion) despite a normal glomerular
filtration rate (GFR)42'43'112. Thus the Gordon syndrome phenotype is quite distinct
from other Mendelian hypertensive disorders in which serum potassium is either
normal or low (Table 1.1). This unusual feature suggests combined K+ and NaCl
retention in Gordon syndrome. This also indicates that a novel pathway distinct from
the aldosterone pathway may be involved, as classically changes in aldosterone
affect BP (NaCl) and K+ in a reciprocal manner.
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Hyperchloremic metabolic acidosis is a variable associated finding, and is due to a
significant decrease in urinary H+ excretion. In addition, patients have suppressed
plasma renin activity. Plasma aldosterone varies from low normal to high normal
(reviewed by42), but is often referred to as inappropriately low with respect to the
observed high level of plasma potassium, a strong stimulus of aldosterone secretion.
Additional features, including retarded growth, intellectual impairment, and muscle
weakness (reviewed by42), have been associated with some cases of Gordon
syndrome. The clinical manifestations of Gordon syndrome are chloride dependent
(corrected when infusion of sodium sulphate or sodium bicarbonate is substituted for
sodium chloride), and are largely treated with low doses of thiazide diuretics (also a
first-line treatment in essential hypertension), specific antagonists of NCC, in
DCT13'43'119.
1.2.2 Proposed Mechanisms Underlying Gordon syndrome
Based on clinical studies in affected patients, two major pathophysiological
• • T7
mechanisms have been proposed to explain Gordon syndrome (reviewed in ). The
first potential mechanism is based on increased paracellular reabsorption of CP, also
known as the "paracellular chloride shunt" hypothesis (Figure 1.3(b)). This chloride
shunt plays a major role in NaCl and K+ homeostasis in CNT and CD, where it has
been suggested that 70% of CI" reabsorption may occur via the paracellular
199
pathway . However, until recently, a lack of understanding of the molecular
architecture of the tight junction, the barrier to paracellular flux, has slowed down the
advancement of this hypothesis. The second proposed mechanism is based on
overactivity of the thiazide-sensitive NCC (Figure 1.3(a)). Despite this, genome-wide
analysis of linkage in Gordon syndrome families revealed no linkage with SLC12A3
encoding NCC, but instead demonstrated locus heterogeneity; mapping three disease
loci, to chromosomes lq31-4285, 17pll-q2185 and 12pl326. This underscores the
heterogeneity of the clinical phenotype42. Three families have also been reported that
97
are not linked to any of these loci, suggesting a fourth unidentified locus . A
breakthrough by Wilson et al. in 2001 identified the genes encoding for two
members of a novel protein kinase family, WNK1 and WNK4, as the two genes
• • *148
underlying Gordon syndrome linked to chromosomes 12 and 17, respectively .
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1.2.3 Identification of Mutations Underlying Gordon syndrome
1.2.3.1 Intronic Deletions in WNK1
In 2001, Wilson et al. showed that a Gordon syndrome kindred with complete
linkage to the chromosome 12pl3 region co-segregated with a 41kb deletion within
the large first intron of a recently described novel kinase, WNK1148. Analysis of a
second Gordon syndrome kindred revealed a 21kb deletion contained within the
same intronic region of WNK1. No mutations in WNK1 coding sequence were
detected in these or sixteen other Gordon syndrome kindreds.
Wilson and colleagues reported a 5-fold increase in the level of WNK1 transcripts,
measured by real-time RT-PCR analysis, of peripheral leukocyte RNA in Gordon
syndrome patients compared to unaffected controls, providing evidence that the
intronic deletion alters WNK1 gene expression. Based on these findings it was
postulated that Gordon syndrome could result from "gain-of-function" WNK1
• 148 • • • •
mutations that increase WNK1 activity . In keeping with this, a gene trap study in
2003 demonstrated that heterozygote WNK1 deficient mice suffered a reduction in
BP of -12 mmHg, with no notable pathological changes in kidney. Interestingly,
blood chemistry and urinalysis results demonstrated normal kidney function, and a
three week low salt diet (0.01% NaCl) treatment failed to induce a significant
difference in water and food intake or urinary output between heterozygote and wild-
type animals. These results demonstrate that WNK1 is a regulator of BP but also
suggest that WNK1 haploinsufficiency may not affect the ability of mice to conserve
electrolytes in response to a low salt diet165.
1.2.3.2 Missense Mutations in WNK4
Subsequent genomic sequence and EST database searches revealed that a WNK1
paralog, WNK4, localised to the genetic interval containing the Gordon syndrome
locus on chromosome 17. Examination of WNK4 in Gordon syndrome kindreds
identified four charge-altering missense mutations, all of which co-segregated with
the disease. Three of these mutations cluster in a span of four amino acids just distal
to the first of two putative coiled-coil domains, within a ten amino acid stretch that is
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highly conserved among all members of the WNK kinase family. The fourth
mutation lies just distal to the second putative coiled coil domain. These findings
implicate WNK1 and WNK4 in a previously unrecognised signalling pathway that
regulates the balance between NaCl reabsorption versus K+ and H+ secretion148.
Intriguingly, no WNK or WNK-like gene is located on human chromosome lq31-42,
suggesting that a completely different protein is involved.
1.3 With No K (Lysine) Kinases
1.3.1 Discovery ofWNK Kinases
WNK kinases comprise a novel family of ser/thr kinases, which show greatest
similarity (approximately 30% sequence identity within the catalytic domain) to
sterile-20 (STE-20) kinases. Xu el al. cloned and characterised the first WNK kinase,
rat WNK1, isolating a 7.2 kb cDNA, encoding a 2126 amino acid protein, from a rat
brain cDNA library15'. The acronym reflects the unusual character of its catalytic
domain which lacks an otherwise conserved lysine residue, hence With No K=lysine
(WNK). Verissimo and Jordan went on to clone and characterise WNK1 in human, a
251 kDa protein composed of 2382 amino acid encoded in an open reading frame
(ORF) of 7149 bp137. The degree of identity between human and rat WNK1 is -86%.
Four members of the WNK kinase family, WNK1-4, have been identified so far in
humans, located on chromosomes 12, 9, X and 17 respectively137'148. It is now
believed that WNKs are present exclusively in multicellular eukaryotes, with
117
homologs identified in Drosophila melanogaster and Caenorhabditis elegans and
at least eight homologs identified in Arabidopsis thaliana, some of which are
believed to contribute to circadian rhythms100'102.
1.3.2 Atypical WNK Kinase Domain
Protein kinases comprise an important superfamily of enzymes (genome-wide this
has been termed a kinome, and has several major branches; see
http://198.202.68.14/human/kinome/) that participate in complex signalling
networks, regulating many cellular processes ranging from cell cycle control to
differentiation. The human protein kinome was recently estimated to possess just
84 •
over 500 members . Structurally these proteins are extremely heterogeneous but
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share high homology over their catalytic core, a region of approximately 250-300
residues organised in twelve subdomains, with several residues that are strictly
conserved.
The WNK family is characterised by the replacement of the conserved catalytic
lysine residue, found in (3 strand 3 of subdomain II of almost all known protein
kinases, by a cysteine. This specific lysine residue is involved in orientating ATP to
facilitate phosphoryl transfer, which is essential for catalytic function. In WNKs the
catalytic lysine is located further N-terminally within the glycine-rich string
(replacing the third glycine in the GXGXXG motif) in P strand 2 of subdomain I151.
This was recently confirmed by the crystallisation of the WNK1 kinase domain94.
Sequence alignment of the catalytic domains of WNK1-4 reveals variations from
typical kinase subdomains I and II, similar to WNK1. The overall degree of amino
acid sequence identity between the catalytic domains ofWNK2, 3 and 4 and that of
WNK1 is -79% 37.
1.3.3 WNK Protein Domains
Besides the highly homologous N-terminal kinase domain, the WNK kinase family
also features two conserved coiled-coil domains and a cluster of conserved charged
amino acid residues in which mutations in WNK4 have been identified in Gordon
syndrome patients. In addition, WNK kinases contain several PXXP motifs, which
could potentially interact with SH3 domains of other proteins (described further in
Chapter 3)109;137;148;151.
1.3.4 WNK Protein Kinase Activity
Upon activation by an upstream signal or sometimes a specific combination of
signals, protein kinases positively or negatively regulate the activity of downstream
target proteins via phosphorylation. Consequently protein kinases are often thought
of as molecular switches, rapidly and reversibly responding to specific signals,
simultaneously integrating multiple signalling pathways and thereby mediating the
appropriate cellular responses.
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Most of the initial biochemical knowledge of the WNK kinase family has come
through work with WNK1. Initial findings described rWNKl as a ser/thr kinase151
whose kinase activity is regulated by two serine residues, located within the WNK
activation loop, serine 378 and 382, which have been proposed to be part of an
1 S9
autophosphorylation domain . Furthermore, it has been reported that NaCl
enhances WNK1 autophosphorylation131, suggesting a role in osmosensing
pathways.
The WNK4 kinase domain is highly homologous to that of WNK1 but studies on
WNK4 kinase activity are more limited. Expressing the kinase domain as a small
GST fusion protein produced no kinase activity when transfected into HEK293
cells147. However, kinase-dependent and independent functions have been identified
for WNK4 in the regulation of renal electrolyte transporters 56'149,161 (see section 1.4).
In addition, Yamauchi identified Claudins (tight junction proteins) as molecular
targets ofWNK4 kinase activity in vitro53'159 (see section 1.4.3).
1.3.4.1 Upstream Signalling and Downstream Targets
Recently, WNK1 was shown to be a novel substrate for protein kinase B/Akt. Vitari
et al. provide pharmacological and genetic evidence that WNK1 is phosphorylated
by PKB on Thr5831'138. This upstream pathway was, more recently, linked to ENaC
regulation via SGK and Nedd4-2153'154 (Table 1.3). The downstream target pathways
of WNK1 kinase activity are still under investigation but Xu et al. also report
evidence that WNK1 activates the ERK5 MAPK pathway through MEKK2/3
(MAP3K)155. WNK1 phosphorylation of Synaptotagmin proteins (involved in vesicle
trafficking) has also been reported64 (Table 1.3). Interestingly some of these studies
indicate that WNK1 function may not be based on its catalytic activity alone, but
may involve a scaffolding role, whereby WNK1 allows the complex assembly of
interacting proteins134'155.
1.3.5 WNK Kinase Expression
When the studies in this thesis began only very limited information regarding the
expression ofWNK1 and WNK4 was available. RNA and protein analysis revealed
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WNK1 expression in virtually all tissues examined, but predominantly in kidney,
heart, and muscle24'137'148. In contrast, WNK4 expression was reportedly restricted to
kidney. Immunohistochemistry studies investigating the nephron segment and
subcellular distributions of these proteins, report cytoplasmic WNK1 expression in
DCT and CD, whereas WNK4 expression was reported in tight junctions of DCT,
148
and in both the cytoplasm and tight junctions ofCCD
Table 1.2: WNK expression.
Tissue Cytoplasm Lateral Tight Ref
membrane Junction
WNK1 DCT & CD Y 147
Epidermis Y 18
Eccrine sweat glands (skin) Y 18
Gall bladder epithelium Y 18
Colonic crypt epithelium Y 18
Oesophagus Y 18
Hepatic bilary ducts Y 18
Pancreatic ducts Y 18
Epididymis Y 18
WNK4 DCT / 147
CCD Y Y 147
Pancreatic ducts Y Y
52
Hepatic bilary ducts Y Y
52
Colonic crypts Y Y
52




Blood-brain barrier epithelium Y Y
52
Over the last two years further evidence of WNK expression has been reported
(Table 1.2) and it has subsequently become apparent that WNK4 is discreetly
expressed in a wider range of tissues (Chapter 4). Studies submitted as part of this
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thesis have also made a significant contribution to the current understanding of
WNK1 gene expression109 and are discussed in detail in Chapters 3 and 9.
1.4 WNK Kinase Regulation of Ion Transport Processes
Mutations in either WNK1 or WNK4 cause Gordon syndrome, a disorder featuring a
Na+ and K+ imbalance. The clinical features of Gordon syndrome can be explained
by distal nephron defects in ion transport processes that are corrected by treatment
with thiazide diuretics. WNK1 and WNK4 are expressed in adjacent distal nephron
segments which ultimately regulate net salt reabsorption as well as net K+ and H+
secretion. All of these considerations prompted the investigation of potential roles for
WNK kinases in distal nephron ion transport processes.
During the course of the studies reported in this thesis, a mass of in vitro functional
data has been reported, predominantly from Xenopus oocyte studies, proposing
diverse regulatory roles for WNK1 and particularly WNK4 in electrolyte transport,
both within and outside kidney (summarised in Table 1.3). These include extensive
interactions with Na+, K+ and CI" transporting systems, including NCC148'161"163,
ROMK56, ENaC133'154, the basolateral isoform of the Na+-K+-2C1" cotransporter,
NKCC1, the apical Cf/anion exchanger, CFEX52, the basolateral Ca2+ channel,
TRPV434, and also Claudin (tight junction) proteins33'160. WNK signalling has also
been associated with Ste-20-related Proline-Alanine-rich Kinase, SPAK35"36'97'113'139,
and synaptotagmins 64, further suggesting a role for this pathway in membrane
trafficking (Table 1.3).
However, the physiological relevance of phenomena observed in experimental
systems must be queried as the genes under study are often overexpressed, or
expressed at inappropriate ratios in relation to each other. Also, normal protein
function may not be observed due to the absence of (or inappropriate presence of)
upstream signals, downstream targets, or other regulatory factors. So although
informative these in vitro findings require further validation particularly in an in vivo
model, before these phenomena can be accepted. While many of these studies will be
discussed at greater length in Chapter 9, interactions forming the basis of currently
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held theories, which are regularly referred to in the chapters to follow, are introduced
here in detail.
1.4.1 WNK4 Inhibits NCC
Recently, two independent studies based in the Xenopus laevis oocyte expression
system examined the regulation of NCC by WNK kinases. It was observed that
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coinjection of oocytes with NCC and wild-type WNK4 reduced Na influx,
compared with NCC injection alone149'161. The C-terminus of WNK4 mediates this
NCC inhibition and Yang et al. have demonstrated that the C-terminal 200 amino
acids of NCC interact with WNK4 in HEK293 cells162. Additional experiments
utilizing either eGFP-tagged NCC149 or immunoprecipitation of surface-biotinylated
NCC161, indicated that WNK4 inhibits NCC function by reducing the amount of
NCC present in the plasma membrane, possibly by increasing the removal of NCC
from the plasma membrane. Wilson et al. performed similar studies with a kinase-
dead WNK4 (D318A) which showed no inhibition of NCC-mediated 22Na influx,
suggesting that WNK4 inhibition ofNCC is kinase-dependent149. This conflicts with
findings by Yang et al. showing that catalytically inactive WNK4 maintains the
ability to inhibit NCC suggesting that this inhibition occurs largely through protein-
protein interactions rather than by phosphorylation161.
1.4.1.1 Mutant WNK4 and NCC Inhibition
Intriguingly, Wilson et al,149 showed total loss, while Yang et al.l6] showed only
50% loss, ofNCC inhibition with WNK4 harbouring the Gordon syndrome-causing
missense mutation Q562E (Q565E in hWNK4). However, WNK4 Q562E retained its
ability to form a complex with NCC. Although Wilson et al. also indicate that
another Gordon syndrome mutation, WNK4 E559K, had also lost effect on NCC
activity, Yang et al. failed to show any loss of inhibiting capacity for either WNK4
E559K or D561A (E562K and D564A in hWNK4). More recently, Yang et al.
demonstrated that WNK4 harbouring the most distal of the Gordon syndrome
mutations, R1164C, was as effective as wild-type WNK4 in its ability to inhibit
1 f>9
NCC . Adding to this controversy, a recent study showed that while WNK4
expression disrupted apical localisation of NCC in polarised MDCK II epithelial
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cells, this inhibitory effect was also observed with coexpression of mutant WNK4
i z:o
D564A . Furthermore, the activity and/or localisation of electrolyte transporters
unrelated to Gordon syndrome (CFEX and NKCC1) was also decreased by both
wild-type and mutant WNK4 expression. Further work will be needed to clarify
discrepancies between these studies and to accurately determine the physiological
relevance of the WNK4-NCC interaction.
1.4.1.2 Causal Chain: WNK1 Regulation of WNK4-Mediated NCC
Inhibition
Mutations in WNK1 or WNK4 cause a broadly similar phenotype, suggesting that
these proteins participate in the same pathway, or in parallel pathways on similar
downstream targets. Interestingly, similar expression studies involving WNK1
showed that although WNK1 alone had no effect on NCC activity, WNK1
suppresses WNK4-induced inhibition of NCC, thereby restoring cotransporter
activity to near base-line levels161. WNK1 physically associates with WNK4 in a
protein complex involving their highly homologous N-terminal kinase domains.
Catalytically active full-length WNK1 is required to suppress WNK4-mediated NCC
• ••• • • • 1 fO
inhibition, possibly explained by WNK1 tetramer formation .
1.4.1.3 Potential Mechanism
Based on these studies it is hypothesised that wild-type WNK4 is an inhibitor of
NCC activity and that this inhibition may be lost due to inactivating WNK4
mutations in Gordon syndrome. Thus, as suggested by the mirror image between
Gordon syndrome and Gitelman's disease, as well as effective treatment of Gordon
syndrome with thiazide diuretics, increased activity of NCC could cause a
transcellular chloride shunt just as hypothesised in the past in explaining features
characteristic of Gordon syndrome. Increased Na+ reabsorption in DCT would
expand plasma volume and raise cardiac output causing hypertension. It would also
reduce the amount ofNa+reabsorption via the electrogenic channel, ENaC, impairing
the development of the lumen-negative potential that is required for normal secretion
of K+ and H+ in the distal nephron. Gain of function mutations causing an increase in
WNK1 expression, as has been reported at least in leukocytes in Gordon syndrome
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patients , would suppress WNK4 activity, activating NCC, and could also lead to
the Gordon syndrome phenotype.
In keeping with WNK4 as a regulator of Na+ flux, a recent clinical study suggests
that WNK4 modulates Na+ transport in airways and that this may be the result of
regulation of ENaC or a K+ channel31.
1.4.2 WNK4 Inhibits ROMK
ROMK channels are located in TAL where they mediate apical K+ recycling to
facilitate Na+ reabsorption through the apical Na+-K+-2Cf cotransporter (NKCC2),
and more distally in DCT-CNT-CD where at least from late DCT (DCT2) distally
ROMK is regarded as forming the major K+ secretory pathway driven by colocalised
electrogenic Na+ reabsorption via ENaC. As one of the prominent features ofGordon
syndrome is hyperkalaemia and WNK4 is expressed in DCT2-CD segments as well
as DCT1, the possibility of a direct role for WNK4 in the regulation of K+ secretion
was examined by Kahle et al. in Xenopus oocytes56. Expression of eGFP-tagged
ROMK2 produced a large K+ current that was markedly inhibited (68% reduction)
by coexpression of WNK4. Further experiments indicated that WNK4 inhibits
ROMK by increasing its clearance from the cell surface (by up to 87%) through
clathrin-dependent endocytosis. Co-immunoprecipitation of a WNK4 fragment
(extending from the end of the kinase domain to the normal C terminus) with the
cytoplasmic C terminus of ROMK, implies that WNK4 and ROMK interact
physically. One possibility proposed by the authors is that WNK4 serves as a
scaffold to bring together ROMK and other factors that target ROMK for
endocytosis. Kinase-dead WNK4 (D318A) also fully inhibited ROMK, indicating
that inhibition ofROMK by WNK4 is not dependent on WNK4 kinase activity.
1.4.2.1 Mutant WNK4 and ROMK Inhibition
The Gordon syndrome mutation Q562E was shown to increase the inhibition of K+
current by 80% and caused a further 87% reduction in ROMK surface expression
compared with wild-type WNK4. Similar results were obtained with WNK4 E559K.
From this study the authors propose that WNK4 inhibits K+ secretion via ROMK in a
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kinase-independent manner by increasing its clearance from the plasma membrane
via clathrin-dependent endocytosis and that the Gordon syndrome missense
mutations appear to increase ROMK inhibition, potentially explaining the impaired
K+ secretion characteristic of this disease. Thus WNK4 appears to inhibit NCC and
ROMK by different mechanisms.
1.4.3 WNK4 Regulates Paracellular Permeability via Claudins
The conspicuous localization of WNK4 in the tight junction complex148 and the
"paracellular chloride shunt" hypothesis proposed to explain Gordon syndrome
(section 1.2.2) prompted both Yamauchi et al. and Kahle et al. to investigate the
possibility that WNK4 regulates paracellular CI" flux. These studies were based in
MDCKII cells which form tight (high transepithelial resistance (TER)), electrolyte
transporting epithelia regarded as having distal tubule/CD characteristics. Although
controversy exists between the two studies over the effect of wild-type WNK433'159,
overall they demonstrate that WNK4 increases paracellular CI" permeability by
reducing TER through phosphorylation of Claudin proteins139, and that Gordon
syndrome WNK4 mutants (D564A159, Q562E and E559K53) further enhance this
effect. Thus, Claudin proteins may be downstream molecular targets of WNK4,
suggesting that WNK4 may function as a specific regulator of the paracellular
pathway, and that mutations in this respect behave as gain-of-function mutations.
1.5 Summary: Roles of WNKs in Integrated Physiology
1.5.1 Molecular Switch Hypothesis
As discussed in section 1.2.2, two models have been proposed to explain Gordon
syndrome, both effectively involving a CI" shunt, routing either transcellularly
(through NCC overactivity) or paracellulary (across "leaky" tight junctions).
Findings from the in vitro studies described above provide evidence for both these
possibilities.
Kahle and colleagues propose a transcellular model whereby in normal physiology
WNK4 acts as a molecular switch simultaneously controlling reciprocal fluxes in
Na+ and K+ (via inhibition of NCC and ROMK, respectively; Figure 1.7). Gordon
Chapter 1. Introduction. 23
WNK Kinases: Novel Regulators of Electrolyte Balance and Blood Pressure.
syndrome mutations are proposed to disrupt inhibition of NCC (increasing NaCl
reabsorption) and enhance ROMK inhibition (proposed to reduce K+ secretion).
However, it is unclear from these in vitro based studies, where in the nephron this
putative effect on ROMK would occur as it is a broadly expressed gene (TAL-CD).
Controversial findings from a more recent study also question whether this ROMK
effect occurs in vivo160. It is tempting to speculate that loss of WNK4 regulation of
NCC alone (resulting in increased electroneutral NaCl reabsorption in DCT and
reducing the potential for K+ secretion via electrogenic transport further distally)
might provide a sufficient explanation for Gordon syndrome, fitting with the long
established overactive NCC hypothesis (Figure 1.3(a))10'56.
ROMK NCC
WNK1-L
Figure 1.7: WNK4 molecular switch hypothesis. WNK4 serves as a molecular switch
simultaneously regulating NaCl reabsorption via NCC and K+ secretion via ROMK. Kahle et
al. propose that at low aldosterone levels, WNK4 inhibits the surface expression of NCC and
ROMK. In hypovolemic states, WNK4-inhibition of NCC is relieved allowing increased NaCl
reabsorption, whereas the routing of ROMK to the plasma membrane is suppressed. In
hyperkalemic states, WNK4-inhibition of ROMK is relieved, whereas the routing of NCC is
suppressed. Yang et al. show thatWNK1-L can inhibit WNK4-mediated inhibition of NCC.
WNK4 regulation of paracellular Cf flux adds an additional possibility to this
molecular switch hypothesis. The Gordon syndrome mutations increase paracellular
Cf reabsorption, depleting the lumen negative charge, and thereby reducing the
driving force for K+ and H+ secretion. Overall, this would enhance NaCl reabsorption
and diminish K+ and H+ secretion (Figure 1.3(b)). This is an alternative or additional
mechanism, by which the Gordon syndrome mutants could lock the switch in a mode
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that expands plasma volume by increasing NaCl reabsorption, while retaining plasma
K+.
Overall these studies demonstrate that in a normal physiological setting WNK
signalling could potentially coordinate transcellular and paracellular flux to achieve
NaCl and K+ homeostasis33'159, and may play a pivotal role in electrolyte balance,
propagating the appropriate renal response to aldosterone signalling. Thus, these in
vitro functional studies provide evidence for both the overactive NCC hypothesis and
the paracellular CI" shunt hypothesis proposed to explain Gordon syndrome and
indeed both could exist in parallel.
1.5.2 Drug targets
The WNK pathway represents an attractive target for development of novel
antihypertensive agents at least as powerful as thiazide diuretics and without the
adverse metabolic effects currently raising concerns about first line use of certain
antihypertensives including thiazides and P-blockers. That they may be free of
thiazide-like metabolic side effects gains support from the lack of such problems
affecting patients with Gordon syndrome.
The studies described above identify WNK1 and WNK4 as strong candidates
possibly involved in contributing to the pathogenesis of essential hypertension.
Interestingly, WNK4 lies within a region of the genome which has been reported to
show a human quantitative trait locus (QTL) for essential hypertension on a genome
scan, and moreover this area is syntenic to a region in the genome of the
spontaneously hypertensive rat (SHR) strain169, harbouring a long known major QTL
for hypertension in this animal model of essential hypertension. A number of case-
control and population based studies have been very recently carried out to look for
association between various single nucleotide polymorphisms (SNPs) in WNK1 and
WNK4 and BP variation. Although WNK4 variants have been identified in
hypertensive patients, results have been inconsistent and the physiological
importance of these genetic variations remains to be determined58'59'169.
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Until very recently there was very little evidence of an association between WNK1
polymorphisms and BP variation. Kokubo et al. found no association between
WNK1 SNPs and clinic SBP or DBP in a large Japanese population39. Whilst overall
the BRIGHT study found no association ofWNK1 with essential hypertension, this
important study shows nominal evidence of an association between one WNK1 SNP
near the promoter region and the severity of hypertension107. Interestingly, a study
published by Tobin and colleagues is the first to report an association between
common genetic WNK1 variants and BP in a white European population135'166.
Although, these findings will need to be confirmed by other epidemiological studies
and also functional studies, they raise the possibility that milder variations than seen
in Gordon syndrome within the WNK pathway may be contributing to human
variations in BP and influence salt sensitivity and the response to antihypertensive
drugs. Whether such genetic markers are of use in predicting the incidence of
hypertension and cardiovascular morbidity and mortality or the response to salt
restriction or particular classes of antihypertensives would require clarification
through further studies.
1.5.3 Concluding remarks
Genetic and physiologic evidence suggests WNK1 and WNK4 as molecular switches
regulating Na+, K+, and CP balance in the distal nephron. Clearly our perception of
the respective physiological roles of WNK1 and WNK4 is largely in its infancy. A
number of interactions of interest have been reported in in vitro studies often in
single non-polarised cells such as Xenopus oocytes. Whilst these early studies are
valuable it still remains to be established if such phenomena apply in vivo in
mammalian kidney to importantly affect electrolyte transport and BP. Unravelling
the mechanisms of these regulatory pathways within kidney has the potential to
deepen our understanding of the integrated physiology of electrolyte balance and
promises to yield insights into new mechanisms involved in essential hypertension.
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Aims
The primary aim of this thesis was to investigate the WNK pathway in kidney and
elucidate its role in electrolyte balance and BP control by addressing the following
aims:
1. To examine the distribution and alternative splicing of WNK1 and WNK4
gene expression in mouse kidney.
2. To produce anti-WNK antisera specific for mouse WNK1 and WNK4.
3. To assess the impact of stimuli, known to affect electrolyte balance and BP,
on WNK pathway gene expression in vivo.
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Chapter 2 Materials and Methods
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2.1 Materials
Unless otherwise stated all chemicals and reagents were purchased from Sigma-
Aldrich Company Ltd., Poole, Dorset, UK.
2.1.1 General Chemicals
BDH-Merck, Poole, Dorset, UK:
Acetone, DPX Mountant, Formaldehyde, Glacial Acetic Acid, Hydrochloric Acid,
Xylene, and any other organic solvents.
Bright, UK:
Cryo-m-bed-embedding compound
Fisher Scientific, Loughborough, Leicester, UK:
Duolite Mixed Resin.
Fluka Chemicals Ltd., Gillingham, Dorset, UK:
Acetic Anhydride, Triethanolamine.
Hayman Ltd., Witham, Essex, UK:
Ethanol.
VWR International, Lutterworth, Leicester, UK:
SuperFrost Plus Slides, Paraformaldehyde.
Whatman® International Ltd., Maidstone, England:
Whatman 3mm Chromatography Paper, Whatman Filter Paper.
2.1.2 Molecular Biology Reagents
Applied Biosystems, Applera, Warrington, Cheshire, UK:
TaqMan™ primers and probes, TaqMan™ PCR core reagent kit.
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Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK:
Anti Rabbit Scintillation Proximity Assay (SPA) reagent, 14C Microscales, ECL™
Western Blotting Detection Reagents, Horseradish-peroxidase linked anti-rabbit
antibody, Hybond ECL™ Nitrocellulose Membrane, Hybond-N+ Membrane,
Hyperfilm ECL™, Rediprime" II Random Prime Labeling System, NICK sephadex
G-50 DNA column.
Anachem Ltd., Luton, Bedfordshire, UK:
NTB-2 photographic emulsion.
Biowhittaker MolecularApplications, Wokingham, Surrey, UK:
SeaKem® LE Agarose (For Electrophoresis).
Canberra Packard, UK:
PicoFluor 40 Scintillant fluid.
H.A. West, Edinburgh, UK:
Arnfix high speed fixer.
Invitrogen Life Technologies/Gibco BRL, Paisley, UK:
Custom Primers, lkb DNA Ladder, lOObp DNA Ladder, Low DNA Mass Ladder,
Low Melting Point Agarose, TRIzol®, Yeast tRNA.
Promega Ltd., Southhampton, Hants, UK:
Nuclease-free Water, Nucleotides, Reverse Transcription System, RNase Inhibitor
(RNasin), RQ1 DNase (RNase-free), Transcription optimised buffer (5x), RNA
polymerases (T3 and T7), Taq DNA Polymerase and buffer.
Qiagen Ltd., Crawley, West Sussex,UK:
QIAquick Gel Extraction Kit, QIAquick PCR Purification Kit.
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Sigma-Aldrich Company Ltd., Poole, Dorset, UK:
Kodak Biomax MS film, Kodak Biomax MR film.
Roche Diagnostics Ltd., Lewes, East Sussex, UK:
RNase A.
2.1.3 Protein Reagents
Bio-Rad Laboratories Ltd., HamelHampstead, UK:
Blotting Grade Blocker Non-Fat Dry Milk, Bradford Protein Assay Reagent,
Precision Plus Protein Standards Dual Color, Tween.
Roche Diagnostics Ltd., Lewes, East Sussex, UK;
Complete Protease Inhibitor Cocktail.
2.1.3.1 Antibodies
Alomone Labs Ltd., Jerusalem, Israel:
Anti-ROMK.
Giftfrom Jan Loffing, University ofFreiburg:
Anti-NCC.
2.1.4 Radioisotopes
Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK:
[l,2,6,7-3H]-corticosterone (2.8-3.9 TBq/mmol), [a-32P]-dCTP (111 TBq/mmol),
35S-UTP (30 TBq/mmol).
2.1.5 Animals
Charles River Laboratories, UK:
C57BL/6J Mice.
DURECT Corporation, Cupertino, CA, US:
Alzet® Mini-Osmotic Pump (Model 2004).
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Sigma-Aldrich Company Ltd., Poole, Dorset, UK:
Dexamethasone.
Special Diet Services (SDS), Witham, Essex, UK:




2.1.6 Materials for plasma assays
Bachem, Merseyside, England, UK:
Angiotensin I.
Diagnostic Products Corporation, LA, USA:
• 19S
Count-A-Coat Aldosterone Radioimmunoassay (including I-Aldosterone).
Giftfrom Dr. JJMorton, Glasgow:
Anti-Angiotensin I.
Reagent ofDr. CJKenyon, Edinburgh:
Anti-Corticosterone.
2.1.7 Equipment
Amersham Pharmacia Biotech, Little Chalfont, UK:
GeneQuant RNA/DNA Calculator, Hyper-processor.
Applied Biosystems, Applera, Warrington, Cheshire, UK:
TaqMan™ ABI Prism 7900 Sequence Detector™.
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Berthold Technology Ltd., St. Albans, Hertfordshire, UK:
Berthold LB 2111 y-counter.
Bio-Rad Laboratories Ltd., Hamel Hampstead, UK.
Electrophoresis Power Pac 300, Mini-Protean 3 Cell, Mini Trans-Blot
Electrophoretic Transfer Cell.
Bio-Tek Instruments Inc., Winooski, Vermont, USA:
EL 312e Bio-Kinetics Microplate Reader.
Dage Inc., Michigan City, Indiana, USA:
Dage MTI CCD72S imaging camera.
EppendorfAG, Hamburg, Germany:
Eppendorf Mastercycler gradient
(PCRs, RTs and denaturation).
FSA Laboratory Supplies, Fissons pic., UK:
Whirlimixer.
Fuji Photo Film Company Ltd., Tokyo, Japan:
Phosphoimager FLA-2000, Phosphoimager screens.
Gallenkamp, UK:
Fan Incubator.
Jouan Inc., Winchester, Virginia, USA:
Jouan A-14 Centrifuge (Ultracentrifuge rpm < 14000).
Hybaid, UK:
Hybaid Omni Slide Wash Module.
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Ika, Labortechnik, Stciufen, Germany:
Ultra-Turrax T8 auto-homogeniser.
Jencons-PLS, Bedfordshire, UK:
Techne Hybridiser HBID, Hybridisation Bottles.
Leica Microsystems, UK:
Leica Cryostat.
Savant Instruments Inc., USA:
DNA Speed Vac® DNA110.
StuartScientific, Staffordshire, UK:
Stuart Gyro-rocker SSL3.
Techniplast, Kettering, Northamptonshire, UK:
Mouse Metabolic Cages.
Wallac Oy:
1450 Microbeta Plus Liquid Scintillation Counter.
(utilised for standard cpm counting)
2.1.8 Software
Applied Biosystems, Applera, Warrington, Cheshire, UK:
Sequence Detection Systems (SDS).
Mathworks, Natick, MA, USA:
MATLAB® v7 Technical Computing Environment and Imaging Processing Toolbot.
Raytest Scientific Ltd., Sheffield, UK:
Fujifilm Fluorescent Image Analyser FLA-200 V.1.0, Aida 2.0 Auto Image Data
Analyser.
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Zeiss Contron KS400 software.
2.1.9 Buffers and Solutions
1.2% Agarose FormaldehydeDenaturing Gel: 17ml formaldehyde (BDH, 101134A)
added to 1.2g of agarose, pre-melted in DEPC-treated water (73ml) and 10X MOPS
buffer (10ml).
Box Buffer:
A - 20ml 20xSSC buffer, 50ml deionised formamide (Sigma, F7503) made up to
100ml in DEPC-treated water (see below).
B - 0.5M NaCl, lOmM Tris, ImM EDTA in dH20.
Blocking Solution (Western blot): 25g powdered milk (Bio-Rad, 170-6404), 500pi
Tween (Bio-Rad, 170-6531), 50mls lOxTBS (see below) made up to 500mls with
dH20.
Deionised Formamide (for use in box buffer): 150ml formamide (Sigma, F7503)
mixed with 15g mixed bed ion-exchange resin (Duolite, MB-6113) for >1 hr, filtered
twice through Whatman filter paper (Whatman, 1001150) and stored protected from
light using sterile glassware.
DEPC-Treated Water: dH20 mixed with diethylpyrocarbonate (DEPC; 1 drop/
100ml), shaken and left for 1-24 hr prior to autoclaving.
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lxDiluent Buffer: 8.25g boric acid, 2.7g NaOH, and 3.5ml conc. HC1 (10M) made
up to litre with distilled water (dh^O), (pH 7.4; containing 0.5% bovine serum
albumin (BSA), 1% methanol and 0.1% ethylene glycol). Stored at -20°C and thawed
at room temperature immediately before use.
250mM EDTA (pH 8.0): 80mls water was added to 9.3g Na2EDTA.2H20. pH
adjusted with NaOH and volume adjusted to lOOmls.
Ethanol in AmmoniumAcetate:
50% - 11.55g Ammonium Acetate dissolved in 250ml ethanol, made up to 500ml
with dH20.
70% - 11.55g Ammonium Acetate dissolved in 350ml ethanol, made up to 500ml
with dH20.
90% - 11.55g Ammonium Acetate dissolved in 450ml ethanol, made up to 500ml
with dH20.
2xHybridisation Buffer: 1.2M NaCl, 20mM Tris-HCl (pH 7.5), 2x Denhardt's
solution (Sigma, D2532), 2mM EDTA (pH 8.0), 0.2mg salmon sperm DNA
(llmg/ml; Sigma, D9156), 0.2mg yeast tRNA (50 mg/ml; Invitrogen, 15401-029)
and 2g dextran sulphate (Sigma, D8906) made up to 10ml in DEPC-treated water,
stored at -20°C.
4x Laemmli Buffer: 4% SDS, 20% glycerol, 2mM DTT, 125mM Tris (pH 6.8), 16%
P-mercaptoethano1, bromophenol blue.
Loading Buffer:
A - 0.35% w/v orange G, 40% glycerol in dH20.
B - 40% sucrose w/ v, 0.25% bromophenol blue (w/v) in dH20.
(fdter-sterilised before use)
Lysis Buffer (Tissue Protein Homogenate Preparation): 50mM Tris (pH 7.5),
0.25M sucrose, 5mM EDTA, lx stock cocktail protease inhibitors (Complete
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Protease Inhibitor Cocktail Tablets, Roche, 11 836 153 001\ inhibition of serine,
cysteine and metalloproteases), made up in dH20.
lOx MOPS Buffer (pH 7): 42g MOPS, 16.6ml 3M sodium acetate (pH5.2) and 20ml
0.5M EDTA dissolved in 1L dH20; adjusted to pH 7. Autoclaved before use.
4% Paraformaldehyde in 0.1MPhosphate Buffer (pH7.5): 20mM NaH2P04, 80mM
Na2HP04 in 1L DEPC-treated water, heated to 80°C prior to addition of 40g
paraformaldehyde using sterile glassware. Stirred for 1 hr to dissolve and stored at
4°C.
Phosphate Buffer: 0.2M NaH2P04 0.6M Na2HP04 5mM EDTA. Autoclaved
before use.
PBS (Phosphate Buffered Saline; pH 7.4): 0.1M phosphate buffer with 137mM
NaCl, 2.7mM KC1 in dH20. Autoclaved before use.
0.1% Ponceau Stain: lOOmg Ponceau in 100ml of 1% acetic acid.
2xPre-hybridisation Buffer: 1.2M NaCl, 20mM Tris-HCl (pH 7.5), 2x Denhardt's
solution (Sigma, D2532), 2mM EDTA (pH 8.0), lOmg salmon sperm DNA
(llmg/ml; Sigma, D9156), 0.2mg yeast tRNA (50 mg/ml; Invitrogen, 15401-029)
made up to 10ml in DEPC-treated water, stored at -20°C.
Resolving Gel (5%; Western Blot): 9.075ml dH20, 1.875ml Acrylamide/bis-
acrylamide (40% stock solution mixture; Sigma, A2917), 3.75ml 1M Tris (pH 8.8),
0.15ml 10% SDS, 112.5pl 10% ammonium persulphate and 15pi TEMED.
RNA Sample Buffer: 50% deionised formamide (Sigma, F9037), 18% formaldehyde
(BDH, 101134A), lxMOPS buffer.
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RNase A Solution: 25mg RNase A (Roche, 10109 142 001) dissolved in ImM Tris,
15mM NaCl made up to 2.5ml with dH20 (lOmg/ml). Heated to 100°C for 15 min
then cooled to room temperature and stored at -20°C. RNase A (lOmg/ml) added to
box buffer B (3pl/ml).
2Ox SSC (Saline Sodium Citrate Buffer; pH7.0): 3M NaCl, 0.3M Na citrate in 1L
DEPC-treated water, pH 7.0. Autoclaved before use.
5MSodium Chloride: 29.55g added to 100ml DEPC-water.
Stacking Gel (4%; Western Blot): 11.3475ml dH20, 1.875ml 1M Tris (pH 6.8),
1.5ml Acrylamide/bis-acrylamide (40%' stock solution mixture; Sigma, A2917),
0.15ml 10% SDS, 112.5pl 10% ammonium persulphate and 15pl TEMED.
IOxTBE Buffer: 0.9M Tris, 0.9M Boric acid, 20mM EDTA (pH 8.0) in dH20.
Autoclaved before use.
IOxTBS (Tris Buffered Saline; pH 7.6): 0.2M Tris, 1.4M NaCl in dH20.
TE Buffer (pH8.0): lOmM Tris-HCl (pH 8.0), ImM EDTA (pH 8.0). Autoclaved
before use.
Transfer Buffer (pH8.3; Western blot): 50mM Tris, 0.38M Glycine, 20% Methanol
in dH20.
0.1M Triethanolamine (pH8.0): 13.3ml Triethanolamine (Fluka, 90280) dissolved
in 800ml DEPC-water, volume adjust to 1L, using sterile glassware.
lxTris/Glycine/SDS Running Buffer (pH8.3; Western Blot): 50mM Tris, 0.38M
Glycine, 0.1% SDS in dH20.
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Type III Loading Buffer (6x): 0.25% (w/v) Bromophenol Blue, 0.25% (w/v) Xylene
Cyanol FF, 30% (v/v) Glycerol in H20. Filter-sterilised before use.
Urea-5.3% Acrylamide Gel: 3.6g urea, 1.32ml Acrylamide/bis-acrylamide (40%
stock solution mixture; Sigma, A2917), 0.1% ammonium persulphate (v/v), lOpl
TEMED in lx TBE.
Wash Buffer A (Low Stringency): 50mMNaPO4 (pFl 7.2), 1% SDS.
Wash Buffer B (High Stringency): 25mM NaP04 (pH 7.2), 1% SDS.
Wash Buffer C (Highest Stringency): 25mM NaP04 (pH 7.2), 0.1% SDS.




Male C57BL/6J mice were obtained from Charles River Laboratories at ~1 weeks of
age. Mice were maintained under controlled conditions of light (lights on 0800 h -
2000 h) and temperature (21-22°C), and allowed free access to standard chow
(61.9% carbohydrate, 18.8% protein, 3.4% oil and 0.6% salt) and drinking water.
Mice were housed two per cage.
2.2.1.1 Animal Experimental Treatments
All treatments were carried out under the terms of the UK Home Office Animals
(Scientific Procedures) Act, 1986. During treatment periods, mice were principally
under my care, with assistance from the staff of the Biomedical Research Facility,
Western General Hospital'. Treatments involved variations in dietary composition,
adrenalectomy (Adx), corticosteroid replacement via subcutaneous mini-pump (MP)
and mild restraint in metabolic cages. Animals were observed regularly for changes
+
Surgical procedures were carried out by Dr. Chris J. Kenyon.
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in bodyweight, food and fluid intake, and in some experiments urinary and faecal
output were also measured. Daily urine and faecal samples were stored at -20°C until
required for electrolyte analysis.
2.2.1.2 Killing and Harvesting of Tissues
At the conclusion of experiments, blood samples were collected by cardiac puncture
rapidly after initiation of terminal halothane-induced anaesthesia by Dr. Chris J.
Kenyon. Blood samples were centrifuged, plasma was removed, put on ice and
rapidly stored at -20°C. Tissues were removed by dissection and quickly frozen on
dry ice. Tissue samples were stored thereafter at -80°C.




Aldosterone RIA was performed using a commercially available kit (Coat-A-Count
Aldosterone, DPC, USA). A range of concentrations of aldosterone was prepared (0-
3,300 pmol/1) to allow the construction of a standard curve. Standards and samples
were incubated in duplicate in aldosterone-specific antibody coated polypropylene
19 S
tubes with I Aldosterone (1ml per sample) at room temperature for 18 hr. Two
19 S •
tubes were prepared with only I Aldosterone solution to document the total counts
19 S #
used per incubation, and two with a mixture of I Aldosterone and steroid free
buffer to estimate non-specific binding. The tubes were decanted thoroughly before
being counted in a y-counter and the concentration of aldosterone in the samples
estimated by comparison with the standard curve (y counts/min vs. pmol/L
aldosterone). The inter- and intra-assay coefficients of variation were <15% and
<10% respectively.
2.2.2.2 Corticosterone Radioimmunoassay*
Plasma samples were diluted tenfold with diluent buffer. A range of corticosterone
concentrations (0-320nM) was prepared to allow construction of a standard curve.
* Corticosterone and renin assays were carried out by Dr. Chris J. Kenyon.
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After heating samples at 80°C for 30 min to denature corticosterone binding
globulin, aliquots (25pi) of diluted plasma were incubated with the rabbit RIA
antibody to corticosterone (final dilution 1:40,000), [1,2,6,7- H]-corticosterone
(specific activity 2.8-3.9 TBq/mmol; final concentration 1.5nM) and scintillation
proximity assay (SPA; anti rabbit) reagent (25pi diluted suspension) in a final
volume of lOOpl diluent buffer. After incubation overnight at room temperature,
samples and standards were counted in a p-counter (LKB Wallac Microbeta counter)
and the concentration of corticosterone in each sample was determined from the
standard curve (P-counts/min vs. nmol/L corticosterone). Intra- and inter-assay
coefficients of variation were 9.4 and 9.2% respectively. In this assay, in comparison
with corticosterone (100%), the cross-reactivities for progesterone,
RO
deoxycorticosterone and Cortisol are 7.7, 6.5 and 5.3 %, respectively .
2.2.2.3 Renin Radioimmunoassay
Plasma for assay of renin was aliqouted (to avoid excessive freeze-thawing) and
treated with great care to avoid protein degradation or unwanted enzyme activity on
endogenous substrate.
Plasma renin concentration (PRC) measures the generation of Angiotensin I (Ang I)
when plasma is incubated with excess angiotensinogen, derived from rat plasma
where angiotensinogen is high and renin absent (after bilateral nephrectomy: BNX
(plasma)). A typical Ang I generating system for measuring PRC involves 9ul BNX
to which lul of plasma sample is added (which may be prediluted five-fold to ensure
the assay has angiotensin in clear excess).
Plasma renin activity (PRA) measures Ang I generated from endogenous renin and
endogenous angiotensinogen. The Ang I generating system is simply the undiluted
sample plasma.
A range of concentrations of Ang I standards (0-400pg/10p.l) prepared with Tris
buffer allowed the construction of a standard curve. 10p.l ofAng I generating system
or standards was then added to 10pl of anti-Angiotensin I in RIA cups in
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quadruplicate at 0°C and centrifuged at 2000rpm for lmin. Two of the four cups
were incubated and shaken for 30 min at 0°C ('cold' standards and samples), whilst
the remaining two cups were incubated and shaken at 37°C ('hot' standards and
samples). All cups were subsequently placed on ice, and 150pl of Tris, containing
19S
approximately 4000-5000 cpm I-Angiotensin I, was added to each cup. All cups
were briefly shaken and incubated at 2°C for 18h. 250pl of charcoal suspension was
then added to each cup and centrifuged at 3000rpm for 15 min at 4°C. The
supernatant was aspirated fully and the free charcoal pellet was counted in a y-
counter. A standard curve converting y-count rate to AngI concentration was
constructed using values obtained for the standards and the concentration ofAng I in
the 'hot' and 'cold' samples were determined by comparison with this curve (y-
counts/min vs. ng/ml AngI). To calculate sample renin level (whether PRA or PRC),
the average 'hot-cold' AngI generated was determined for each sample and
expressed as ng Angl/ml plasma/hr.
2.2.2.4 Protein Estimation Assay
The protein concentrations of tissue homogenates were determined colorimetrically
using a Bradford Protein Assay Reagent (Bio-Rad, UK). A range of protein standards
(0.05-0.5mg/ml) was prepared in duplicate in lysis buffer from the provided protein
standard (BSA). Bradford Protein Assay Reagent was diluted 1:5 in dPEC). Diluted
Bradford Protein Assay Reagent (200pl) was added to protein standard (1 Opl) or
appropriately diluted tissue homogenate/lysate in a 96-well plate, mixed and left at
room temperature for 20 min to allow colour development. Absorbance of samples at
A,570nm (A570) was measured using an ELISA (Enzyme linked immunosorbent
assay) plate reader, and the concentration of protein in each sample was estimated by
comparison with the standard curve (A570 vs. mg/ml protein concentration).
2.2.3 RNA Extraction
Total RNA was extracted from tissues using TRIzol® Reagent (Invitrogen) - a
mono-phasic solution containing phenol and guanidine isothiocyanate. This reagent
maintains RNA integrity whilst disrupting cells and dissolving cell components.
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2.2.3.1 Tissue Homogenisation
Immediately prior to RNA extraction, tissues were fragmented, whilst still deep
frozen, on dry ice to increase the surface area of tissue exposed to TRIzol® and aid
homogenisation. 1ml TRIzol® was added per 50mg tissue whilst frozen and samples
were homogenised on ice using a mechanical homogeniser; homogenising
intermittently to avoid any sample heating.
2.2.3.2 Phase Separation
Following homogenisation, samples were allowed to equilibrate to RT then left for 5
min to allow complete dissociation of the nucleoprotein complexes. 0.2ml
Chloroform per ml TRIzol® used in original homogenisation was added to each
sample. Samples were mixed by repeated inversion for 15 sec then incubated at RT
for 3 min. Samples were centrifuged at 12,000g for 15 min at 4°C resulting in a
lower red phenol-containing phase (containing proteins), an interphase (containing
DNA and denatured proteins) and an upper aqueous phase containing RNA.
2.2.3.3 RNA Precipitation
The upper aqueous phase from each sample was transferred into a fresh Eppendorf
and the RNA was precipitated by addition of an equal volume of isopropanol.
Following addition of isopropanol, samples were incubated at RT for 10 min prior to
centrifugation at 12,000g for 10 min at 4°C. The RNA precipitate forms a visible gel¬
like pellet on the side of the tube.
2.2.3.4 RNAWash
Following centrifugation the supernatant was removed and the RNA pellet was
washed with 1ml 75% ethanol (per ml TRIzol® in original homogenisation). Pellets
were vortexed and centrifuged at 7000g for 5 min at 4°C.
2.2.3.5 RNA Resuspension
Following the RNA wash, the ethanol was removed and the pellets were briefly air-
dried on ice for 5 min, being careful not to completely dry out the RNA, which
greatly reduces solubility. RNA pellets were resuspended in 200-500pi DEPC-
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treated water (volume depending on pellet size). RNA was then ethanol-precipitated
by adding 3M sodium acetate pH 5.2 (0.1 x sample volume) and 100% ethanol (2.5 x
sample volume). Ethanol-precipitated RNA was stored at -20°C until required.
2.2.3.6 RNA Quantification
Before use, RNA was quantified using a GeneQuant RNA/DNA Calculator. 10pi of
each RNA sample was precipitated by centrifugation at 12,000g for 10 min at 4°C.
Supernatant was removed and the RNA pellet was washed with lOOpl 75% ethanol.
The pellet was vortexed and centrifuged at 12,000g for 5 min. Following the RNA
wash, the ethanol was removed, the pellet was briefly air-dried on ice and
resuspended in lOOpl TE buffer (pH8.0). The absorbance at >„260nm (A260) and
^280nm (A280) was determined to assess concentration and purity. Only RNA with
a A260/A280 of 1.8-2.0 was used.
2.2.4 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
2.2.4.1 Reverse Transcriptase Reaction
First strand cDNA synthesis was performed using a Reverse Transcription System
(Promega, A3500). lpg of total RNA was precipitated by centrifugation at 12,000g
for 10 min at 4°C. Supernatant was removed and the RNA pellet was washed with
lOOpl 75% ethanol. The pellet was vortexed and centrifuged at 12,000g for 5 min.
Following the RNA wash, the ethanol was removed, the pellet was briefly air-dried
on ice and resuspended in 7.4pl DEPC-treated water. This RNA sample was then
denatured at 75°C for 3 min in a reaction mixture containing lx reverse transcription
buffer, 8U RNasin and 0.2pg random primers, and then immediately snap-cooled on
ice. A second mixture containing lx reverse transcription buffer, 5mM MgCk, 16U
RNasin, ImM each of dATP, dCTP, dGTP and dTTP, and 15U AMV-reverse
transcriptase, was added to the denatured RNA sample. This was then reverse
transcribed by incubating at 28°C for 15 min, followed by 42°C for 60 min.
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2.2.4.2 PCR Reaction
Forward and reverse oligonucleotide primers were designed to target mouse mRNA
sequences of interest, based upon published sequences made available through the
nonredundant Genbank/EMBL, EST and mammalian genome databases all publicly
accessible via websites such as that of NCBI (National Centre for Biotechnology
Information, National Library ofMedicine, Bethesda, MD, EISA.) and former HGMP
(Human Genome Mapping Project, Hinxton, UK) with their useful sequence analysis
and BLAST search facilities.
5pl of cDNA template (diluted 1:20 in DEPC-treated water) was used in each PCR
reaction containing lx DNA polymerase Reaction Buffer (containing 2.5mM MgCE)
and made up to a final volume of 25pi with DEPC-treated water. A second mixture
containing lx DNA polymerase Reaction Buffer (containing 2.5mM MgCE), lOOpM
dNTP (dATP, dCTP, dGTP and dTTP; Promega U1420), 15pmol forward primer,
15pmol reverse primer and 1.25 U Taq DNA Polymerase (5U/pl; Promega, M2865)
was made up to 25pl in DEPC-treated water. A negative control reaction containing
DEPC-treated water rather than cDNA template was performed in parallel to detect
any contamination of PCR reagents generating PCR products.
PCRs were performed on an Eppendorf Mastercycler Gradient with a heated lid (set
to 110°C). The templates in the first 25pl PCR buffer mixture were heated to 95°C
for 3 min for initial denaturation, incubated on ice for 1 min before the addition of
the remaining 25 pi containing Taq polymerase. All samples then underwent 30-40
cycles of PCR amplification (denaturation at 95°C for 1 min, primer annealing at
60°C (unless otherwise specified) for 1 min and elongation at 72°C for 2 min). Upon
completion of the PCR programme, samples were incubated at 72°C for a further 10
min to ensure elongation of products to full length and chilled to 4°C prior to gel
electrophoresis.
2.2.4.3 Gel Electrophoresis
RT-PCR products were analysed by agarose gel electrophoresis. Gels were prepared
by melting 0.8-1.2% (w/v) agarose in 0.5x TBE and adding lpl/lOOml of ethidium
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bromide (10 mg/ml). After pouring into a gel mould with appropriately sized combs
in place, gels were allowed to set at room temperature then placed in 0.5x TBE in a
gel tank.
lpl DNA ladder (Invitrogen, 15615-016 (1Kb) or 15628-019 (lOObp)) was mixed
with 2pi loading buffer (loading buffer A was most commonly used; the use of
loading buffer A or B was determined by the size of the expected PCR product) and
9pl DEPC-treated water and loaded into the first well on each gel to allow
determination of PCR product size. lOpl of each RT-PCR product was mixed with
2pl loading buffer and loaded into individual wells in the gel. Gels were
electrophoresed at 100V until the loading buffer band was approximately 3A of the
way down the gel and were then photographed under UV light at k254nm.
2.2.5 Real-time PCR
Real-time PCR exploits the 5'-3' exonuclease activity of Taq DNA Polymerase to
cleave a probe during the PCR reaction. The Taxman® probes used in our studies
incorporate 6-carboxyfluorescin (FAM) reporter dye covalently attached at the 5'
end and 6-carboxytetramethyrhodamine (TAMRA) quencher dye attached via a
linker arm at the 3' end. When the probe is intact, the proximity of the reporter dye to
the quencher dye results in suppression of the reporter fluorescence. During the PCR
reaction, if the target of interest is present the probe specifically anneals between the
forward and reverse primer sites. The 5'-3' exonuclease activity of Taq DNA
Polymerase then cleaves the probe separating the reporter dye and the quencher dye,
which results in increased fluorescence of the reporter. Accumulation of PCR
products is detected directly using the ABI PRISM 7900 Sequence Detection
System, which monitors the increase in fluorescence of the reporter dye. The cleaved
probe fragments are displaced from the target, and polymerisation of the strand
continues. This process occurs in every cycle and does not interfere with the
exponential accumulation of product. The increase in fluorescence signal is detected
only if the target sequence is complimentary to the probe and is amplified during
PCR. Because of these requirements, any non-specific amplification is not detected.
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cDNA pool cDNA sample
1:40 dilutions
cDNA standards
1:10, 1:20, 1:40, 1:80
Figure 2.1: Schematic representation of real-time PCR set-up. cDNA standards were
prepared from a pooled aliquot of all cDNA samples. cDNA (standards and samples) and
assay mastermix were transferred to a 96-well plate from which they were aliquoted into a
374-well reaction plate using a multichannel pipette.
Data analysis was carried out using Sequence Detection Systems (SDS) software.
Before analysing data the baseline and threshold values are adjusted. The baseline is
a range of cycles before genuine amplification of PCR product is detected and is set
so that the initial amplification curve begins at a cycle that is greater than the
maximum value of the baseline. SDS software uses a default range of cycles 3-15 to
establish the baseline, which may be adjusted if necessary. Once the baseline range is
determined, the threshold value is automatically set at 10 standard deviations above
the mean baseline fluorescence within the exponential phase of the logarithmic scale
amplification plots. The threshold can be adjusted manually if necessary. The cycle
number at which a PCR amplification plot crosses this threshold is known as the Ct
value for the sample. The Ct value is predictive of the quantity of input cDNA. The
more of the target gene present in the sample the earlier it will be detected in the
PCR cycles and the lower the Ct. A standard curve is constructed using serial
dilutions of cDNA. Relative target gene mRNA abundance in samples is extrapolated
from the standard curve (CT value vs. target gene abundance) and expressed in
arbitrary units. Target gene data are then normalised to an endogenous control,
TATA-box binding protein (TBP), and calibrated to the control group in the study.
Details of the real-time PCR assays used in this study are described in Table 2.1 and
2.2. PCR cycling conditions are outlined below.
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PCR was performed in a lOpl reaction mixture containing 5.0pl of TaqMan
Universal PCR Master Mix (Applied Biosystems, Foster City, CA), 200nM of each
primer, 5nM probe, 4.5pl of template (1:40 dilution of cDNA synthesised as
described in section 2.2.4.1) in 384 well plates (Figure 2.1). In order to generate a
standard curve; an aliquot of cDNA from each sample was collected and used to
form stock cDNA. Serial 1:10 dilutions of the stock cDNA were included as standard
samples on the plate in a similar manner to test samples. Non-template negative
controls were also constructed by substitution of nuclease-free water for cDNA. Each
sample was assayed in duplicate or triplicate. Thermal cycling conditions comprised
an initial denaturation step at 95°C for 10 min and 40 cycles of; 95°C for 15 sec and
60°C for 1 min.
Table 2.1: Primer and probe sequences for real-time assays by design.





























Table 2.2: Real-time assays on demand.
GENE ASSAY Accession No. Exon boundary Assay position
cHKA Mm00446786_m1 NM_138652.1 15-16 2410
NCC Mm00490213_m1 NM_019415.1 19-20 2370
OSR1 Mm01351757_m1 BC046453.1 1-2 316
ROMK-T Mm00444727_s1 NM_019659.2 2-2 931
SPAK Mm00444101_m1 NM_016866.2 1-2 352
TBP Mm00446973_m1 NM_013684.1 3-4 523
2.2.5.1 Evaluation of TBP as an Endogenous Control in Kidney.
An endogenous control is used to normalise the expression levels of target genes by
correcting for potential differences in starting amounts of cDNA, in techniques such
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as real-time PCR. It is important to demonstrate that while expression levels of the
target may range widely, that of the endogenous control remains constant. Thus,
when conducting this test, it is crucial to load identical amounts of cDNA for each
test sample.
In order to confirm the uniformity of TBP expression in our samples, we introduced
a known concentration of a specific RNA transcript into each of our RNA samples
prior to reverse transcription, to act as an exogenous control using the following
method. The Drosophila gene, Wingful (WF; NM_079995/AY078993), was selected
as our RNA spike to avoid any sequence homology with mammalian transcripts
(confirmed by a series ofBLAST searches).
A fly homogenate was prepared by homogenising 10 flies in 500pi TRIzol®
Reagent. A further 500pl TRIzol® Reagent was added to the homogenate prior to
RNA extraction as outlined in section 2.2.3. To collect a pure aqueous RNA phase
free from exoskeletal components, the phase separation step was performed twice.
Drosophila cDNA was synthesised as described in section 2.2.4.1 and a WF
transcript was amplified by PCR (conditions as outlined in section 2.2.4.2). Flanking
T3 and T7 phage polymerase consensus sites were introduced by nested PCR
(conditions as outlined in section 2.2.7.3.1; see Table 2.3 for primer sequences). The
resulting WF PCR fragment was purified using a QIAquick PCR Purification Kit and
concentrated in a DNA speed vac. Recovery of the DNA fragment was assessed by
electrophoresis of lpl of the DNA solution through an agarose gel as described in
section 2.2.4.3 and a Low DNA Mass Ladder (Invitrogen, 10068-013) was used to
determine approximate DNA concentration. WF RNA was transcribed in vitro at
37°C for 2 hr in a reaction containing -1.2-1.6 pg cDNA, 2mM ATP, CTP, GTP and
UTP, lOmM dithiothreitol (DTT), 2.5pl RNasin, and 2.35pl T3 RNA polymerase (40
units) in a total volume of lOOpl lx transcription optimised buffer. Following
incubation, 2pl RQ1 DNase (RNase free; Promega, P118B) was added and reactions
incubated at 37°C for a further 15 min to degrade the DNA template, after which
reactions were placed on ice and purified using NICK columns. The column was
prepared by washing through with 3ml TE buffer (pH 8.0). The transcribed RNA
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mixture was then applied to the column. The column was washed with 400pl TE
buffer and the initial elutant discarded. The transcribed RNA was eluted in an
additional 400pl TE buffer, aliquoted and stored at -80°C until required. RNA
concentration was quantified (0.014pg/pl) using a GeneQuant RNA/DNA Calculator.
WF RNA was introduced into experimental RNA samples prior to reverse
transcription (described in section 2.2.4.1) by spiking the H2O used in this reaction
with WF RNA (1:10,000 dilution, ~lpg Wingful RNA per reverse transcription
reaction). As the concentration ofWF present in each sample was constant, we were
able to assess the uniformity of TBP gene expression by real-time PCR, by
comparing it to that ofWF.
Preliminary work showed TBP to be an excellent control for gene expression in
kidney, showing no significant variation over a range of relevant and comparable
treatments (dietary and induced hormone changes).
2.2.6 Northern Analysis of RNA
2.2.6.1 RNA Electrophoresis and Capillary Transfer
Total RNA was separated by electrophoresis on a 1.2% agarose formaldehyde
denaturing gel. A 100ml gel was prepared by melting 1.2g of agarose in 73ml DEPC-
treated water and lOx MOPS buffer (10ml), and adding 17ml formaldehyde before
pouring into a gel mould with appropriately sized combs in place. RNA was prepared
for electrophoresis by precipitating 15pg of RNA by centrifugation at 12,000g for 20
min at 4°C. Supernatant was removed and the RNA pellet was washed with 100pl
75% ethanol. The pellet was vortexed and centrifuged at 12,000g for 10 min.
Following the RNA wash, the ethanol was removed, the pellet was briefly air-dried
on ice and resuspended in 15pl RNA sample buffer. The RNA sample was denatured
by incubation at 65°C for 10 min and snap-cooled on ice for a further 10 min. 4pl
sterile Type III loading buffer and 0.5pl ethidium bromide (10 mg/ml) was added to
each sample of denatured RNA. The RNA was loaded into the wells on the gel and
electrophoresed in lx MOPS buffer in a gel tank at 90V for 4-6 hr, until the front
band of the loading buffer was % of the way down the gel. The gel was photographed
under UV light (X = 254nm) with as little exposure as possible to minimise RNA
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damage. The presence of intact 28S, 18S and 5S Ribosomal RNA bands indicated
that the integrity of the RNA was intact. The gel was soaked for two 10 min intervals
in lOx SSC buffer for 10 min before blotting onto a nylon membrane. A wick of
Whatman 3MM chromatography paper was placed over an upturned gel mould in a
plastic tray containing lOx SSC buffer and the gel placed on top (upside down). A
piece of nylon membrane cut to the same size (prewetted) was smoothed on top of
the gel and this was covered with 3 layers of 3MM filter paper and approximately
10cm of paper towels. A glass plate and light weight was placed on the top to secure
the apparatus, and a builder's spirit level was utilised to ensure "evenness" of the
tower. Capillary transfer was allowed to take place overnight at room temperature.
The following day, the membrane was removed and washed in 2x SSC to remove
any gel fragments and the efficiency of transfer checked by photographing both the
gel and the membrane under UV light (A, = 254nm). The membrane was air-dried for
~15 min and cross-linked by baking for 2 hr at 80°C between two sheets of 3MM
Chromatography paper. Membranes were stored at 4°C until required.
2.2.6.2 Hybridisation to 32P-labelled cDNA
The membrane was placed in a Techne hybridisation bottle containing 20ml
hybridisation buffer (0.5M NaP04/7% SDS) that had been pre-heated to 65°C
(Techne Hybridiser HBID). Denatured Salmon testes DNA (lOmg/ml; 200pl) and
denatured yeast tRNA (50 mg/ml; 8pi) was then added to this. The membrane was
prehybridised in a Hybaid hybridisation oven at 65°C for a minimum of 2 hr. The
•29
P-labelled cDNA probe (prepared as described in section 2.2.6.3) was denatured
before use by heating to 100°C for 10 min, followed by snap-cooling on ice for 10
min. Denatured probe was added directly to the hybridisation buffer
(1.5xl06counts/ml hybridisation buffer) and the membrane was hybridised with the
probe overnight at 65°C. The probe was then disposed of and the membrane was
rinsed with wash buffer A. This was followed by a further two washes in the same
wash buffer at 65°C for 10 min. The level of radioactive signal remaining on the
membrane was checked and if this was too high the membrane was washed 1-2 times
in wash buffer B at 65 °C for 10 min. If necessary, a super high stringency wash was
carried out 1-2 times in wash buffer C at 68°C for 10 min. The membrane was
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wrapped in parafilm and exposed to a Fujifilm imaging screen for between 5 min-24
hr and the level of hybridised probe quantified using a Fuji FLA2000
phosphoimager. Membranes were also exposed to Kodak Biomax MS film at -70°C
for 1-7 days.
Membranes were stripped after probing by a 20 min wash with boiling 0.1% SDS.
Stripping was confirmed by exposing the membrane to Kodak Biomax MS film at -
70°C overnight.
2.2.6.3 Preparation of 32P-labelled probes
2.2.6.3.1 Preparation of cDNA templates by PCR
cDNA templates were prepared by PCR (as described in section 2.2.4.2) for various
genes of interest, to be used subsequently for the synthesis ofDNA probes for use in
Northern hybridisations. Prior to use as cDNA templates for probe generation, all
PCR products were purified using either a QIAquick PCR Purification Kit or a
QIAquick Gel Extraction Kit (Qiagen, Crawley, UK). Using the second purification
method, the sample was first electrophoresed on a low melting point agarose gel
(made as in section 2.2.4.3 but using low melting point agarose). The DNA fragment
was visualised under UV light, excised from the gel using a scalpel, purified from the
gel using the QIAquick Gel Extraction Kit and resuspended in 50pi DEPC-treated
water. DNA fragments were concentrated in a DNA speed vac. Recovery of the
DNA fragment was assessed by electrophoresis of 1 pi of the DNA solution through
an agarose gel as described in section 2.2.4.3.
2.2.6.3.2 32P-Labelling of cDNA
Rediprime® II (RPN1633/4, Amershctm) random primed DNA labelling kit was used
to label the DNA fragments. Approximately 20ng of DNA template was aliquoted
into an Eppendorf, made up to 45pi with sterile TE buffer and denatured at 100°C for
10 min, and snap-cooled on ice for a further 10 min. In the meantime, 5pi [a32P]-
dCTP was added to the Rediprime"8 pre-mix to allow maximum rehydration of the
lyophilised mix, and incubated at room temperature. The denatured probe was added
to the rehydrated Rediprime® mix by pipetting -12 times and incubated at 37°C for
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30 min. Unincorporated radioactivity was removed by passing the mixture through a
NICK column. The NICK column was prepared by washing with 3ml TE buffer
(pH8.0) before application of the mixture. The column was washed with 400j.il TE,
the elutant discarded and the labelled DNA eluted from the column with a further
400pl TE. The probe was precipitated by adding 2pl tRNA (50 mg/ml), 40pl 3M
sodium acetate pH5.2 and 1126pl 100% ethanol (cold), and centrifuging at 12,000g
for 15 min. Supernatant was removed and the pellet was washed with lOOpl 75%
ethanol. The pellet was vortexed and centrifuged at 12,000g for 5 min. The ethanol
was then removed, the pellet was briefly air-dried and resuspended in 400j.il TE
buffer (pH8.0). The activity of the probe was assessed by mixing 4pi of probe with
400pl of PicoFluor 40 scintillant fluid and counting in a P-counter. The probe was
used if the specific activity was greater than 15,000cpm/pl.
2.2.7 35S In Situ Hybridisation
In situ hybridisation (ISH) allows the visualisation of the exact cellular and/or
structural location of specific mRNAs (indicating transcription of the corresponding
gene) by hybridisation of a 33S-labelled 'antisense' RNA probe to the mRNA of
interest. 3?S-UTP labelled RNA 'sense' probes of similar length, nucleotide content
and specific activity were included in experiments in order to assess the specificity of
the hybridisation seen.
Only RNase free, sterile solutions and equipment were used for ISH experiments in
order to prevent degradation of target mRNA by exogenous RNases.
2.2.7.1 Slide Preparation
Prior to use, glass microscope slides were coated in 3-aminopropyltriethoxysilane in
order to prevent section dehiscence. Slides were racked and washed in the following
series of solutions; 0.2M HC1 for 3 min, DEPC-treated water for 3 min, 2% 3-
aminopropyltriethoxysilane in acetone {Sigma, A3648; dehydrated by filtering
through NaSCE) for 10 sec, acetone for 3 min (twice), and finally DEPC-treated
water for 3 min. Slides were air-dried for 30-60 min before baking at 50°C for 4-16
hr. Dried slides were wrapped in aluminium foil and stored for up to 3 months.
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2.2.7.2 Tissue Section Preparation
Tissues were routinely frozen on dry ice immediately after dissection from the
animal and stored at -80°C until required.
Frozen tissue sections were cut using a Leica cryostat. Tissues frozen at -80°C were
placed in the cryostat chamber at -20°C and allowed to equilibrate for approximately
30 min. Following equilibration, tissues were embedded in Cryo-m-bed embedding
compound and positioned in the correct orientation for sectioning. 10pm thick
sections of tissue were transferred to aminopropyltriethoxysilane-coated slides, and
stored at -80°C until required.
2.2.7.3 Synthesis of 35S-UTP Labelled Ribo-Probes
2.2.7.3.1 Preparation of cDNA templates by PCR
cDNA templates were prepared for various genes of interest, to be used subsequently
for the synthesis of RNA probes for ISH analysis, using a nested PCR method.
Firstly, the standard PCR method outlined in section 2.2.4.2, was used to generate an
initial PCR product. When abundant clean product of expected size was generated,
1/400 and 1/8000 dilutions were made and used as templates in a second 'floppy'
PCR where primers included 5' extensions containing phage polymerase consensus
sites, with sense and antisense primer pairs incorporating T3
(TCTAGATTAACCCTCACTAAAGGGA) and T7
(GGATCCTAATACGACTCACTATAGGG) sites, respectively. The 'floppy' PCR
program used 5 cycles of [45 s at 95°C, 45 s at 55°C, 120 s at 72°C], followed by 30
cycles of [45 s at 95°C, 45 s at 69°C, and 120 s at 72°C], and finally 10 min at 72°C.
The dilution (1/400 or 1/8000) that produced the cleanest 'floppy' PCR product was
used to generate a probe template stock.
Prior to use as cDNA templates for probe generation, all PCR products were purified
using either a QIAquick PCR Purification Kit or a QIAquick Gel Extraction Kit
(Qiagen, Crawley, UK). Using the second purification method, the sample was first
electrophoresed on a low melting point agarose gel (as in section 2.2.4.3 but using
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low melting point agarose). The DNA fragment was visualised under UV light,
excised from the gel using a scalpel, purified from the gel using the QIAquick Gel
Extraction Kit and resuspended in 50pl DEPC-treated water. Recovery of the DNA
fragment was assessed by electrophoresis of lpl of the DNA solution through an
agarose gel as described in section 2.2.4.3.
2.2.7.3.2 35S-UTP-Labelling of cDNA
0.5-lpg of cDNA template (prepared as described in section 2.2.4.1) was transcribed
by incubation at 37°C for 60-90 min in a reaction mixture containing ImM ATP,
CTP and GTP, 4pl 35S-UTP (1.48 MBq/pl), lOmM dithiothreitol (DTT; Sigma,
D9779), 0.4pi RNasin (40U/pl; Promega, N211A), and lpl appropriate RNA
polymerase (T3, sense (17U/pl; Promega, P208C); T7, antisense (20U/pl; Promega,
P207C)) in a total volume of lOpl lx transcription optimised buffer. Following
incubation, lpl DNase 1 (RNase free) was added and reactions incubated at 37°C for
a further 10-15 min to degrade the DNA template, after which probes were placed on
ice for 1-5 min and purified using NICK columns, to remove unincorporated
radioactivity. The column was prepared by washing through with 3ml TE buffer (pH
8.0). The probe mixture was then applied to the column. The column was washed
with 400pl TE buffer and the initial elutant discarded. Labelled probe was eluted in
an additional 400pl TE buffer.
For each probe, the total activity was estimated by counting lpl of probe in 1ml
PicoFluor 40 scintillant fluid in a P-counter (minimum activity required 2x105 cpm/
pi). The purity of each probe was determined by running an aliquot (typically 0.5-
lxl06 counts) on a urea-5.3% acrylamide gel and exposing the gel to Kodak Biomax-
MR film (HA West Ltd, Edinburgh, UK). High quality probes should produce a
single black band on the developed film. Probes were stored at -20°C until required,
for up to 3-4 weeks.
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2.2.7A Fixation Protocol
Slides were removed from the -80°C freezer and kept on dry ice until the start of the
fixation procedure. Slides were fixed in ice cold 4% paraformaldehyde in 0.1M
phosphate buffer for 10 min (maintains tissue morphology and inhibits endogenous
ribonucleases). Slides were rinsed twice in lx PBS for 5 min, acetylated in 0.1M
triethanolamine with 0.25% acetic anhydride for 10 min (reduces non-specific
binding of the probe to positively charged amino groups in tissues) and rinsed in lx
PBS for 3 min. Following dehydration through a series of ethanol solutions (70, 80
and 95% ethanol in DEPC-treated water) slides were air dried for 30 min.
2.2.7.5 Prehybridisation and Hybridisation Steps
Following fixation, slides were pre-hybridised with 200p.l/slide of 2x pre¬
hybridisation buffer diluted 1:1 with deionised formamide, at 50°C for 2 hr.
Dampening two layers of Whatman 3MM chromatography paper with box buffer A
humidified the slide boxes, hence preventing tissue sections from drying out.
Sense and antisense probes were thawed and added to 2x hybridisation buffer diluted
1:1 in deionised formamide to give a final probe concentration of lOxlO6 cpm/ml.
Probes were denatured at 75 °C for 10 min and snap-cooled on ice before addition of
1 OmM DTT. Pre-hybridisation buffer was drained from slides and 200pl appropriate
probe in hybridisation buffer was applied to slides. Slides were hybridised in sealed,
humidified boxes at 50°C for an optimum of 16 hr.
2.2.7.6 RNase Treatment and Washes
Following hybridisation, slides were washed three times in 2x SSC for 5 min and
carefully wiped dry around the sections with lens tissue. 200pl of RNase A (30pg/
ml in box buffer B) were applied to each slide and slides were incubated at 37°C for
1 hr in humidified boxes (1 layer of Whatman 3MM chromatography paper
dampened with box buffer B) to remove unhybridised probe.
Following RNase treatment, slides were washed in 2x SSC at room temperature for 1
hr, then in O.lx SSC at 60°C for 1 hr, and finally in O.lx SSC heated to 60°C and
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allowed to cool to room temperature for the duration of the wash (1 hr). After
washes, slides were dehydrated through a series of ethanol solutions containing 0.3M
ammonium acetate (2 min in each of 50, 70 and 90% ethanol) and air-dried.
2.2.7.7 Visualisation of Hybridisation
Slides were exposed to Kodak Biomax-MR film for 1-10 days. 14C-microscales were
included with each exposure to calibrate autoradiograph greyscales in the image
analysis process. Afterwards, slides were individually dipped in NTB-2 photographic
emulsion (diluted 1:1 with water at 42°C) and exposed in light-tight boxes for a
period of 1 day to 5 weeks at 4°C. Slides were developed in D19 solution (diluted
1:1 with water) at 15°C and fixed in Amfix solution (diluted 1:5 with water at 15°C)
and rinsed in water.
2.2.7.8 Image Analysis
For image analysis autoradiographic films were scanned on a high resolution flatbed
scanner and any damaged or inadequate sections were excluded. Dipped slides were
visualized using a Zeiss microscope and images were captured using a Dage MTI
CCD72S imaging camera and Zeiss Contron KS400 software. Digital image analysis
was performed using custom-written applications within the environment of the
Image Processing Toolkit ofMATLAB® version 7 (The Mathworks. Inc. MA) using
16-bit grayscale TIFF images, and scaling across an intensity range from O(black)-
65535(white). This allows semi-quantitative image analysis of autoradiographic
films and dipped emulsion slides from ISH studies measuring the areas and grayscale
intensities (or silver grain densities) as an index of expression level. Measured
grayscale levels are converted to equivalent dpm of bound radioactive probe by
calibrating from co-exposed 14C-microscales specifically designed for this purpose
(RPA511 [10 levels between 3.7-3635MBq/g] and RPA504 [8 levels between 1110-
31890MBq/g]; Amersham). Alignment of consecutive sections involved systematic
rotation and linear displacement of one image relative to the next calculating their
normalized cross-correlation and iteratively proceeding to find the optimal
alignment, where this value is a maximum. The aligned images could then be
displayed as different red and green channels of a single overlaid merged image. The
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software was useful in facilitating selection of regions (typically complex shapes
delineated by an expression threshold contours) showing expression highly
significantly above background levels. The threshold expression levels (or level)
above which expression was to be included for analysis were entered on graphical
sliding scales, each of which plotted an expression contour line at the threshold
value. Regions within the contour (having expression above threshold) were analysed
to calculate area, average expression in grayscale and Bq/g derived from scaling
units via automatic calibration using the microscales. Background was low with
sense section backgrounds having a greyscale level not significantly different to zero.
2.2.8 Western blotting
Antisera were tested for the ability to detect WNK1 and WNK4 by western blotting.
Soluble and insoluble protein fractions were prepared from kidney homogenate as
described below and the protein concentration estimated using the protein estimation
assay described in section 2.2.2.4.
2.2.8.1 Preparation of tissue homogenates
Kidneys were removed from storage at -80°C, roughly dissected while frozen, added
directly to lysis buffer (~0.5mg tissue per 1ml buffer) and mechanically
homogenised. Homogenates were centrifuged at lOOOrpm for 1 min at 4°C to spin
down insoluble tissue debris. The supernatant was removed and centrifuged for 1 hr
at 14,000rpm at 4°C to separate the soluble protein fraction (supernatant) from the
insoluble protein fraction (pellet). Soluble protein was aliquoted and stored at -80°C
until required. Insoluble protein was resuspended in homogenising buffer (-1/5
original volume) supplemented with 0.1% Triton X-100. Laemmli buffer (4x) was
added to aid resuspension. Pipetting and denaturing at 100°C for -10 min with
intermittent vortexing resuspended the pellet. This insoluble protein fraction was
aliquoted and stored at -80°C until required.
2.2.8.2 Separation and transfer of proteins by SDS-PAGE
1mm thick SDS-PAGE gels were prepared in the vertical electrophoresis system
(Mini-Protean 3 Cell, Bio-Rad). 5% resolving gel was poured between glass plates to
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two-thirds of their height. The surface was covered with water-saturated butanol until
the gel set. The butanol was then washed out and a 4% stacking gel poured on top,
and a comb added and allowed to set.
Samples of 30pg of protein were diluted 1:4 in 4x Laemmli buffer and denatured for
5 min by heating to 99°C, snap-cooled on ice for 5 min and immediately loaded into
separate wells on the SDS-PAGE gel. Samples were electrophoresed in lxLaemmli
(Tris-Glycine) running buffer at 20mA along with molecular weight markers (Bio-
Rad, 161-0374) until the 75kDa marker reached the base of the gel. Proteins are
separated according to their weight, with smaller species migrating further over the
same period. The stacking gel was removed and the resolving gel was pre-soaked in
cold transfer buffer, along with Hybond ECL™ Nitrocellulose Membrane, for 15 min.
Proteins were then transferred to the membranes by electroblotting (Mini Trans-Blot
Electrophoretic Transfer Cell, Bio-Rad) in cold transfer buffer at 250mA for 3 hr at
4-7°C. Complete transfer was verified by the loss of marker dyes from the gel.
2.2.8.3 Membrane staining
Membranes were stained in 0.1% Ponceau for ~1 minute (until clear bands were
visible) and washed briefly in dH20 to remove excess stain. Membranes were then
placed on a glass plate and cut into strips as required, and destained in 400pM NaOH
for ~1 minute (until stain disappears), washed by dipping briefly in dH20 and
neutralised in lxPBS.
2.2.8.4 Blocking membranes & antibody preparations
Membranes were transferred to dishes containing blocking solution and left
overnight at 4°C (or 1 hr at room temperature) on an orbital shaker (Stuart Gyro-
rocker SSL3) to reduce non-specific binding. Primary antibody dilutions in blocking
solution were added to the membrane for 2 hr at room temperature, followed by 5x 5
min washes in blocking solution on the orbital shaker. Secondary antibody dilutions
in blocking solution were applied to the membrane for 1 hr at room temperature. This
was followed by 3x 10 min washes in lx TBS to remove unbound antibody before
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proceeding to bound antigen visualisation using the Amersham ECL system (see
below).
A second antibody application could be made to the same membrane after the
existing antibody complex had been stripped. Blots were incubated for 1 hr with
stripping buffer on the orbital shaker, washed 3x 5 min in lx TBS, then blocked as
before. Stripping was usually confirmed by ECL™ detection (see below) prior to re¬
use. ECL™ reagents were washed off in lxTBS and stored at -4°C until required.
2.2.8.5 Protein detection and quantification
The antibody complex bound to the membrane was visualised using ECL™
(enhanced chemoluminescence) Western Blotting Detection Reagents (Amersham
Biosciences, RPN106). Secondary antibodies are attached to a horseradish-
peroxidase molecule which catalyses the oxidation reaction of luminol in the
presence of hydrogen peroxide and light is emitted. The light produced exposes
chemiluminescence-sensitive film in areas corresponding to the specific antigenic
protein bands on the membrane. Following the application of secondary antibody and
subsequent 3 washes in lxTBS, 1:1 mixtures of ECL™ Reagent 1 and 2 were applied
to the membrane for 1 min, which was then drained (excess carefully blotted off),
wrapped in transparent film, and placed under Elyperfilm ECL™ for a period of time
sufficient to obtain visible bands. The film was developed using a hyper-processor.
2.2.9 Immunohistochemistry
Immunohistochemistry involves the binding of specific antibodies to target proteins
in tissues, then attaching a visualisation system typically involving a secondary
antibody and a system locally generating an amplified colour reaction (e.g. involving
horseradish peroxidase) which enables their precise cellular localisation.
2.2.9.1 Sectioning
5pm sections were cut using a microtome, floated on a 42°C water bath and
recovered onto SuperFrost Plus slides. Slides were dried at 40°C to heat fix tissue to
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the slides. For fresh-frozen tissue sections were cut and mounted as described in
section 2.2.7.2, and stored at -80°C.
2.2.9.2 Rehydration
To enable the antibody to penetrate the tissue effectively, paraffin section slides were
dewaxed by 2x 5min treatments in xylene, rehydrating through an ethanol series
(100%-95%-70%; 20 sec each), washing in dH^O 2x5min and then in lxPBS
2x5min.
2.2.9.3 Antigen Retrieval
Some antibodies require an extra step termed "antigen retrieval" which assists in
ensuring adequate exposure of the target epitope and enhances immunodetection. For
this purpose rehydrated slides were placed in a pressure cooker, containing either
0.01M sodium citrate buffer or 0.05M glycine/EDTA buffer, boiled under pressure
for 5 min and left to rest in hot buffer for 20 min21. Following antigen retrieval,
slides were washed in lx PBS 3x3min.
2.2.9.4 Antibody Additions
The protocol used involved the sequential application of (1) a primary antibody, (2) a
biotinylated secondary antibody, (3) an avidin horseradish peroxidase (HRP)
complex and (4) a visualisation process whereby colourless DAB (diaminobenzidine
tetrahydrochloride) and H2O2 allow local generation of a brown colour (oxidised
DAB) by HRP revealing when the antigen is within the tissue.
Endogenous peroxidase was blocked in 3% H2O2 in Methanol for lOmin, followed
by washes in lxPBS 3x3min. If a HRP detection system was not used this blocking
step was omitted from the protocol. Endogenous avidin and biotin was blocked using
an avidin/biotin blocking kit (Vector Laboratories, Peterborough, UK). Tissues were
incubated with avidin for 15min, washed in lx PBS for 2min, then incubated with
biotin for 15min and washed in lxPBS for 2min. Non-specific binding between the
tissue and the antibody was blocked by incubating tissues in 1:5goat serum/5%BSA
for 4hr.
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Primary antibodies were diluted in l:5goat serum/5%BSA, added to each slide and
incubated at 4°C overnight. Slides were then washed in lx PBST 3x3min.
Biotinylated secondary antibodies were diluted in l:5goat serum/5%BSA and
incubated at room temperature for lhr. Following this incubation, slides were washed
in lx PBST for 3x3min.
A fresh Avidin-Biotin-HRP complex (ABC Elite, Vector Laboratories, Peterborough,
UK) was then added to each slide for 1 hour at room temperature. This ABC
complex was prepared 30min prior to use by adding 9pl ofABC Elite reagents A and
B to 1ml lx PBS ensuring binding between avidin and HRP.
Slides were then rinsed in lx PBST 3x3min and DAB added following the kit
instructions (Vector Laboratories, Peterborough, UK). This was incubated until a
satisfactory level of brown immunohistochemical stain developed, and then finally
slides were transferred to a dFEO wash for 30-60 sec to stop the reaction.
The ABC technique enables the visualisation of the target protein location. The
complex binds to biotin on the secondary antibody and when hydrogen peroxide
(enzyme substrate) is added, the chemical reaction causes the enzyme to transfer
hydrogen from DAB to the peroxide. The oxidised DAB forms a dark brown
precipitate at the site of enzyme activity.
2.2.9.5 Tissue Staining
Sections were counterstained in haematoxylin (FLO based) and then dehydrated
through a series of ethanol washes (70, 80, 95, 100, 100% ethanol - 20 sec each)
ending finally with 2x5min xylene treatments. Sections then were coverslip DPX
mounted.
2.2.9.6 Immunohistochemistry on fresh-frozen sections
Fresh frozen sections are fixed directly from frozen in 10% Neutral Buffer Formalin
for 10 min and washed in lxPBS 2x5min. Fresh frozen sections do not require an
antigen retrieval step. Endogenous peroxidase is blocked in 0.3%H2O2 in dfUO for 30
min, followed by washing in lxPBS for lOmin. From this stage onwards frozen
sections are treated similarly to paraffin sections.
Chapter 2. Materials and Methods. 62
WNK Kinases: Novel Regulators of Electrolyte Balance and Blood Pressure.
2.2.10 Statistics
Data are expressed as mean±SEM, P<0.05 was considered significant, and
comparisons between groups analyzed by one-way ANOVA and Neuman-Keuls
post-hoc testing, unless otherwise stated. Least significant difference post-hoc test
for planned comparisons (ANOVAlsd) was also used if Neuman-Keuls testing was
borderline non-significant. Changes are routinely expressed as % change
(mean±SEM) relative to control values. Where changes are of a larger scale, they are
expressed as fold change (mean±SEM), again relative to control values, and 95%
confidence intervals are quoted.
Table 2.3: Primer sequences.
TARGET SEQUENCE (5'-3') ORIENTATION PCR USE
yENaC GCCCGTCACAAACATCTACAATGCTGC Sense S -
yENaC CTTGGCCAGGTCAGTCTTGTTGAGC Antisense s -
yENaC tctagattaaccctcactaaagggaTCAGGAACATCTACAACGCTGC Sense N ISH
yENaC ggatcctaatacgactcactatagggCCAGGTCAGTCTTGTTGG Antisense N ISH
cHKA CAGCAGGGGCTCTTCAGAAAC Sense S -
cHKA TTGTCCCACCAGCTTCCAGG Antisense s -
cHKA tctagattaaccctcactaaagggaGCTCTTCAGAAACAAAGTCATC Sense N iSH
cHKA ggatcctaatacgactcactatagggGGACCAGCTTCCAGGGTAG Antisense N ISH
NCC GCATTCATTCCTCAAGCAGGAAGGTAG Sense S -
NCC GGTGTGCCATACTCCTGCAGTAGG Antisense S -
NCC tctagattaaccctcactaaagggaTTCCTCAAGCAGGAAGGTAGC Sense N ISH
NCC ggatcctaatacgactcactatagggTGCCACCCGACTTGACCTTG Antisense N ISH
NKCC2 AAGATGTCGGTCAGCATCCCTTCC Sense S -
NKCC2 CCATCATTGAATCGCTCTCCTTAAGAAGA Antisense S -
NKCC2 tctagattaaccctcactaaagggaCAGTCGCTTTCAGGTCCATG Sense N ISH
NKCC2 ggatcctaatacgactcactatagggCATCGCACCAGCACACCTTTC Antisense N ISH
ROMK1 CACACAACTCCACTCTTGAGTTAACC Sense S -
ROMK1 (Core) GATGTTTGAACATCCTTTCTGTCAGTGC Antisense S -
R0MK1 tctagattaaccctcactaaagggaAGCAAGCATCATTGTGAGGC Sense N ISH
ROMK1 ggatcctaatacgactcactatagggATCAGCACTCTGCACATACAC Antisense N ISH
R0MK2 GCATCCAAACTCTCGAATCAAAGGTG Sense S -
R0MK2 (Core) GATGTTTGAACATCCTTTCTGTCAGTGC Antisense S -
ROMK2 tctagattaaccctcactaaagggaGAATCAAAGGTGCAAGGGAC Sense N ISH
R0MK2 ggatcctaatacgactcactatagggTCATGGATTGCTGGGGTAAAC Antisense N ISH
R0MK3 AGGAAGCTCCATGAAGTGCACC Sense S -
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TARGET SEQUENCE (5'-3') ORIENTATION PCR USE
R0MK3 (Core) GATGTTTGAACATCCTTTCTGTCAGTGC Antisense S -
R0MK3 tctagattaaccctcactaaagggaCACCCTTGACAGGGCTC Sense N ISH
R0MK3 ggatcctaatacgactcactatagggCCTGATCCTTACCGAGTC Antisense N ISH
ROMK-T TCCACRTTTACCCCAGCAATCCATGAG Sense S -
ROMK-T CCCACACATGAAAGAATTGATTATAACTCC Antisense S -
ROMK-T tctagattaaccctcactaaagggaTCAGGGCACTGACAGAAAG Sense N ISH
ROMK-T ggatcctaatacgactcactatagggCCACACAAGGAGTRCGGTTG Antisense N ISH
WNK1-L (EX1) CTTGTCAGTGCTGAGTGGGAGTC Sense S NH
WNK1-L (EX1) CAGATTTTGTTAACTTTCGATCCTGCAATTC Antisense S NH
WNK1-L (EX1) tctagattaaccctcactaaagggaGCAACCTAGTGTACCTGC Sense N ISH
WNK1-L (EX1) ggatcctaatacgactcactatagggTCCACAGTGGTTTCGGTG Antisense N ISH
WNK1-S (EX4a) AGAAACTACTAGTAGCAAAATCCCTGTC Sense S NH
WNK1-S (EX4a) GCTTCACTCCCTCATTTATACAATCC Antisense S NH
WNK1-S (EX4a) tctagattaaccctcactaaagggaGCCAAGCTAAATAGATTGTTG Sense N ISH
WNK1-S (EX4a) ggatcctaatacgactcactatagggCATTTATACAATCCTTTTGAGAAC Antisense N ISH
WNK1-T (EX6-9) GTATCCGACAAAACAAAGATGAAAGATATTCC Sense S NH
WNK1-T (EX6-9) CTGTATTCCCTGCTGCTGAGGATG Antisense S NH
WNK1-T (EX6-9) tctagattaaccctcactaaagggaGTTGCTCAAGAAATGGTTGA Sense N ISH
WNK1-T (EX6-9) ggatcctaatacgactcactatagggATGTTGGATAGGTTGTGAAG Antisense N ISH
WNK1 (EX4b) TTATGGAAGGTGCAGCCACTAGTGG Sense S -
WNK1 (EX4b) CTCAACCATTTCTTGAGCAACATCTTCTG Antisense S -
WNK1 (EX4b) tctagattaaccctcactaaagggaAGGTGCAGCCACTAG Sense N ISH
WNK1 (EX4b) ggatcctaatacgactcactatagggCCACTGTTGCACCAG Antisense N ISH
WNK1 (EX8) CTAGTATATCTGTGTTGTCTGATGGAACC Sense S Splicing
WNK1 (EX15) GTCATTGTTCACCATAATTGTTGCTATCTC Antisense S Splicing
WNK1 (EX11) CAACATCCTCAGCAGCAGGGAATAC Sense S -
WNK1 (EX11) GAGATGGGAAGCCCTGGTACAAAAC Antisense S -
WNK1 (EX11) tctagattaaccctcactaaagggaCTTCCAGTTTCCCAGACAG Sense N ISH, NH
WNK1 (EX11) ggatcctaatacgactcactatagggTACAAAACATCTCCAGAGG Antisense N ISH, NH
WNK1 (EX12) GATGTTTTGTACCAGGGCTTCCCATC Sense S -
WNK1 (EX12) CGTCTGAATGTGCACTGTCTGCAG Antisense S -
WNK1 (EX12) tctagattaaccctcactaaagggaGCTTCCCATCTCGACTG Sense N ISH, NH
WNK1 (EX12) ggatcctaatacgactcactatagggCTCCAGAACTGCTTGCTG Antisense N ISH, NH
WNK1 (EX1) CCAAGGCAGTGGGAATGTCCAATG Sense S -
WNK1 (EX7) CGTTTTCTCTTAATTAAGGACACCCTATC Antisense S -
WNK1 (EX1) GTCGCTTTCTCAAATTTGACATCGAAATC Sense N -
WNK1 (EX7) CTTTGATAGCTTTAGCCATGGTCTTGTG Antisense N -
WNK1 (EX2) GCAGGATCGAAAGTTAACAAAATCTGAAAG Sense N NH
WNK1 (EX2) ACGTCTTAAGTGTTCCAGATGTCATTAG Antisense N NH
WNK1 (EX3) GAAAATCAAAGTTTTAAGAAGCTGGTGTC Sense N NH
WNK1 (EX3) TCTTGGCAAAAGAAGCCCGCTTTAGAG Antisense N NH
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TARGET SEQUENCE (5'-3') ORIENTATION PCR USE
WNK1 EX4) ACCCCAGAGTTTATGGCTCCTGAG Sense N NH
WNK1 EX4) CACTCCACTGGTCACTCGAC Antisense N NH
WNK1 EX5) GTGGAGTGAAGCCAGCCAGTTTTG Sense N NH
WNK1 EX5) GAATATCTTTCATCTTTGTTTTGTCGGATAC Antisense N NH
WNK1 EX6) GACCTTTTGAACCATGCCTTTTTCCAG Sense N NH
WNK1 EX6) CTCAACCATTTCTTGAGCAACATCTTCTG Antisense N NH
WNK1 polyA) GTTGTGAGCTGTGTGTGAAAGATAAGG Sense S NH
WNK1 polyA) CAGACCTCACTCAGAATGACTAAACC Antisense S NH
WNK4 EX6-9) GAACGAGAGGTTCACCATCCAGG Sense S NH
WNK4 EX6-9) CATCTGAGGCGTAGCTATCCCCAG Antisense S NH
WNK4 EX6-9) tctagattaaccctcactaaagggaCAGGAGATGGTAGCCTTG Sense N ISH
WNK4 EX6-9) ggatcctaatacgactcactatagggTAGCTATCCCCAGGAG Antisense N ISH
WNK4 EX1) CTTCCCATGCTAGCACCTCGAAATAC Sense S -
WNK4 EX1) ACGTTGCCACAGCCTGGGTTTC Antisense S -
WNK4 EX1) tctagattaaccctcactaaagggaCCTCGAAATACGGAGACT^ Sense N ISH
WNK4 EX1) ggatcctaatacgactcactatagggCTGGGTTTCTGTGTCCTC Antisense N ISH
WNK4 EX10) GGATAGCTACGCCTCAGATGC Sense S -
WNK4 EX10) GCTCTGGTCTGAGACACTAGTGAC Antisense S -
WNK4 EX10) tctagattaaccctcactaaagggaCTCAGATGCGGCATCAG Sense N ISH
WNK4 EX10) ggatcctaatacgactcactatagggACTAGTGACCCGGAGC Antisense N ISH
WNK4 EX12-13) GAAATTGCAGCTGCCATGGTATACAATG Sense S -
WNK4 EX12-13) CTTCTCTGGGGCTCTGCATTGG Antisense s -
WNK4 EX12-13) tctagattaaccctcactaaagggaGCGAGATGGATTCC Sense N ISH
WNK4 EX12-13) ggatcctaatacgactcactatagggCATTGGGTGGGCCTG Antisense N ISH
WNK4 EX14-15) CTTCTCTCTGGCTGTGATGACTGTG Sense S -
WNK4 EX14-15) AAGCTGGGGCTTTCCCTCTTCAG Antisense S -
WNK4 EX14-15) tctagattaaccctcactaaagggaTTTCCCTTGCTTCTTGTGAC Sense N ISH
WNK4 EX14-15) ggatcctaatacgactcactatagggCTTCAGATATAGGTGCCAG Antisense N ISH
WF CATGCCGGTTTCTATCTGCGCAAG Sense S -
WF GTTGTCCTTCTTATTGCGATGCTCC Antisense S -
WF tctagattaaccctcactaaagggaCTGATTCCCGTGGGATTG Sense N SPIKE
WF ggatcctaatacgactcactatagggCGTCGATCTTGATATTGACC Antisense N SPIKE
Nucleotide sequence in lowercase indicates T3 (sense) and T7 (antisense) RNA polymerase
footprints incorporated into primer sequences. Northern hybridisation probes were typically
generated by straight PCR (S; section 2.2.6.3.1), whereas ISH probes involved an additional
nested PCR (N; section 2.2.7.3.1) reaction to incorporate T3 and T7 RNA polymerase
binding sites. Both Northern hybridisation and ISH to exons 11 and 12 of WNK1 used the
nested PCR product. Nested PCR was also used to produce Northern hybridisation probes
against exons 2, 3, 4, 5, and 6 of WNK1 to ensure amplification of WNK1 cDNA only
(confirmed by sequencing) across the highly conserved kinase domain region.
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Chapter 3 WNK1 mRNA distribution and
alternative splicing in mouse.
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3.1 Introduction
Following the identification of a causal link between mutations in the WNK1 gene
148
and Gordon syndrome it has become of key importance to establish the role played
by this unusual protein kinase in electrolyte balance and BP control. Although the
underlying genetic cause of Gordon syndrome remained a mystery for several years
it was widely accepted that the novel phenotype, featuring hypertension accompanied
by hyperkalemia42'43, meant that a novel BP control pathway distinct from the
aldosterone pathway could be involved. The effective treatment of Gordon syndrome
patients with thiazide diuretics13'43'119, a first-line treatment for essential
hypertension, also emphasises that understanding the genes and pathway involved in
Gordon syndrome is particularly valuable as it might yield some clues as to the
causes of essential hypertension.
Intriguingly, cases attributed to WNK1 mutations in this autosomal dominant
disorder are due to intronic deletions and are not recognised as directly affecting
• 148 •
WNK1 coding sequence . It is of great interest how such WNK1 mutations, in a
widely expressed gene, cause an autosomal dominant disease, with a mechanism
seemingly explicable by a distal nephron-limited ion transport defect43'92. One
possibility sees the intronic region involved in transcriptional regulation, and some
preliminary evidence maintains this as a reasonable explanation. Alternatively, this
apparently "silent" mutation may alter the complement of spliced products
transcribed from the gene. Such superficially "silent" mutations have been shown on
closer investigation to cause dominant diseases by altering splicing, for example, in
71 •
the fibrillin-1 gene, causing Marfan syndrome . Thus, evidence relating to promoter
use or alternative splicing of WNK1, especially selectively relating to kidney, is
likely to be of particular value in understanding the role of this gene and how it is
disrupted to cause hypertension and electrolyte imbalance in Gordon syndrome.
To elucidate the novel WNK1 BP control pathway active in distal nephron we have
examined WNK1 expression in detail in mouse. The studies presented here describe
and detail, several isoforms produced from the WNK1 gene, some of which show
strikingly different tissue-specific distributions, including one showing abundant
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expression in kidney that is seen at low level, if at all, in other tissues. Such
modifications, generating this transcriptional diversity, also produce predicted
proteins of very different structure and will radically affect function. The findings
reported thus help elucidate not only probable mechanisms by which the WNK1
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Figure 3.1: Schematic representation of WNK1 cDNA structure showing primer
positions, (a and b) denote the cDNA structure of WNK1 and kidney-specific WNK1
containing exon 4A, respectively, with vertical bars representing splice junctions and dashed
vertical bars indicating 3'-polyadenylation sites, A1 and A2. Numbers within rectangles refer
to exon numbers. Primers are represented by arrows (—►) and numbered P1-P28. Additional
primer details are given in Table 2.3. Horizontal dashed lines specify the cDNA region
amplified by PCR using the corresponding primer pairs, (c) shows the cDNA sequence of
exon 4A. The predicted amino acid sequence also shown would continue in frame across the
splice site to exon 5.
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3.2 Materials & Methods
Materials and common molecular biology methods are described in Chapter 2.
3.2.1 Northern Hybridisation Analysis
mWNKl northern probes used in this study were constructed against: exons 6-9,
P5/P6 (860 bp); poly-A, P3/P4 (875 bp); exonl, P1/P2 (928 bp); exon 2, P15/P16
(180 bp); exon 3, P17/P18 (187 bp); exon 4, P19/P20 (161 bp); exon 4A, P9/P10
(340 bp); exon 5, P21/P22 (96 bp); exon 6, P23/P24 (212 bp); exon 11, P25/P26 (462
bp); exon 12, P27/P28 (278 bp). cDNA templates for Northern probe production
were PCR amplified (section 2.2.6.3.1) using the primer pairs detailed in Table 2.3.
The primer numbering system used here refers to Figure 3.1 which illustrates relative
primer/probe positions.
3.2.2 ISH Analysis
mWNKl ISH probes used in this study were constructed against: exon 1 (434 bp);
exon 4A (280 bp); exons 6-9 (552 bp); exon 11 (460 bp); exon 12 (283 bp); exon 4B
(108 bp). cDNA templates for ISH probe production were PCR amplified using a
nested PCR protocol (section 2.2.7.3.1) and primer pairs are detailed in Table 2.3.
3.3 Results
3.3.1 Discovery of Kidney-specific kinase deficient transcript
The mouse WNK1 gene (mWNKl) is large, spanning >120 kb, with a coding region
showing 86% identity with human WNK1 (hWNKl). mWNKl produces large
transcripts (>10 kb) with cDNA encoded by 28 exons (Figure 3.1a), having a
predicted 2377 amino acid protein. Northern blot hybridisation with exons 6 to 9
revealed widespread distribution of these large transcripts (Figure 3.2a) with high
expression seen in testis > heart, lung, kidney, placenta > skeletal muscle, brain, and
low-level expression elsewhere. Additional Northern blots show placental transcripts
are of similar size to the major widely found isoform. In kidney, a smaller, more
abundant mWNKl transcript is seen, differing in size by at least 1.5 to 2 kb (Figure
3.2a). A 3'-polyadenylation (poly-A) site ^47 (Figure 3.1) is positioned approximately
800 bp downstream of the ORF. To assess whether the use of an alternative poly-A
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site could account for this size difference, cDNA sequence encoding a second poly-A
site approximately 2400 bp downstream of the ORF was isolated (Figure 3.1, A2).
Northern blot hybridisation with cDNA between these alternative poly-A sites,
revealed a similar expression profile to that described above (Figure 3.2b). Both
transcripts in kidney were detected implying most WNK1 transcripts terminate at the
second 3'-poly-A site (Figure 3.1, A2) and thus differential polyA site use is not the
mechanism behind the generation of the different WNK1 isoforms seen in kidney by
Northern blot. Having excluded this possibility, a probe to exon 1, overlapping the
ORF (Figure 3.1), was designed within the 5' region of WNK1. Northern blot
hybridisation probing for exon 1 revealed a similar expression profile for the large
mWNKl transcript but strikingly the smaller kidney-specific transcript was
completely undetected, indicating it lacks exon 1 (Figure 3.2c).
To investigate whether this kidney-specific isoform lacked further 5' exons, nested
PCR was used to produce separate probes against exons 2, 3, 4, 5, and 6 ofmWNKl
(Figure 3.1), ensuring amplification of mWNKl cDNA only (confirmed by
sequencing) across the highly conserved kinase domain region. Northern blot
analysis of kidney and testis RNA, showed that probes to exons 2, 3, and 4 only
detect the large mWNKl transcript, and not the smaller kidney-specific isoform
(Figure 3.2d). In contrast, probes to exons 5 and 6 detect both mWNKl transcripts.
Thus, the smaller mWNKl transcript in kidney lacks exons 1 to 4. Screening
submitted expressed sequence tag (EST) databases suggested an alternative exon
preceding exon 5 in kidney, positioned between exons 4 and 5 in the genomic
sequence and therefore termed exon 4A. Conclusively, Northern blot hybridisation
probing for this exon only detects the smaller mWNKl transcript (Figure 3.2d),
confirming inclusion of exon 4A in the kidney-specific isoform (Figure 3.1b).
3.3.2 Spatial distribution of WNK1 Expression
3.3.2.1 Distribution of Total WNK1 (WNK1-T) Expression in Kidney
ISH to exons 6 to 9 allowed detailed study of WNK1-T expression in mouse kidney.
Figure 3.3 reveals clear WNK1 expression above background in distal nephron
extending from early DCT (DCT1) into CNT and at lower level into CCD (lower
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Figure 3.2: Northern analysis of WNK1 expression. Hybridisation with a probe
incorporating exons 6-9 (a) detects widespread expression of large transcripts,
approximately 10.2 kb in size. In addition, smaller and more prominent transcripts are
detected in kidney (lane 5). This expression profile is also observed in (b) when hybridising
with the poly-A probe (refers to sequence located between the two 3'-polyadenylation signals
A1 and A2). (c) Probing with exon 1 fails to detect the smaller kidney-specific transcripts, (d)
Northern analysis reveals differential expression of individual exons in WNK1 isoforms in
kidney (K) and testis (T). Hybridisation with probes against exons 2, 3, 4, 5 and 6 detect the
large WNK1 isoform, strongly in testis but weakly in kidney. The smaller and more abundant
kidney-specific isoform is only detected by probes to exons 5 and 6. A probe to an
alternative exon, 4A, detects the smaller kidney-specific isoform only. Hybridisation with a
probe to exon 11 detects the large WNK1 isoform in testis but signal is low for either isoform
in kidney. In contrast, hybridisation with exon 12 readily detects both the kidney-specific
isoform and the large WNK1 testis isoform. WNK1 expression was studied in (a, b, and c)
across a range of mouse tissues. Lane 1, brain; lane 2, forebrain; lane 3, skeletal muscle;
lane 4, heart; lane 5, kidney; lane 6, liver; lane 7, lung; lane 8, spleen; lane 9, stomach; lane
10, duodenum; lane 11, jejunum; lane 12, ileum; lane 13, colon; lane 14, testis; Iane15,
placenta (E16.5).
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expression level in medullary rays; Figure 3.3). Strong expression in DCT continues
adjacent to glomeruli and is seen looping close to their vascular pole (Figure 3.3 right
panels) the site of the macula densa. Additionally, lower expression, approaching but
above sense background levels, is distributed more extensively. This appears to have
a different origin from the higher expression seen in DCT (i.e. different WNK1
transcripts; see below). Figure 3.4 illustrates the nephron anatomy and structures
involved in the expression patterns described.
3.3.2.2 Distribution of WNK1-L and WNK1-S Expression in Kidney
To investigate the renal distribution of the two WNK1 isoforms, adult kidney
sections were hybridised with probes to exons 1, 4A, and 6 to 9 (Figure 3.5, top left
panel) allowing detection of the long, short, and both isoforms, respectively. Probing
with exon 1 detects widespread signal at a low level (Figure 3.5a), whereas with
exon 4A, only strong punctate signal in cortex is detected (Figure 3.5c). The
expression pattern seen with exons 6 to 9 is thus a combination of that seen with
exons 1 and 4A (Figure 3.5e).
Thus, the majority of WNK1-T expression is due to WNK1-S and limited to renal
cortex (Figure 3.5(c)). Analysis of dipped slides reveals high levels of WNK1-S in
distal tubules dropping off sharply distally from CNT-CCT-CCD (Figure 3.6(c)) and
proximally dropping 10-fold at the TAL:DCT junction (Figure 3.6(a-b)) with
expression (including the macula densa) falling off in late TAL. Hence WNK1-S has
only a limited weak extension into medullary rays. Serial sections show strong
WNK1-T cortical (labyrinth) expression (attributable to WNK1-S) overlapping NCC
expression in DCT but also extending beyond the NCC overlap, representing
particularly extension into CNT (Figure 3.7).
3.3.2.3 Distribution of WNK1-L and WNK1-S Expression in Development
These probes were also hybridised to embryo tissue slices (E16.5), to examine
developmental mWNKl expression. Probing with exons 6 to 9 revealed a wide
mWNKl distribution, with high expression in tissues such as placenta, nasal
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Figure 3.3: ISH of WNK1 in mouse kidney. ISH study using probe to WNK1 exons 6-9,
panels show images of emulsion dipped slides (Eosin/Cresyl Violet counterstain) captured at
x40 (left) and x200 magnification. View of renal cortex with a medullary ray (MR) demarcated
between the parallel lines and cortical labyrinth lateral to them. Below dashed line is outer
medulla. Bright field on top (black = strong expression), corresponding dark field view on
bottom (white = expression whilst very highest expression (showing black on bright field)
obscures light - hence appearance of strongest expressing tubules as black-holes with ring
outlines on darkfield view (bottom left). Short black arrows indicate glomeruli, a = examples
of DCT largely adjacent to glomeruli, b = example of CNT in mid-cortical labyrinth arcades
(adjacent to radial vessels), c = CCD in medullary rays. GA = glomerular arteriole. Left
panels: Study with long exposure (5 weeks) demonstrating wide range of expression level.
Note regional expression at 3 levels: (i)widespread low level (low level white seen in
darkfield), (ii)higher in CCD (faint but distinct tubular outline seen on dark field, pale grey on
bright field) and (iii) highest in DCT and CNT (darker grey/black on bright field and bright ring
with black hole centre when silver grains confluent). Right panels, (3 week exposure) note
proximity of strongly expressing DCTs to glomerulus and its vascular pole (between
arterioles) and stronger expression than in CCD. See Figure 3.4 for detailed illustration of
nephron anatomy.
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Figure 3.4: Nephron structure. Several distal nephrons draining into one CCD are shown.
Distal nephron begins in the renal medulla in TAL (numbered), which ascends into cortical
medullary rays and enters the cortical labyrinth contacting its glomerulus (specialized macula
densa cells at contact point) then shortly beyond this enters DCT, CNT and finally
initial/cortical collecting tubule (ICT/CCT) which re-enters medullary rays as CCD and re-
descends into medulla. Nephrons of superficial glomeruli (e.g. TAL1) typically have a simple
structure, with a short usually unbranched CNT. In contrast in most species, nephrons of
mid-cortical (e.g. TAL2) and some juxtamedullary glomeruli (TAL3+4) commonly drain
through well developed branched arcades of CNT. A considerably higher proportion of
nephrons form arcades in mouse than human. Arcades are arranged around vascular axes
with CNT being close to arcuate and especially intralobular vessels. The dashed boxes and
lettering delimit regional views relevant to Figure 3.6. (grey letters) and Figure 4.3 (red
letters).
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Figure 3.5: Analysis of WNK1 expression by ISH of mouse adult kidney and fetal
sections (E16.5). Cryostat sections were subjected to ISH analysis using a range of probes
against WNK1 (section 3.2.2.). Left columns of top panels show local distribution within the
kidney (a, c, e, g, i and k). Right columns of top panels show corresponding developmental
expression patterns (b, d, f, h, j and I). Bottom panel shows sense controls for both kidney (m
and n) and fetal (o and p) sections. Exposure times for detection of ISH signal were as
follows: exon 1, (a and b) 1 day; exon 4A, (c) 1 day, (d) 4 days, (n) 1 week; exon 6-9, (e and
f) 1 day, (m) 3 days; exon 11, (g, h, and o) 3 days; exon 12, (i and j) 3 days; exon 4B, (k, I,
and p), 2.5 weeks. Key: B = brain; K = kidney; L = lung; P = placenta.
Chapter 3. WNK1 mRNA distribution and alternative splicing in mouse. 75
WNK Kinases: Novel Regulators of Electrolyte Balance and Blood Pressure.
Figure 3.6: WNK1-S gene expression in mouse kidney. ISH studies: in bright field view in
5(a, top) and 5(b); blue dark-field in 5(a, lower) and dark-field in 5(c). Note WNK1-S gene
expression is present in late TAL (T) including at the macula densa (MD) but rises to much
higher levels in DCT (D) and CNT(C) reducing somewhat by CCT. (d) Strong WNK1-S
cortical (labyrinth) expression is seen beyond NCC overlap (DCT), representing particularly
extension into CNT, (NCC being DCT-restricted). *- glomerulus; dashed line - position of
renal capsule; U, proximal tubule emerging from urinary pole of glomerulus (see also Figure
3.4 grey labeled boxes).
epithelium, lung, intestine, regions of the brain and developing renal cortex (Figure
3.5f). As expected, the expression patterns, revealed by probing with exons 1 and
4A, were components of that seen for exons 6 to 9, with exon 1 widely expressed,
particularly in placenta, lung, kidney, intestine, thymus, and forebrain (Figure 3.5b),
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Figure 3.7: WNK1 expression overlaps NCC in DCT. ISH for the genes indicated in
mouse kidney. (a)Two-colour dark-field views for paired serial saggital sections, merging
showing co-localisation (yellow shift). (b)Two-colour merge views of panel (a; merge) at
higher magnification. WNK1-T expression in distal nephron overlaps NCC in DCT but
extends beyond this segment representing particularly extension into CNT. NCC (expressed
only in DCT).
whereas exon 4A revealed much lower expression, with high signal detected in
restricted regions such as nasal epithelium, forebrain, thymus and kidney (Figure
3.5d). Sense control sections showed no specific hybridisation (Figure 3.5).
3.3.3 Evidence of WNK1 alternative splicing
3.3.3.1 Alternative Splicing of Exons 11 and 12
EST sequences suggest that alternative splicing of mWNKl, primarily concerning
exons 11 and 12, takes place in some tissues (Figure 3.1). To investigate this, kidney
and testis RNA was subjected to Northern blot analysis with probes specific for each
of these exons. Exon 11 hybridisation studies detect the large mWNKl isoform in
testis, but signal is greatly diminished for either isoform in kidney (Figure 3.2d),
suggesting that exon 11 is usually spliced out in both kidney mWNKl transcript
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classes. In contrast, hybridisation with a probe to exon 12 shows strong signal for
mWNKl in testis and for the smaller kidney-specific transcript. The large mWNKl
transcript in kidney is also detected at a lower level (Figure 3.2d). To investigate
tissue-specific and developmental variations in these splicing events, adult mouse
kidney and fetal (E 16.5) sections were subjected to ISH analysis. The expression
patterns seen when probing adult kidney sections with either exon 11 or 12 are
similar to that described above for exons 6 to 9, showing low-level, widespread
expression throughout the kidney, overlaid with strong punctate cortical expression
(Figure 3.5, g and i). However, developmental expression studies using these probes
indicate that although many fetal tissues express both exons similarly, there is
striking tissue-specific splicing in some developing organs. For example, transcripts
containing exon 11 are abundant in some neural tissues but are rare or absent in
placenta (Figure 3.5, h and j). Sense control sections showed no specific
hybridisation (Figure 3.5).
RT-PCR studies across exons 11 and 12 confirm these splicing events (Figure 3.8a).
Amplification in kidney, by means of primers spanning the exon 7/8 splice site down
to the exon 15/16 splice site shows two major bands, corresponding in size to PCR
products having either exon 11, or both exons 11 and 12 spliced out (Figure 3.8b).
Additional RT-PCR studies that use alternative primers spanning this region also
show major bands, similarly representative of these splice variants.
3.3.3.2 Alternative Splicing of Exon 4B
EST sequences also suggest that in addition to exons 4 and 4A, a third exon
positioned between exon 4A and 5 in the mouse genomic sequence and therefore
termed 4B, may precede exon 5 in some mWNKl transcripts (Accession No.
AK052468). The EST evidence suggests that unlike the kidney-specific transcripts
described above containing exon 4A, which lack all known upstream exons,
transcripts containing 4B splice directly from exon 4 to exon 4B to exon 5. ISH
analysis probing with exon 4B shows a similar pattern to that seen previously in
kidney, with high cortical expression overlaying a low widespread distribution
(Figure 3.5k). However, splicing events producing transcripts containing exon 4B
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Figure 3.8: Detection of WNK1 alternative splicing, (a) Ethidium bromide-stained agarose
gel, showing RT-PCR-amplified fragments in duplicate. These products were amplified with
mWNKl primer pair P7 and P8, spanning a region from the exon 7/8 splice site down to the
exon 15/16 splice site (lanes 3 and 4). A negative control is seen in lane 2. Lane 1 shows a
100 bp DNA ladder, (b) Schematic depiction ofWNKI alternative splicing involving exons 11
and 12. The major products seen correspond to (iii) and (iv). (c) Schematic representation of
the major predicted WNK1 -derived proteins. mWNKl is 2377 amino acids in length and is
particularly serine-, glutamine- and proline-rich, having 26 PXXP sites potentially recognised
by SH3 domains. Black bars denote four putative coiled coil domains, and a conserved WNK
autoinhibitory domain is represented by horizontal stripes (identified in rWNK1 by Xu et
a/.152). Black arrowheads indicate the positions of predicted potential phosphorylation sites;
intriguingly none of which overlap with the region encoded by exons 11 and 12. Exon 11
encodes a leucine zipper (LXXLL) motif. WNK1-S has a truncated N-terminus, lacking one
coiled coil domain and deleting a major portion of the kinase domain. This region is
substituted with a highly cysteine-rich stretch of thirty amino acids.
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appear to be rare, judged by the lower ISH signal (requiring exposures several-fold
longer for clear detection). Furthermore, signal detected on fetal sections was low
and widespread, lacking the striking tissue-specific differences in expression levels
seen with probes to other exons (Figure 3.51), and was only marginally higher than
that seen for sense controls (Figure 3.5p).
3.3.3.3 Evidence of Further Novel mWNK1 Transcripts
As described above, Northern blot studies examining expression of exon 11 detect
very weak signal for the transcripts of both long and short WNK1 isoforms in
kidney, despite their high expression in testis. In contrast, ISH studies suggest that
exon 11 is expressed at levels comparable with exon 12 in kidney. This discrepancy
led to further Northern blot analysis looking for evidence of further novel mWNKl
transcripts in kidney containing exon 11. These studies revealed at least two novel
mWNKl transcripts in kidney and testis, evidently several kb smaller than the two
isoforms described above (Figure 3.9). Intriguingly, transcripts of similar size were
detected in additional northern analysis of exon 4A expression in both tissues (Figure
3.9).
3.4 Discussion
This study details WNK1 gene expression in mouse, reporting a broad distribution
across a range of tissues. Several WNK1 transcript classes are demonstrated,
showing tissue-, developmental-, and nephron-segment-specific expression.
Importantly, in kidney, the most prominent transcripts are smaller than elsewhere,
• *1S7
having the first four exons replaced by an alternative 5'-exon (exon 4A) , thereby
deleting the kinase domain. This phenomenon of a shorter predominant kidney
• • • • 148
WNK1 isoform (WNK1-S) has been reported in previous studies , appears to be
conserved between species, and was previously attributed to alternative 3'-
1 8* 1 T7" 148* 1 S1
polyadenylation (shown here to be incorrect) ' ' ' . Unlike WNK1-L which has
a low-level widespread renal distribution, WNK1-S expression is largely confined to
the distal nephron, with expression highest in DCT and CNT, dropping sharply both
distally in CCD and proximally in cortical TAL (cTAL), with weak expression
detected in macula densa. We were the first to report the difference between these
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Figure 3.9: Detection of smaller WNK1 transcripts in kidney and testis by Northern
blot. Probing with exon 4A detects the kidney-specific WNK1 transcript (B), but also reveals
two additional transcripts several kb smaller (C and D) in both kidney (K) and testis (T).
These transcripts are also seen when probing with exon 11, which also detects the large
WNK1 transcript (A) as expected.
WNK1 isoforms showing unique and detailed renal distributions and including the
sequence of novel 5'exons and the predicted amino acid sequence for WNK1-S109.
Shortly after our report an independent study supported our findings24 (Chapter 9).
Alternative splicing of exons 11 and 12 is prominent; with transcripts containing
exon 11 abundant in neural tissues and testis, but predominantly absent in placenta.
In kidney, we show that exon 12 is usually included in WNK1-S, whereas exon 11 is
largely absent in both WNK1-L and WNK1-S. Alternative splicing of these exons
has also been reported for hWNKl137. Furthermore, the published rat WNK1
sequence (Accession No. NM_053794) corresponds to the splice variant lacking both
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exons. Further studies indicate the production of substantial levels of novel smaller
alternatively spliced transcripts from the WNK1 gene, with Northern blot analysis
implicating the inclusion of both exons 11 and 4A. These smaller transcripts are seen
in kidney but also in testis, a tissue in which exon 4A expression was previously
unsuspected because testis lacks obvious expression of the much larger 'kidney-
specific' 4A transcript. Preliminary investigations suggest that these transcripts differ
from this largely kidney-specific 4A transcript, described above, being much smaller
in size. However, RT-PCR in testis easily amplifies a product from exon 4A to exon
11, suggesting these smaller transcripts contain this region.
This study was the first to assess WNK1 expression in development by means of ISH
analysis, demonstrating that WNK1 is widely expressed in the mouse embryo (E
16.5), in both epithelial tissues (e.g., developing renal cortex, intestine, lung, nasal
epithelia, and placenta) and in nonepithelial tissues (e.g., regions of the CNS). Again,
there are tissue specific differences in the pattern of transcripts expressed in
developing organs, with WNK1-L showing high widespread but non-uniform
expression and WNK1-S showing high expression only in restricted sites. The
importance of WNK1 in development is emphasised by a study reporting
homozygote WNK1 deficient mice are embryonic lethal with embryos failing to
survive past day 13 of gestation163.
It would have been reasonable to have supposed WNK1, a kinase, probably regulates
ion transport through the activity of its kinase domain. However, the major WNK1
transcript in kidney lacks this functional entity as a result of the replacement of exons
1 to 4 with exon 4A (Figure 3.8c). Additionally, a coiled coil motif predicted just N-
terminal to the kinase domain is lost, possibly disrupting interactions with molecular
targets. This implies that the remainder of the WNK1 protein makes an important
functional contribution to the WNK1 regulatory pathway. Exons 11 and 12 are of
key interest because, splicing of this region is conserved between species, is clearly
tissue-specific, and would produce a repertoire of proteins likely to be co-expressed
in the same tissues and cells (Figure 3.5). Intriguingly, although WNK1 contains
numerous potential phosphorylation sites (-66), no such site occurs within the
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exonll-12 region, implying that signalling through protein kinase pathways acting
on WNK1 is not affected by such splicing events. Clearly, experimental studies are
required to fully investigate these possibilities.
Also of interest is the addition of thirty amino acids to the N-terminus of kinase-
deficient WNK1-S, contributed by exon 4A. This exon may have no major functional
effect other than deleting the kinase domain. However, this sequence is strikingly
cysteine rich. Within a cluster of six likely very reactive cysteine residues, at least
three have a high predictive index for forming either disulphide bonds or bonds with
other molecules (e.g., metal-containing moieties). Moreover, the N-terminal
positioning of this cysteine cluster may promote this region as a potential point of
anchorage to other structures. Furthermore, the novel small bands seen by Northern
blot clearly indicate the production of WNK1 transcripts lacking several kilobases
compared with the kidney-specific 4A band. Therefore, it is very likely that these
may add to the repertoire of variation in WNK1 protein structure having profound
effects on WNK1 function.
The transcriptional modifications described above would greatly influence the
potential complement of proteins produced from the WNK1 gene and may be the
manifestations of different functional aspects of the WNK1 gene that have been
conserved in evolution. Kinase-deficient WNK1-S proteins may act to inhibit other
WNK1 proteins with "active" kinase domains, via interactions through the remaining
coiled-coil motifs (Figure 3.8c). This is supported by the recent report of a WNK1
autoinhibitory domain, positioned between residues 515-569 in the rat sequence,
which is conserved between species and also within the WNK family (Figure 3.5c).
Preliminary evidence was also reported for WNK1 tetramer formation via the coiled-
coil motif C-terminal to the autoinhibitory domain (Figure 3.8c)152.
This work provides a number of insights into the cause of Gordon syndrome. WNK1
expression is examined in some detail, further elucidating kidney-specific and distal-
nephron-specific WNK1 transcripts. The findings described imply the use of
alternative promoters, one initiating transcription in exon 1 and the second giving
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rise to transcripts having exon 4A in place of exons 1-4. It is therefore reasonable to
suggest that cis elements within intron 1 (>34 kb in mouse) affect the second
promoter regulating such 4A transcripts. Dominant negative regulation could arise
from intronic deletions causing Gordon syndrome leading to abnormally high
expression of kinase-deficient WNK1-S transcripts in kidney, in turn causing
excessive inhibition of "normal" WNK1 function. Alternatively, the intron 1
deletions could interrupt splicing enhancer or silencer sequences, thereby disrupting
the normal complement of alternatively spliced WNK1 transcripts. A similar effect is
seen in Marfan syndrome, another autosomal dominant disorder affecting connective
tissue, where a superficially "silent" intronic mutation actually results in exon
skipping71. In Ataxia-telangiectasia, an intronic deletion in the ATM gene results in
aberrant inclusion of a cryptic exon110.
The pathway disrupted in Gordon syndrome involving WNK1 is regarded as
different from other signalling pathways known to regulate BP. The findings
presented here reveal the central importance of the transcriptional control of this
gene in generating a complement of kidney-specific, WNK 1-derived proteins. The
correct balance within this complement of proteins must mediate the effects on ion
transport that constitute this novel BP regulatory pathway. Clearly the regulation of
alternative promoter use and splicing is likely to participate in the control of BP by
WNK1-derived proteins.
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Chapter 4 WNK4 mRNA distribution in
mouse.
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4.1 Introduction
In a number of in vitro studies, WNK4 has been proposed to regulate many renal
electrolyte transporters (Table 1.3). The renal localisation of these electrolyte
transporters ranges from proximal tubule, for example CFEX52, to the more distal
nephron segments, for example NCC in DCT149'161, ROMK in DCT2-CD:>6, and
NKCC1 in outer medullary collecting duct (OMCD) . Moreover some putative
interacting transporters are located in the apical plasma membrane, for example
NCC, others in the basolateral membrane, for example NKCC1, while WNK4
interaction with Claudins is expected to be localised in lateral tight junctions53,159. In
order to assess the potential in vivo significance of specific molecular interactions
identified in vitro, it is essential to establish which tissues and cells types show
WNK4 gene expression in vivo. Within kidney, which shows the highest WNK4
expression, it is important to establish the nephron segment expression of WNK4, as
the molecular make-up of the nephron varies greatly from segment to segment. For
example, although the basolateral Na+/K+-ATPase pump is expressed by all cells
throughout the distal nephron, the machinery responsible for apical Na+ transport
varies from segment to segment; NKCC2 in TAL, NCC in DCT, ENaC in CNT and
CD. So depending on where WNK4 (and similarly WNK1) is expressed, the
complement of potential interacting candidates and the pathways in which they
participate may vary. Having determined WNK1 gene expression in mouse
(described in Chapter 3), the next logical step was to similarly investigate WNK4
gene expression and distribution in this model species. Bioinformatic evidence from
sequence databases and the distribution of ESTs suggest transcriptional diversity of
WNK4. Accordingly, additional studies were undertaken to assess the possibility of
WNK4 alternative splicing.
4.2 Materials and Methods
Initially no mouse WNK4 cDNA sequence was available, so one was "stitched"
together in April 2002 from a "contig" constructed in house with high quality
C57BL/6 mouse sequence (from ESTs, cDNAs, and high quality mouse genome
trace sequence giving >3-fold coverage for all but 108bp (2-fold) of the 4144bp
stitched cDNA). The junctions between the 19 exons were determined by use of
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genomic sequence and reference to the equivalent human WNK4 gene structure. In
January 2003 a 3718bp cDNA submitted by the Lifton group (AY187027) was
released, having 100% identity to the in house sequence which extended 74bp and
352bp 5' and 3' of the AY187027 sequence, respectively. By sequence comparison
and BLAST alignment it became apparent there was evidence suggestive of
transcript heterogeneity and alternative splicing that could be assessed by examining
expression of exons 1, 10, 12-13 and 14-15. Accordingly, in addition to the main
investigation ofWNK4 gene expression utilising a probe sequence spanning exons 6-
9, additional probes to these regions were utilised in assessing for variant WNK4
transcript expression. For primer sequences, used in the generation of ISH probes for
analysis ofWNK4 gene expression see Table 2.3.
(a)
it.





Figure 4.1: Mouse WNK4. (a) Schematic representation of WNK4 cDNA structure showing
exon composition and standard probe position. The cDNA structure of WNK4 is illustrated
with vertical bars representing exon:exon boundaries. Numbers within rectangles refer to
exon numbers. Black box specifies the standard WNK4 cDNA region (exons 6 to 9) targeted
in hybridisation studies, (b) Schematic representation of the predicted WNK4 protein
showing the kinase domain (black box), coiled coil domains (grey boxes), and the familial
autoinhibitory domain (checked box; originally identified in rWNK1, be subsequently found in
all WNK kinases including WNK4147). Three out of four of the mutations in WNK4 that are
associated with Gordon syndrome are clustered in a conserved acidic region (depicted by a
dashed line) just distal to the first coiled coil domain, (c) Northern blot analysis of WNK4
expression. Hybridisation with a probe incorporating exons 6 to 9 detects WNK4 in mouse
kidney.
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4.3 Results
4.3.1 WNK4 expression in adult mouse kidney
Mouse WNK4 (mWNK4) is encoded by 19 exons contained within 17kb of genomic
DNA on chromosome 11, producing a 4139 bp mRNA transcript (Figure 4.1(a)). The
predicted 1222 amino acid mWNK4 protein (Figure 4.1(b)) shows 86% identity to
human WNK4 (hWNK4) but is shorter than the human orthlog by 21 amino acids.
Preliminary Northern hybridisation analysis with exons 6 to 9 detected mWNK4 in
kidney as expected (Figure 4.1(c)). Longer exposure of this blot suggested weak
expression of a smaller WNK4 transcript in kidney and also even weaker expression
of full-length WNK4 in testis. These bands were extremely faint and very difficult to
detect on scanned images, and are therefore not shown.
4.3.2 Spatial distribution of WNK4 in mouse adult kidney
To investigate the renal distribution of WNK4, adult mouse kidney sections were
hybridised with exons 6 to 9. WNK4 gene expression is illustrated in Figures 4.2 and
4.3 with an overview of expression shown in Figure 4.2 and key expression details in
Figure 4.3. The nephron anatomy and structures involved (and their abbreviations) in
superficial and deep distal nephrons are illustrated in Figure 3.4. Although WNK4 is
expressed at lower levels than WNK1 (3-4 fold longer exposures for WNK4 than for
WNK1(-S or -T; Chapter 3), WNK4 has a broader distribution than WNK1 in
kidney with strong expression seen in both renal cortex and medulla. WNK4 gene
expression is strongest in distal tubule structures (DCT/CNT), similar to WNK1-S,
but extends beyond distal tubule, at somewhat reduced levels, more proximally into
TAL including macula densa and medullary TAL (mTAL; Figure 4.3(a), (b), (d),
(g)) and more distally at quite low expression levels (compared to DCT) in CD
(Figure 4.4(f)). Thus, substantial WNK4 expression extends into medullary rays and
outer (but not inner) medulla (Figures 4.2(a), 4.3(g)) involving much too high a
proportion of tubules to be due to outer medullary CD (OMCD) alone (yENaC vs.
WNK4 -Figure 4.3(g)) rather resembling the density of mTAL tubules (shown by
NKCC2 - Figure 4.3(g)).
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WNK4
ROMK WNK4
Figure 4.2: ISH analysis of WNK4 gene expression in kidney. (a)Serial transverse
section (dark-field view). (b)Two-colour dark-field views for paired serial saggital sections,
merging showing co-localisation (yellow shift). Note that WNK4 expression coincides with
WNK1-S in the cortex, but unlike WNK1-S, major WNK4 expression extends substantially
into medullary rays and outer medulla where it has a similar distribution pattern to that of
ROMK.
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Figure 4.3: WNK4 gene expression in specific nephron segments. ISH studies in bright
field, dark-field and blue dark-field (dark-field under blue light to limit tissue stain visibility).
Throughout the panels (4.4 a-g) similar regions of view are illustrated in Figure 3.4 (red
labeled (a-g) boxes). Simple label abbreviations are used as in Figure 3.4 or below, (a)
WNK4 expression in TAL (T) in medullary ray, crossing boundary (dashed line) to contact
glomeruli (♦) in cortical labyrinth, (b) Substantial expression in segment of macula densa
(MD), and higher still in DCT (D), also seen in (c). U = proximal tubule emerging from urinary
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dashed outline) fall outside the plane of section, (e) Extensive WNK4 expression throughout
a well developed deep cortical arcade. Vascular axis (arcuate artery (AA) and vein (AV) and
intralobular artery (IA) and associated glomeruli are seen in left panel. Note extensive DCT
loops adjacent to glomerulus marked (•) in left panel. Dashed arrow = connections of DCT
convolutions (out of section plane), (f) Superficial cortex with loops of DCT and ICT/CCT
passing near renal capsule. Whilst both segments have WNK4 expression, note level is
strikingly higher in DCT. Dashed line = renal capsule, (g) Views of ISH studies for the genes
indicated in inner stripe of renal outer medulla (a segment with TAL and collecting duct
(OMCD) as largest tubules - upper panels x50 dark-field, lower x100 blue dark-field. Note
the relative density of WNK4 positive tubules is hugely different and greater than that for
yENaC (y-subunit of ENaC: an OMCD marker), but similar to NKCC2 (Na+K+CI cotransporter
type2: a TAL marker). Dashed red line = boundary of outer and inner medulla (I).
4.3.3 WNK4 Splicing
To investigate potential splicing of WNK4 adult kidney sections were hybridised
with exons 1, 10, 12 to 13 and 14 to 15. Our standard probe against exons 6 to 9 of
WNK4 was used in this study as a positive control. No differences were seen in
WNK4 spatial distribution (Figure 4.4). Sense control sections showed no specific
hybridisation.
4.3.4 WNK4 expression outside kidney
Clues from the literature, the distribution of WNK1 expression (Chapter 3), as well
as evidence from our Northern hybridization analysis (section 4.3.1) and fetal ISH
(section 4.3.5), highlighted a number of tissues, including testis and brain, as possible
sites of WNK4 expression outside the kidney. Adult mouse brain and testis were
hybridized with a probe against exons 6 to 9 of WNK4. When brain tissue was
harvested for these studies, the pituitary gland was placed on top of the brain prior to
freezing at -80°C. This allows easy sectioning of this small tissue. Highest WNK4
expression was detected in the pituitary gland, with lower expression seen in the
dentate gyrus and the cerebellum (Figure 4.5(a)). High WNK4 expression was also
detected in the epithelia of testis and epididymis; seen clearly over the lower level
uniform hybridization elsewhere (Figure 4.5(b)). ISH analysis of other tissues
including lung, liver, and heart did not clearly detect WNK4 expression.
4.3.5 WNK4 expression in mouse development
Fetal tissue sections (El6.5) were also hybridised with the WNK4 exon 6-9 probe to
examine WNK4 expression in development. This revealed a limited mWNK4
distribution (Figure 4.6), with highest expression seen in colon and tongue and
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weaker punctate expression seen in kidney. Sense control sections showed no
specific hybridisation.
EX1 EX1 EX6-9 EX6-9









Figure 4.4: ISH analysis of potential WNK4 splicing. Hybridisation of adult mouse kidney
sections with probes designed against exons 1, 10, 12 to 13 and 14 to 15 showed no
differences in distribution pattern compared to kidney sections hybridised with a probe
against exon 6 to 9 used as standard throughout our localisation studies. Hybridisations with
sense probes are shown in the left panel, and antisense hybridisations are shown in the right
panel.
4.4 Discussion
Using a probe against the WNK4 region just distal to the kinase domain we detected
WNK4 expression in kidney by Northern blot. The detection of a very faint smaller
band in kidney with longer exposure suggests the possibility of alternative splicing or
alternative 3'-polyadenylation of WNK4. Renal localisation studies by ISH show
strong WNK4 expression in distal nephron segments, important in long-term
1 fv47*89 ...
electrolyte balance ' ' with strongest WNK4 expression in distal tubule (DCT,
CNT) extending at substantially lower level into CD. WNK4 expression extends to
TAL including macula densa and represents stable expression at a substantial level.
This has not been recognised before and may indicate different WNK4 isoforms or
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post-translational modifications affect WNK4 in TAL . These seem particularly
common in transport pathways e.g. NKCC2 in TAL.
In vitro, WNK4 can interact directly or indirectly via other kinases (e.g. OSR1,
SPAK, other WNKs), to regulate proteins of key importance in TAL-DCT transport,
including NCC149;161, ROMK56 and, it appears, NKCC297;139. The prospect WNK4
may regulate transport in TAL-DCT (including macula densa) is intriguing, as
upregulated NaCl reabsorption here would be expected to drive hyperkalaemia,
acidosis and low-renin hypertension: all features of Gordon syndrome and
manifesting the inverse of Gitelman's and Bartter salt-wasting syndromes of DCT
and TAL, respectively. NCC overactivity accounts particularly well for Gordon
syndrome, including the thiazide hyper-responsiveness and hypercalcuria features of
WNK4 Gordon syndrome families; their normomagnesemia, however, appears
87
anomalous . Interestingly, normagnesemia would be expected with upregulated
NaCl transport in TAL (normagnesemia in Bartter's) which, in macula densa, would
promote low-renin hypertension with augmented afferent arteriolar resistance.
Gordon syndrome features were lacking in transgenic mice expressing human
Gordon syndrome mutant WNK4 protein in TAL and DCT (at heterogeneous
levels)160. Expression was transgenic cDNA-driven rather than genomic, altering
distribution and curtailing native potential for transcriptional diversity. These studies
report ROMK localisation appears unaltered by co-localised Gordon syndrome
mutant WNK4 protein160. However, the basis for absence of Gordon syndrome
features in these mice remains uncertain as this was not the goal of this work.
Lifton and colleagues report renal WNK4 expression in DCT and CCD seen by
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immunohistochemistry but could not detect WNK4 elsewhere in kidney . Clearly
this reported expression profile apparently restricted entirely to cortex conflicts with
the strong medullary expression seen here by ISH. This immunohistochemistry study
utilises a WNK4 antibody directed against the peptide, MGQMRRPPGRNLRR
(residues 657-670 of WNK4), encoded within exon 10 of human WNK4148. One
possible explanation for the discrepancy in WNK4 distribution profiles between the
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two techniques is that there is transcriptional or post-translational heterogeneity, for
example through splicing or post-translational processing which removes or modifies
the epitope recognised by this particular antisera.
Figure 4.5: Extra-renal WNK4 expression. Adult mouse brain (a) and testis (b) were
hybridized with a probe against exons 6 to 9 of WNK4. (a) WNK4 expression is seen in the
pituitary gland (frozen on top of brain when dissected for ease of sectioning), dentate gyrus
and cerebellum, (b) High WNK4 expression is seen in the epithelia of testis and epididymis,
over lower level uniform expression.
Ce, cerebellum, DG, dentate gyrus; E, epididymis; Pi, pituitary; T, testis
Chapter 4. WNK4 mRNA distribution in mouse. 94
WNK Kinases: Novel Regulators of Electrolyte Balance and Blood Pressure.
Figure 4.6: WNK4 expression in mouse development. Mouse foetal sections (E16.5)
were hybridized with a probe against exons 6 to 9 of WNK4. Highest expression is detected
in colon and tongue, with lower level punctate expression in kidney.
B, brain; C, colon; K, kidney; P, placenta; To, tongue
The potential existence of alternative WNK4 isoforms was previously highlighted by
additional bands on the WNK4 immunoblot in the original Lifton study reporting
WNK gene mutations in Gordon syndrome and also by the weaker small WNK4
band suggested by our Northern hybridisation analysis (data not shown). At the time
of this study the WNK4 gene was not fully annotated in the NCBI database.
However, EST evidence suggests the possible splicing of exons 12 to 13 and 14 to
15. Exon 10 is also of interest as this is the exon encoding the epitope for the
antibody used in immunohistochemistry studies. The possibility that WNK4 may be
transcriptionally regulated to produce a kinase-deficient isoform similar to WNK1-S,
also highlighted exon 1 for investigation. Using individual ISH probes specific for
exons 1, 10, 12 to 13, and 14 to 15, we examined the specific distribution of these
WNK4 exons, but failed to find any evidence of their differential expression in
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kidney. In conjunction with the absence of any RT-PCR evidence of splicing during
ISH probe production, this suggests that alternative splicing of these exons in WNK4
is either too rare to detect or simply does not occur in kidney. It is possible such
transcriptional diversity may be clearly present in other organs expressing WNK4.
Another possibility for the discrepancy between our findings and
immunohistochemistry evidence is that a portion of the WNK4 protein (including the
epitope against which the Lifton antibody was raised) is not exposed in certain
situations. For example in certain nephron segments, binding of WNK4 with a
potential interacting partner may shield the epitope and prevent antibody binding.
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Indeed, as WNK4 may localise in tight junctional complexes in some nephron
segments this may limit the accessibility of WNK4 epitopes in
immunohistochemistry. Having employed probes against five different regions of
WNK4 and detected a similar distribution in each case, it is likely that the
distribution reported here is accurate. At times the principal mechanisms proposed
for the action of the WNK pathway have focused on WNK gene expression in CD. It
1 17 • •
is clear from CD-specific knockout of aENaC , where mice have only minor
perturbation of electrolyte handling and normal BP, that CD might not be so pivotal
to these matters as previously thought. Our findings suggest the vast majority of both
WNK1 and WNK4 expression lies more proximally than CD and consequently it
seems quite possible these more proximal segments play the key role in the WNK
pathway regulation of electrolyte handling and BP.
Longer exposure also detected WNK4 expression by Northern hybridisation at a
much lower level in testis, suggesting that although WNK4 was originally thought to
be restricted to kidney, it seems to be expressed in other tissues although at lower
levels. Moreover, additional ISH studies demonstrating WNK4 expression in the
epithelia of testis and epididymis, and foetal colon suggest that WNK4 may play a
role in the regulation of electrolyte transport in epithelial tissues beyond the kidney.
Indeed, a study by Kahle et al. demonstrating discreet WNK4 expression in several
• S9 •
non-renal epithelia by immunohistochemistry supports such a theory . The precise
role ofWNK4 in non-epithelial tissues such as brain (including the pituitary gland)
has yet to be determined.
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Chapter 5 Antibody Development to
WNK1 and WNK4.
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5.1 Introduction
Antibodies specific for mouse WNK1 or WNK4 were not available at the
commencement of this study. Initial reports of WNK expression utilised antibodies
1 A O
raised against human WNK1 and WNK4 . The distribution patterns reported in this
study, based on immunohistochemistry on mouse kidney using these antibodies,
differ from our findings based on ISH studies using multiple probes against the same
genes (Chapters 3 and 4). Notably WNK4 expression was not detected outside the
cortex, conflicting with our studies repeatedly showing strong medullary WNK4
expression (Chapter 4). Interestingly, western blot analysis using this WNK4
antibody detected two bands (supplementary information). However, the reason for
this remains obscure and the identity or significance of the second band was not
discussed148.
Moreover, antibodies capable of differentiating between the different isoforms of
WNK1 from any species were not available. Not only is the WNK1 antibody used by
Wilson et al. unable to differentiate between WNK1-L and WNK1-S, but this
antibody is directed against an epitope encoded by exon 12 which is subject to
alternative splicing in many tissues. For example, no WNK1 protein expression was
• 148 • ...
detected in heart despite strong evidence ofWNK1 expression in this tissue from
Northern hybridisation studies.
The determination of mouse WNK1 and WNK4 cDNA sequences, and the
identification of cDNA sequence unique to each WNK1 isoform, (exons 1-4 of
WNK1-L and exon 4a ofWNK1-S; Chapter 3) made the prospect of raising specific
anti-WNK antisera possible.
5.2 Materials and Methods
5.2.1 Peptide selection
Eurogentec, a commercial company with headquarters near Seraing, Belgium (near
Leige University), specialising in peptide antibodies, was chosen for production. The
initial and most important step of peptide antibody production is peptide selection.
Two peptides for each isoform (where possible) were selected to boost our chances
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of success and avoid the inherent risk of obtaining antibodies that recognise the
peptide used for production but not the protein from which the sequence has been
derived. The amino acid sequences of WNK1-L, WNK1-S and WNK4, predicted
from the cDNA sequence, were inspected to choose suitable regions to use in
peptide-carrier conjugates for antisera generation (Table 5.1). Great care was taken to
avoid homologous regions (particularly the kinase domain, and familial
autoinhibitory domain), regions subject to alternative splicing (e.g. exons 11 and 12
of WNK1), hydrophobic sequences and also regions with a strongly predicted
secondary structure (unlikely to be exposed in native protein). Amino acid sequences
favouring flexibility, lack of secondary structure, and predicted as likely to be
surface-exposed were of key interest given the high predicted antigenicity of these
combined characteristics (albeit within a still inexact science). Peptides were chosen
for WNK1 which would differentiate between WNK1-L and WNK1-S, or detect
both (WNK1-T). Peptide selection for WNK1-S was difficult because only a 30
amino acid stretch of unique sequence exists at the N-terminus, encoded by exon 4a.
This region is also extremely cysteine-rich, which can be problematic for peptide
antibody production. Use of peptides with internal cysteines is largely precluded as
cysteine residues are often used to conjugate the peptide to the carrier protein. Only
one peptide sequence unique to WNK1-S was predicted to be suitably antigenic
(Table 5.1).
Table 5.1: Peptides selected for antibody production.
Target Peptide Coding Exon KLH Coupling
WNK1-T GRHEGRTTKRHYRKS Exon 14 C-terminus
WNK1-L RRHTMDKDSRGAA Exon 1 C-terminus
WNK1-S MDFMKKDFC Exon 4A C-terminus
WNK4 PDPPDSAGPTRSPP Exon 1 C-terminus
WNK4 RASKGVTFAGDIGRM Exon 18 N-terminus
5.2.2 Conjugation and immunisation
The selected peptides were covalently coupled to a carrier protein, keyhole limpet
hemacyanin (KLH; from the mollusc Megathura crenulata), a standard carrier
protein favoured for raising polyclonal antisera to peptide-carrier conjugates, where
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KLH assists in enhancing the antigenicity of these short peptides. Two specific
pathogen free (SPF)-rabbits were immunised with conjugated peptide, inoculated
initially in Freund's complete adjuvant and boosting monthly in Freund's incomplete
adjuvant over a three month period (involving four injections, and four bleedings).
The immunisation protocol chosen was the Eurogentec Double X program whereby
two SPF-rabbits are immunised with both conjugated peptides, derived from the
same protein. This cost-effective program, on which there were additional savings at
the time of arrangement, corresponds to two normal complete peptide antibody
production programs, but reduces the number of rabbits required from four to two. In
this way antibodies against both peptides are produced in each rabbit. Antibodies can
be separated following production according to antigen-specificity by affinity
purification for each peptide separately.
5.2.3 ELiSA testing
Eurogentec provided an ELISA antisera testing service against both components of
the conjugate inoculated: the delivered free peptides and the carrier protein (KLH).
The ELISA results indicated detection of both peptide antigens at >1/100 to 1/1000
dilution by both rabbit antisera for WNK1 (WNK1-Rabbit 1, WNK1-R1; WNK1-
Rabbit 2, WNK1-R2) and also WNK4 (WNK4-Rabbit 3, WNK1-R3; WNK4-Rabbit
4, WNK4-R4). However, the ELISA results for WNK1-S antisera (WNKIS-Rabbit
5, WNK1-R5) were negative, suggesting that this antibody production program was
less successful.
The antisera were further tested by western blotting and immunohistochemistry
according to the methods outlined in Chapter 2.
5.3 Results
5.3.1 Western blotting
The antisera generated were tested for the ability to detect WNK1 or WNK4 in
kidney lysate protein on western blots. The predicted WNK4 and especially WNK1
proteins are very large, ranging from 1,222 amino acids (WNK4) to 2,377 amino
acids (full-length WNK1). We expected to detect a ~250kDa band for WNK1-L, a
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~207kDa band for WNK1-S and a ~132kDa band for WNK4. Alternative splicing of
exon 11, exon 12 or both exons 11 and 12 would reduce WNK1 (both isoforms) by
~16kDa (154 amino acids), ~10kDa (95 amino acids) or ~26kDa (249 amino acids)
respectively. These estimates do not consider any post-translational modifications
which may occur.
WNK4 has been reported to localise to tight junction complexes in some kidney
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tubule cells . It has also been suggested that WNK1 may be present in a large
protein complex in the cell94. For this reason individual strips cut from a western blot
with alternate lanes of both soluble and insoluble mouse kidney protein were
processed with four antisera (WNK1-R1/R2 and WNK4-R3/R4). Soluble and
insoluble protein fractions were prepared from kidney homogenate as described in
section 2.2.8.1. Briefly, following centrifugation in lysis buffer soluble protein was
retained in the supernatant wheras insoluble protein precipitated in a pellet, which
was then resuspended for separation by SDS-PAGE.
As WNK1 and WNK4 are very large proteins, great care was taken to ensure both
adequate separation and Western blot transfer of kidney lysate proteins. Protein
integrity was confirmed by staining SDS polyacrylamide gels with coomassie blue.
Adequate protein transfer was confirmed by reversibly staining membranes with
Ponceau red. Preliminary studies encountered a number of problems including high
background on the membranes. This may be because the antisera were not affinity-
purified. Further dilution of the secondary antibody (from 1:1000 to 1:10,000)
reduced (but did not eliminate) background in most cases. Blocking with
5%Milk/lxTBS/0.1%Tween was standard, but variations using different blocking
agents were tried when attempting to optimise immunodetection and reduce
background.
5.3.1.1 WNK4 Immunodetection by WNK4-R3
WNK4-R3 antiserum was tested over a range of blocking conditions (varying
concentrations of milk/BSA and TBS). Ultimately, 5% BSA /lxTBS/0.1%TWEEN
seemed the best blocking solution, while still allowing detection of two potential
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WNK4 bands: WNK4a and WNK4b (Figure 5.1). The WNK4a band, although
occasionally faint, was detected in the insoluble fraction at a 1:1000 dilution of
WNK4-R3. This band was bigger than expected (~180kDa), and appeared "fuzzy".
This may be due to related post-translational modifications of WNK4 producing a
series of bands varying slightly in size and larger than the unmodified protein.
WNK4b, a smaller more distinct, band (~1 OOkDa) was detected in the soluble
fraction. The relevance of this smaller band is also difficult to assess but it may be
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Figure 5.1: WNK4 immunodetection by Western blot with WNK4-R3. Strips from a
Western blot are shown, containing alternate lanes of soluble (S) and insoluble (I) kidney
protein lysate. WNK4-R3 antiserum detects two bands across a range of antibody dilutions
and blocking conditions: a faint and "fuzzy" band (~180kDa), termed WNK4a, in the insoluble
fraction; and a smaller, more distinct band (~100kDa), termed WNK4b, in the soluble
fraction. 5% BSA was a potent blocking agent allowing detection of both WNK4a and
WNK4b with little or no background or unspecific binding.
5.3.1.2 WNK4 Immunodetection byWNK4-R4
WNK4-R4 antiserum was also tested across a range of conditions. A similar band to
that detected by WNK4-R3 (WNK4a) was seen in both fractions (faint but strongest
in insoluble fraction) by WNK4-R4 (1:1000) blocking with
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5%Milk/lxTBS/0.1%Tween (Figure 5.2). Detection was enhanced by reducing the
antiserum dilution (1:500). On varying the degree of blocking treatment very little
difference was observed between 5% and 7.5%Milk in the blocking solution.
Increasing the blocking solution further to 10%Milk began to reduce the detection
signal. The second smaller band detected by WNK4-R3, WNK4b, was not detected







5%Milk 5%Milk 7.5%Milk 10%Milk




S I S I S I SI
Figure 5.2: WNK4 immunodetection by Western blot with WNK4-R4. Strips from a
Western blot are shown, containing alternate lanes of soluble (S) and insoluble (I) kidney
protein lysate. WNK4-R4 antiserum detects a similar band to that detected previously,
WNK4a, in both fractions. Reducing the antisera dilution (1:500) enhanced detection in
blocking solutions containing either 5%Milk or 7.5%Milk. The second smaller band detected
by WNK4-R3, WNK4b, was not detected by WNK4-R4.
Differences between the two WNK4 antisera suggest that they are raised against
distinct inoculated epitopes. The WNK4 epitope against which WNK4-R3 is raised
may only be exposed in the insoluble fraction but also in a protein of smaller size,
possibly a cleaved fragment of WNK4, in the soluble fraction. The WNK4 epitope
against which WNK4-R4 is raised is apparently exposed in both protein fractions,
but is not present in this potential smaller WNK4 variant.
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5.3.1.3 WNK1 Immunodetection
Antisera raised against WNK1 were also tested across a range of conditions but
showed less promising results. A very faint band (WNKla), which was larger than
expected (280kDa; possibly due to post-translational modifications), was detected for
WNK1 in both fractions by WNK1-R1 (1:1000; Figure 5.3). Due to its size this band
likely represents WNK1-L, although it is impossible to determine whether or not
alternative splicing of exon 11 and/or 12 has occurred. Detection was enhanced
slightly by reducing the antisera dilution (1:500) and increasing the secondary
antibody. An additional smaller band (WNKlb; -140 kDa) was occasionally
detected for WNK1 in both fractions (usually stronger in the soluble fraction). This
WNKlb band is much smaller than would be expected for WNK1-S, and its nature
and relevance remain uncertain. It is possible that this WNKlb band may be related
to the small novel WNK1 bands seen by Northern hybridisation (section 3.3.3.3).
No bands of appropriate size were detected by WNK1-R2 antiserum under any of the
conditions tried. However, it is still possible that this antiserum would detect native
WNK1 protein by a different technique such as immunohistochemistry.
5.3.1.4 Future work
Despite difficulties with this western analysis potential bands for WNK1 and WNK4
were detected. It is noteworthy that bands detected by antisera raised against WNK1
were not detected by antisera raised against WNK4 and vice versa. WNK1-S antisera
were not tested by western blotting, as this antibody production program lagged
behind that ofWNK1 and WNK4. Future work could include western analysis of this
antisera. A limited amount of free peptide was supplied by Eurogentec. A logical
next step could involve pre-absorption of antisera with antigen. In addition,
immunoblots could be repeated with pre-immune antisera. These techniques would
confirm specific antigemantisera interaction and identify any non-specific binding. In
the case of multiple bands, it would also allow resolution of which immunised
peptide contains the epitope detected in which protein band. It may also be
worthwhile to test antisera derived from earlier bleeds in case a superior but transient
anti-WNK immune response was evident.
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Figure 5.3: WNK1 immunodetection by Western blot with WNK1-R1. Strips from a
Western blot are shown, containing alternate lanes of soluble (S) and insoluble (I) kidney
protein lysate. WNK1-R1 antiserum detects two bands across a range of antibody dilutions
and blocking conditions: a very faint band (~280kDa), termed WNK1a in the insoluble
fraction; and a smaller band (-140 kDa), termed WNK1b in both fractions (usually stronger in
the soluble fraction).
5.3.1.5 Immunodetection of recombinant WNK4
Shortly after this western analysis we contacted Dr. Dario Alessi and colleagues
(University of Dundee) who have generated recombinant WNK4 protein. Using our
antisera raised against WNK4 (WNK4-R3 and WNK4-R4) in parallel with their own
antibodies, they were able to demonstrate detection of recombinant WNK4 protein
(FLAG-tagged) by both WNK4-R3 (most potent) and WNK4-R4 (Figure 5.4). In a
similar study, however, they were unable to detect endogenous WNK4 protein from
tissue lysates. This suggests that endogenous WNK4 may be modified in some way
or may exist in a protein complex, and so is not in a form capable of interacting with
these antibodies.
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Figure 5.4: Immunodetection of recombinant FLAG-tagged WNK4. Both WNK4 antisera
(1:500; in 5%BSA/1xTBS/0.1%Tween) recognised purified FLAG-tagged recombinant WNK4
protein at levels as low as 1ng by western blot.
5.3.2 Immunohistochemistry
The antisera were also tested for the ability to detect WNK1 or WNK4 in their native
state by immunohistochemistry. mRNA localisation studies by ISH provided strong
clues as to the expected distribution of WNK1 and WNK4 protein (Chapters 3 and
5.3.2.1 WNK antisera testing by immunohistochemistry
An initial round of immunohistochemistry on adult mouse paraffin-embedded kidney
sections was carried out using a series of dilutions (1:500, 1:1000, 1:1500) of the
antisera: WNK1-R1, WNK1-R2, WNK4-R3 and WNK1S-R5. All sections
underwent a process of antigen retrieval in sodium citrate buffer and the DAB
detection system was used. A negative control was included, whereby the primary
antibody was rabbit IgG (I-1000, Vector). No specific antibody:antigen binding was
detected in this immunohistochemistry for any of the antisera in comparison to the
negative control.
Following this initial negative immunohistochemistry result, we decided to select just
one antiserum (WNK1-R1) and process it through a series of different conditions.
Immunohistochemistry was carried out using lower dilutions ofWNK1-R1 on both
frozen and paraffin-embedded adult mouse kidney sections. Evidence from Northern
blots suggest that WNK1 is strongly expressed in testis and so additional paraffin
4).
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embedded testis (and ovary) sections were included to determine any tissue-specific
problems. Paraffin sections underwent antigen retrieval in either sodium citrate
buffer or glycine/EDTA buffer. An alternative detection system (APAAP) was also
tried instead ofDAB. No specific antibody:antigen binding was detected for WNK1-
R1 antisera in any of the tissues tested, frozen or paraffin-embedded, in comparison
to negative controls.
5.3.2.2 Positive control for analysis by immunohistochemistry
After these negative immunohistochemistry studies it became important to have a
positive control and steps were taken to work up a commercially available antibody
to mouse ROMK (APC-001, Alomone Labs) and an antibody to mouse NCC (gift
from Jan Loffing) for use as such a positive control in further studies in kidney.
Immunohistochemistry was carried out on paraffin-embedded sections of adult
mouse kidney using serial dilutions (1:25, 1:50, 1:100, and 1:200) of the anti-ROMK
antibody. Sections underwent a process of antigen retrieval in sodium citrate buffer
and the DAB detection system was used. No specific antibody:antigen binding was
detected in comparison to a negative control.
A second round of immunohistochemistry was carried out using an antibody raised
against NCC. Both paraffin embedded (+/- undergoing sodium citrate buffer antigen
retrieval) and frozen adult mouse kidney sections were processed. DAB detection
revealed specific staining for NCC in distal nephron segments, following antigen
retrieval on paraffin embedded sections. Staining was predominantly apical, as
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expected, in tubules typical of DCT in morphology and cortical distribution ' .
Negative controls showed no specific antibody:antigen binding.
5.3.2.3 Future immunohistochemistry studies
Unfortunately due to a shortage of time, further immunohistochemical work was not
possible. Ideally, future analysis of WNK antisera should be carried out alongside
both positive and negative controls. The anti-ROMK and particularly anti-NCC
antibodies used in this study seemed good candidates to act as a positive control.
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They are both expressed at substantial levels in kidney with distinct distribution
patterns. The anti-ROMK antibody has been reported to work in
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immunohistochemistry studies on kidney in the past. It is unclear why this antibody
did not work in our studies. Perhaps further variation of conditions such as tissue
fixation, antigen retrieval, blocking, antibody dilution, and detection may yield
positive results for this antibody in the future. Further work including the anti-NCC
antibody as a positive control would facilitate assessment of the WNK antisera using
a protocol demonstrated to work in kidney, so that firm conclusions could be drawn
about the effectiveness of these antisera in immunohistochemical detection ofWNK
proteins in mouse tissues.
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Figure 5.5: Detection of NCC by immunohistochemistry. Images of paraffin embedded
mouse kidney sections (magnification: left, x10; right x40) counterstained with hematoxylin.
Anti-NCC antibody (1:500) detects NCC in DCT (arrowheads) looping close to glomeruli (*).
Negative controls show no specific signal.
5.4 Discussion
At present there is a lack of commercially available high quality anti-WNK
antibodies. In particular, there are no antibodies capable of differentiating between
the WNK1 isoforms. The original study reporting the distribution of WNK1
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expression employed an antibody raised to an exon which is often subject to
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alternative splicing . Most in vitro WNK studies currently rely on commercial
antibodies raised to incorporated protein tags (e.g. FLAG). However, such antibodies
are not useful when investigating in vivo expression of native protein.
We have attempted to raise antisera to mouse WNK1 (long, short, and total) and
WNK4. Western analysis detected potential bands for both proteins in mouse kidney.
A potential band, larger in size than expected, was detected for WNK1. Limited
western blot analysis described in other studies, however, report a band of similar
size137. Thus, it is possible that this size difference is due to post-translational
modifications ofWNK1, such as glycosylation or phosphorylation, which would not
be unexpected given the sheer size of this protein. Anti-WNK4 antisera also detected
a larger band than expected, and the "fuzzy" appearance of this band suggests post-
translational modifications.
Although not striking, these results are promising, particularly as others in the WNK
field have been unable to detect native protein in tissue lysates, despite readily
detecting recombinant protein in vitro. Perhaps WNKs are sequestered in
multiprotein complexes as suggested in some studies, possibly even in tight
junctions, which shield the targeted epitopes from antibody binding. Bands that were
inappropriately smaller in size were also detected for both WNK1 and WNK4. These
smaller bands suggest the possibility of a post-translational cleavage event. In fact,
smaller bands were detected for WNK1 by Northern hybridisation (Figure 3.9).
Many kinases are subject to such post-translational cleavage events, with subsequent
trafficking of the cleaved fragment elsewhere in the cell . Such a cleaved WNK
fragment may play regulatory role within the WNK pathway.
The success of our immunohistochemistry studies with the anti-NCC antibody
facilitates further assessment of these WNK antisera in conjunction with this strong
positive control. If successful this would greatly broaden the possibilities for future
work on this pathway, and could potentially resolve the discrepancy between the
protein distributions reported by Lifton and colleagues and our ISH localisation
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studies reported in Chapters 3 and 4. Clearly, further work is required to determine
the potential applications of these anti-WNK antisera.
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Chapter 6 Dietary Electrolyte Driven
Responses in the Renal WNK Kinase
Pathway in Vivo.
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6.1 Introduction
The role of WNK1 and WNK4 in the control of electrolyte balance and BP first
• • • • 148
became apparent with their mutation being associated with Gordon syndrome , a
disorder featuring a NaCl/K+ and H+ imbalance. Patients are hyper-responsive to
thiazide diuretics, further implicating a renal42'112 electrolyte handling defect as the
basis of this disease. Mutations in either WNK1 or WNK4 cause a broadly similar
phenotype (hypertension and hyperkalaemia despite a normal GFR) suggesting that
WNK1 and WNK4 function in a common pathway. Unlike most monogenic
disorders affecting BP, which feature reciprocal Na+ and K+ (and/or H+) imbalances
and share a relationship to the aldosterone pathway (Table 1.1 and Figure 1.6),
Gordon syndrome features concurrent NaCl and K+ (and/or H+) retention13'42'148. This
unusual characteristic indicates the existence of a novel "WNK pathway" functioning
in normal physiology to enable independent balance of K+ and Na+ (and ECF
volume) by the kidney, ultimately regulating electrolyte balance and maintaining BP
within the normal range. The BP-regulatory role of this WNK pathway is conserved
in evolution as WNK1+/- mice are hypotensive165.
Expression studies109'148 (including those described in Chapters 3 and 4 of this thesis)
demonstrate that components of the WNK pathway, most notably WNK1-S and
WNK4, co-localise with a number of important electrolyte transporters in nephron
segments which have major influence on long-term NaCl reabsorption, BP, K+ and
acid-base balance47'82; processes all disrupted in Gordon syndrome. Early functional
studies suggest that, at least in vitro, WNK1 and WNK4 may regulate a number of
these renal electrolyte transporters (Table 1.3). Most intriguingly, Xenopus oocyte
studies suggest a WNK signalling pathway where WNK4 restrains two major
effectors of kidney electrolyte transport: K+ secretion via ROMK56 and NaCl
reabsorption via NCC149'163, reducing their cell surface expression. Evidence also
suggests that WNK1-L can in turn suppress this WNK4-mediated inhibition161'162,
providing further support for the theory that WNK1 and WNK4 participate in a
common pathway. However, at the time of our studies described in this chapter, there
were no reports of a functional role for kinase-deficient WNK1-S, the predominant
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WNK1 isoform in kidney, nor was there any information on how the WNK pathway
may be regulated in vivo in mammalian kidney.
Based on findings from this Xenopus oocyte work, the WNK molecular switch
theory was proposed (section 1.5.1)10'56. This hypothesis suggests that regulation of
renal electrolyte transport by the WNK pathway plays a key role in normal
physiology, powerfully contributing to the renal response to fluctuations in blood
volume and K+ load. This WNK molecular switch would generate a response
matching each of these stimuli that may complement aldosterone which is similarly
induced by the very different stimuli of hypovolemia or K+ load. To begin to test this
hypothesis, we chose to focus on one side of this molecular switch, principally
examining the response of the WNK pathway to dietary K+ flux. In order to progress
from the valuable insights of these Xenopus oocyte studies, we adopted a more
relevant model, the mouse, which allowed us to investigate the physiological role of
the WNK pathway in vivo, in an epithelial, renal, mammalian system. It is well
established that the full renal response to maintain normal BP or to compensate for
altered dietary electrolyte intake involves a substantial component that is slow to
fully develop (taking many hours/days), persistent and accompanied by significant
changes in nephron ultrastructure and gene expression16,44. Based on this we tracked
the in vivo gene expression responses of the WNK pathway to chronic challenges
altering renal electrolyte handling in mice, driven through variations in dietary
electrolyte intake and aldosterone level.
6.2 Materials and Methods
6.2.1 Animal Treatments
The K+-diet study involved adult male C57BL/6J mice, housed in pairs in mouse
metabolic cages. Following three days of acclimatisation, groups (n=6) of mice
commenced specific diets as outlined in Table 6.1. Batch-analysis confirmed diets
were well matched for Na+ (0.28±0.05%: all diets) and CI" content (0.7±0.12%: NK
and LK). Mice took the specified diets for 10 days, with daily monitoring of
bodyweight, food and water intake and 24hr urine collections for volume and
electrolyte composition. Measurement of K+, Na+ and CI" in urine collections
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allowed changes in electrolyte balance in response to the altered dietary intake to be
monitored. Electrolytes were expressed as a ratio of creatinine or Na+-excretion
(Cl/Cre, K/Cre, K/Na). Collections over a 24hour period and normalisation to
creatinine standardises measurements, making these observations much more robust
against inaccuracies of incomplete collections.
Table 6.1: Experimental groups in the dietary K+ study.
Group Treatment Description K+ Composition
LK Low potassium (0.006%)K+diet
NK Normal potassium (0.33%)K+ diet
HK High potassium (3.3%)K+, (4.4%)Cf diet
The aldosterone study' involved adult male C57BL/6J mice, housed in pairs in
normal cages. Groups of mice (n=6) were given normal (0.3%) Na+ diet and had
subcutaneous MP implanted delivering treatments as outlined in Table 6.2.
Table 6.2: Experimental groups in the aldosterone study.
Group Treatment Description MP Infusion Delivery Rate
Adx Bilateral adrenalectomy* Saline only -
Ctrl Control Saline only -
Aldo150 High Aldosterone Aldosterone 150 pg/kg/d
*0.9% saline drinking water
The Na+-diet experiment"" involved adult male C57BL/6J mice, housed in pairs in
mouse metabolic cages. Animals were allowed one week to acclimatise, following
which they commenced specific Na+-dietary treatments (as outlined in Table 6.3)
lasting 7 days.
6.3 Results
6.3.1 Effects of Chronic Variation in Dietary K+ in Vivo.
Mice were given group treatments varying dietary K+-intake for 10 days
(LK/NK/HK; Table 6.1).
+
Dr. Elaine Marshall provided resources for this study.
i Wei Xue provided resources for this study.
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Table 6.3: Experimental Groups in Na+ Study.
Group Treatment Description Na+ Composition
LNa Low sodium 0.03% Na+ Diet
NNa Normal sodium 0.3% Na+ Diet j
HNa High sodium 3% Na+ Diet
6.3.1.1 Bodyweight, Food Intake and Fluid Balance
The LK group showed borderline lower weight becoming significant vs. HK (but not
NK) at the end of the experiment (25.6±0.6g versus 27.3±0.6g, respectively; p=0.03)
but mice appeared healthy throughout (Table 6.4 and Figure 6.1(a-c)). Both HK and
LK groups developed a higher fluid intake and urinary output compared to the NK
group (HK vs. NK significant at conclusion: >3.4-fold higher intake (p<0.05) and
>4.9-fold higher output (p<0.01)).
6.3.1.2 Urinary Electrolytes
Mice were allowed a period of three days (days 1-3) to acclimatise to metabolic
cages. Following this, during the initial 3 days of active treatment with specific diets
(days 4-6) K/Cre and Cl/Cre rose 6.8-fold and 4.9-fold respectively with HK,
remained unchanged with NK and K/Cre showed a dramatic 24.4-fold decrease with
LK. After day 5-6 group K/Cre ratios did not significantly change indicating re-
establishment of appropriate electrolyte balance. The HK and LK groups
demonstrated a >17-fold increase and a >14-fold decrease respectively in K/Na by
day 6 (Figure 6.1(d-f)).
6.3.1.3 Plasma Measurements
As expected, HK induced a small but significant increase in plasma K+ within the
normal range (HK vs. NK: 4.85+0.2 mmol/L versus 4.1±0.2 mmol/L respectively,
p=0.03). Plasma aldosterone was elevated with HK (1879 ±387pmol/L versus NK,
793 ±207pmol/L), but was unchanged with LK (834 ±297pmol/L; Table 6.4). Plasma
renin activity (PRA) and corticosterone did not change significantly across the
treatment groups (Table 6.4).
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Figure 6.1: Effect of dietary K+ intake on metabolic measurements. Mice were treated
with LK/NK/HK diets (as outlined in Table 6.1) for 10 days, and daily measurements of (a)
food intake, (b) fluid intake and (c) urine output were recorded. Urinary electrolyte excretion
was measured daily , reflected changes in dietary electrolyte intake and was expressed as a
ratio of creatinine or Na+-excretion (Cl/Cre, K/Cre, K/Na: d-f) A transient decrease in food
intake was observed in the HK group on day 4 immediately following the introduction of
treatment diet.
6.3.1.4 WNK expression responses to dietary K+ challenge
Specific real-time PCR assays were used to detect WNK expression responses to
dietary K+ intake (Figure 6.2). This real-time PCR analysis indicated that both renal
WNK1-S and WNK4 expression is regulated by increasing dietary K+ intake.
Specifically WNK1-S was downregulated by 20±9.3% with LK (p=0.04) and
upregulated by 30±10.4% with HK (p=0.01, a 50±10.2% rise from LK to HK), as
was total WNK1 (WNK1-T: 24±7% increase, P=0.0009) compared to NK (Figure
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Table 6.4: Metabolic measurements in K+ Study.
'
-— Low K(LK) Normal K(NK) High K(HK)
Initial Bodyweight(g) 29.7±0.7 28.8+0.5 29.8+0.6
Final Bodyweight(g) 25.6+0.5 26.9+0.3 27.3+0.6
Plasma K+(mM)A 4.13+0.22 4.08+0.22 4.85+0.2
Plasma Na+(mM)u 145.4+0.4 146+0.6 144.3+0.7
Plasma CI'(mM)c 114.4+ 1.54 112+1 114.5+1.05
Plasma Creatinine(pM)D 13.8+2.24 14.4+1.21 12.5+1.44
Aldosterone(pmol/L) 834.2+297.2 793+206.8 1878.7+387.1
PRA(ng/ml/h) 4.38+1.12 4.45+0.83 5.71+0.34
Corticosterone(nmol/L) 345.8+48.8 342+58.2 300+42.6
chemistry analysers and remained within the normal range for all groups. Normal plasma
ranges for: AtC, 3.0-8.3mmol/L91, but carefully taken having a narrower range probably
nearer 3.8-6.8mmol/133146:168; BNa+, 139-157mmol/L; cCf, 104-119mmol/L17; DCreatinine, 5-
67micromol/L91. Values are means±SE.
In regions with clear WNK1-S expression (Figure 6.3(b)) ISH analysis showed
upregulation in cortex by HK (vs. NK: 2.1±0.6-fold, (p=0.003) [1-3.3; 95%
confidence interval]). WNK1-S distribution remained cortical without striking
change. Over kidney regions with clear WNK4 expression there was a 2.3±0.6-fold
[1.1-3.5] upregulation in expression with HK (p=0.02) (Figure 6.3(c)), whilst the
apparent possible increase in WNK4 with LK (82±51.3% vs. NK) did not reach
significance.
6.3.2 WNK expression response to aldosterone challenge
As aldosterone plays a key role in K+ secretion we also examined the effect of
fluctuations in aldosterone level on WNK expression. In this experiment, groups of
mice were given treatments (Table6.2) involving excess aldosterone via MP (Aldo;
150pg aldosterone/kg/day?0) or adrenalectomised (Adx; supplemented with 0.9%
saline drinking water) to abolish aldosterone production. Real-time PCR showed that
WNK1-S expression rose significantly across the Adx-aldo excess range (43±7.6%,
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p=0.0002). Specifically, aldo treatment induced a 32±6.7% [18.9-45.2] WNK1-S
upregulation (p=0.0002) without affecting WNK1-L or WNK4 expression (Figure









Figure 6.2: Schematic representation of WNK cDNA structure showing 5'-exon
composition and probe positions. The cDNA structures of the 5'-regions of kinase-intact
WNK1-L (containing exons 1-4), kinase-deficient WNK1-S (containing exon 4a in place of
exons 1-4) and WNK4 are illustrated with vertical bars representing exon:exon boundaries.
Numbers within rectangles refer to exon numbers. Black boxes specify the cDNA region
probed by ISH. Double-headed arrows indicate the exon:exon boundary crossed by probes
used in real-time PCR studies. Horizontal dashed lines indicate further exons not included in
this illustration.
6.3.3 WNK expression response to dietary Na+ challenge
To test whether varied dietary Na+ induces similar WNK expression changes, mice
were fed diets with a specific Na+ content (LNa/NNa/HNa; Table 6.3) for 6 days.
WNK1-S showed a just significant downregulation, by 39±16% of control levels,
between HNa and LNa (p=0.049, ANOVAlsd; Figure 6.5). No other significant
changes in WNK expression were observed across the treatment groups.
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Figure 6.3: WNK expression in response to varied K+ intake, (a) Real-time PCR results
from renal RNA from groups of mice (n=6) with variations in dietary K+. WNK1-S expression
is significantly downregulated with LK whilst WNK1-S and WNK4 are upregulated with HK.
No significant changes were observed in WNK1-L expression across the experimental
groups, (b-c) ISH analysis ofWNK1-S (n=6) and WNK4 (n=6 for LK and HK groups and n=4
for NK group owing to some sections being unsuitable for full analysis) in kidney did not
detect any major shifts in distribution and level of WNK expression with varied dietary K+at
the regional level, (i) Representative sections and (ii) densitometric analysis from ISH
studies. WNK1-S (b) and WNK4 (c) have different expression profiles with WNK1-S
expression restricted to the cortex, and WNK4 restricted to cortex and outer medulla. WNK1-
S and WNK4 expression are both upregulated with HK.
*p=0.009; **p=0.04; ***p=0.01; #p=0.003; ##p=0.02.
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Figure 6.4: WNK expression in response to variations in aldosterone. Mice were given
(n=6) subcutaneous (Alzet®) MP treatments for 6 days as outlined in Table 6.2. PRA and
aldosterone measurements allowed confirmation of adequacy of treatments. WNK1-S
expression was upregulated by chronic aldosterone treatment (150pg/kg/day, 6 days) but
was unchanged in the absence of aldosterone following Adx. No changes in WNK1-L or
WNK4 were observed across the experimental groups.
*p=0.0002; **p=0.02.
6.4 Discussion
This study is one of the first to investigate the WNK pathway in vivo in a
physiologically relevant system, the mouse. It is well established that relevant
aspects of human physiology and their disorders are very well modelled in mice
particularly mechanisms of electrolyte handling and the extent to which
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abnormalities in such mechanisms affect long-term BP control ' ' . For example,
where transgenic models of human distal nephron disorders have been created, the
disease phenotypes have been largely faithfully reproduced e.g. Liddle's syndrome11^
and Bartter syndrome76'132.
Up to now, Xenopus oocyte studies have provided invaluable evidence of WNK
pathway regulation of important mediators of distal nephron electrolyte transport
(Tablel.3). These key studies led to the proposal that the WNK pathway plays a
fundamental role in normal physiology, determining the renal response to
fluctuations in blood volume and K+ load, essentially forming a molecular switch. In
the current study we have attempted to investigate one side of this WNK molecular
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switch in vivo by challenging mice with varied dietary K+ intake and examining the
renal WNK gene expression response.
We found notable changes in renal expression ofWNK genes with varied dietary K+
intake, indicating that the WNK pathway responds in vivo to this physiological
determinant of electrolyte balance and BP. WNK1-S expression changes correlate
with K+-intake, stressing the importance of this isoform, and segments strongly
expressing it (DCT and CNT), in K+ homeostasis. High K+-intake also increased
WNK4 expression. These coordinated WNK expression changes seem functionally
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Figure 6.5: WNK expression in response to varied Na+ intake. Mice were treated with
LNa/NNa/HNa diets for 7 days as outlined in Table 6.3. WNK1-S showed a just significant
downregulation (by ANOVALsd) between high and low Na+ diet. No other significant changes
in WNK expression were observed across the treatment groups.
*p=0.049 (ANOVAlsd)
The theory that both aldosterone-dependent and independent mechanisms are
involved in K+-secretion47'82, made examination of effects of fluctuations in
circulating aldosterone levels of potential interest. In a preliminary investigation of
this, we looked at renal WNK gene expression using resources from another study'
where animals had very low aldosterone (due to Adx), normal aldosterone (control
group) or high aldosterone (11.2-fold elevation versus controls via MP infusion). Our
Chapter 6. Dietary electrolyte driven responses in the renal WNK kinase pathway in vivo. 121
WNK Kinases: Novel Regulators of Electrolyte Balance and Blood Pressure.
findings indicate that aldosterone does not regulate WNK1-L or WNK4 expression
but may play some role in WNK1-S regulation. However, aldosterone seems unlikely
to be the sole regulator ofWNK1-S expression. Indeed, lack of effect of Adx (loss of
aldosterone) suggests decreased WNK1-S expression with LK was aldosterone-
independent and indeed plasma aldosterone in the LK and NK groups were not
significantly different. Furthermore, the observed WNK1-S expression changes do
not correlate with plasma aldosterone. Thus similar changes in WNK1-S expression
accompany very different aldosterone elevations, 2.3-fold (with HK) and 11.2-fold
(with aldosterone infusion). This evidence suggests aldosterone-independent
regulation ofWNK1-S expression.
This is supported by Gordon syndrome physiology where plasma aldosterone is often
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in the normal range and a phenotype of combined hypertension and hyperkalaemia
(indicative of both NaCl and K+ retention) could not be produced by a mutation
solely in the aldosterone pathway which classically regulates Na+ and K+ balance in a
reciprocal manner14. The nephron must switch via a different mechanism to a mode
uncoupling Na+-reabsorption and K+-secretion56. It may be that on a HK diet the
animals become more responsive to aldosterone: such increased aldosterone-
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responsiveness has been reported in mice with Liddle's syndrome . So, although
aldosterone levels are much lower with HK treatment compared to treatment where
aldosterone is given in excess, similar upregulation of WNK1-S occurs. Clearly
further studies may fully clarify the relative importance of aldosterone in WNK
expression regulation.
We also took a preliminary look at the opposite side of the WNK molecular switch.
As sodium balance is key in determining ECF volume and influencing BP WNK
gene expression responses across a wide range (100-fold) of chronic dietary Na+
intake1 were studied. With variations in dietary Na+, a trend to lower WNK1-S
expression as dietary Na+ reduced just reached significance when comparing high
and low Na+ groups. It is intriguing that this might represent a response of the WNK
pathway to subtle reductions in ECF volume as dietary Na+ falls. Clearly, to examine
this side of the switch properly would require more extensive experiments to look
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more directly at this regulation and involve studies where volume status is accurately
controlled.
How do these results expand understanding of this novel WNK pathway? The
pathology of Gordon syndrome highlights the importance of DCT (where WNK1-S
is strongly expressed) in electrolyte balance and BP control, as patients are usually
hyper-responsive to thiazide diuretics13'42,119. Xenopus oocyte work suggests WNK4
may inhibit NCC in DCT and WNK1-L prevents this inhibition149'161. This work
provides some of the first clues as to the role in vivo of WNK1-S, the predominant
WNK1 isoform in kidney.
WNK1-S is kinase deficient, but retains domains (e.g. coiled-coils) likely involved in
multimeric/tetrameric WNK1 assembly151'152. Intriguingly, strongest WNK1-S and
WNK4 expression co-localise in DCT-CNT, where they may contribute to the same
mechanism regulating K+ homeostasis. Consequently, we propose in DCT-CNT,
WNK1-S could bind and counterbalance WNK1-L effects, especially shielding
WNK4 from inhibition. Alternatively, WNK1-S could shield WNK4 from any form
of inhibitory kinase (not just WNK1-L), interacting directly with a WNK-binding
site on WNK4 or on an inhibitory kinase. Thus, an increase in WNK1-S or WNK4
(as in our in vivo study) would downregulate NCC-mediated NaCl reabsorption in
DCT, increasing distal Na+ delivery. This directly stimulates K+-loss, as Na+ is
4-89
reabsorbed distally to DCT1 via ENaC, in exchange for K . This putative pathway
is illustrated in Figure 6.6. This phenomenon accompanies thiazide diuretic treatment
driving a similar increase in K+-secretion82. Finally, downregulation ofWNK1-S on
chronically reducing dietary Na+ suggests this distal delivery of Na+ is restrained
when there is a need to conserve body sodium and ECF volume.
We propose that the alleged molecular switch56 suggested to explain Gordon
syndrome is based on the distal delivery ofNa+ (Figure 6.6). This hypothesis is also
supported by careful ultrastructural studies57 showing that on a HK diet early CNT
4~ 4" S 7 •
develops extensive hypertrophy and increased Na /K -ATPase . Similar CNT
changes occur with NCC-/- Gitelman's mice or high dose thiazide diuretics where
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High K+ Intake
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Figure 6.6: Schematic depiction of potential WNK pathway in distal nephron. The WNK
pathway is suggested to regulate the extent of NaCI reabsorption in (early) DCT in the
manner of the alleged molecular switch56 proposed in explaining Gordon syndrome. A high
K+ intake switches to lower Na+ reabsorption via NCC in DCT so distal Na+ delivery rises
allowing K+ to be cleared. In Gordon syndrome, however, the switch appears to be jammed
in the opposite direction. Excessive reabsorption of Na+ occurring in DCT, due to loss of
inhibition of NCC by the WNK pathway, would lead to a reduction in distal Na+ delivery.
Consequently, K+ could not be cleared efficiently, leading to both hypertension and
hyperkalaemia.
reduced DCT reabsorption directs NaCI distally predisposing to hypokalaemia. In
Gordon syndrome the switch appears jammed in the opposite direction,
inappropriately engaging a response these studies suggest is normal when body K+ or
Na+ (and so ECF volume) are falling and require conservation. Excessive Na+-
reabsorption in DCT (diminished inhibition ofNCC) reduces distal Na+ delivery and
K+-secretion, causing hypertension and hyperkalaemia (Figure 6.6).
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Chapter 7 Distribution and Regulation of
ROMK Gene Expression in Mouse.
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7.1 Introduction
The kidney plays a dominant role in long-term regulation of both BP and K+ balance,
features that are simultaneously disrupted in Gordon syndrome. The renal
mechanisms achieving such regulation of K+ balance are far from fully understood,
take many minutes/hours to fully develop, are powerful in restoring K+ balance, and
sophisticated in usually achieving this with minimal effect on other electrolytes or
fluid balance. Whilst in health this results in the regulation of K+ and ECF
volume/BP seemingly little influenced by one another, it is revealing that when key
elements in such homeostatic control are disrupted (e.g. mutations of the aldosterone-
ENaC or the WNK kinase pathways or the renal epithelial K+ channel ROMK, see
below) there are usually linked disorders in K+, BP and indeed also acid-base
regulation (Table 1.1 and Figure 1.6). This clearly shows these largely seemingly
unconnected renal homeostatic processes are in fact interwoven. In this regard the
channel ROMK is of key importance being both important in K+ handling and in its
various forms at the intersection of these key pathways.
Dietary K+ intake plays a key role in modulating K+ secretion: an increase in K+
intake stimulates, whereas a low K intake inhibits K secretion ' ' . Remarkably,
during K+ depletion, the CD switches from a largely K+ secreting segment to a site of
K+ reabsorption. In severe K+ restriction several attendant processes assist in renal
function with minimal K+, including the induction and recycling of NH4+, an ion
which can substitute for K+ to maintain key transport of NaCl by NKCC2 and
Na+/K+-ATPase. The colonic isoform of the H+/K+-ATPase pump (cElKA) in OMCD
may play an important role in this K+ scavenging switch when renal function is run in
a K+ conserving state as it is reportedly upregulated in K+-deficiency4'28'61'62'103'105.
Increased cHKA could facilitate increased K+ reabsorption and/or proton secretion
(facilitating NFE"1" excretion) in the OMCD depending on the extent of K+ recycling.
In a normal or high K+ state, K+ secretion is mediated by a two step process: entry
through the basolateral Na+/K+-ATPase pump of principal cells, and secretion into
the lumen along an electrochemical gradient via apical K+ channels. Patch-clamp
studies identified "epithelial K+ channels" apparently capable of such apical K+
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secretion in distal nephron. Many years later a cDNA was identified encoding a
member of the ATP-sensitive inward rectifying K+ channel family, with apical
expression in distal nephron seeming to fulfil such a function, the ROMK channel47.
This epithelial K+ channel is reported to mediate net K+ secretion in CNT and CCD
and also apical K+ recycling in TAL3'47. Loss-of-function mutations in the human
ROMK gene (KCNJ1) cause Bartter syndrome1'127, featuring hypokalaemic
metabolic alkalosis and renal salt wasting, consistent with the crucial role of ROMK
in facilitating NaCl reabsorption through NKCC2 (despite a low luminal K+
concentration) in the TAL. A ROMK-/- mouse has been generated73, confirming that
ROMK forms the 30 pS (low conductance) K+ recycling/secretory channel in the
TAL and CD and is also required for expression of the 70 pS (medium
conductance) K+ recycling channel in the TAL75.
The ROMK gene contains several exons producing alternatively spliced
transcripts8'9'11'12'48'60'124'164'167, with ROMK1-3 being the major kidney isoforms. Rat
ROMK1 and ROMK2 are similar to the corresponding human isoforms, however a
rat homolog of the third human ROMK isoform has not been identified47. At the time
of these studies the exon-intron structure and alternative isoforms of the mouse
ROMK gene were less well defined. Alternative splicing of ROMK generates
proteins that differ in the amino acid sequence and length of their NH2 termini, but
are identical to each other over the remainder of the peptide. Some studies of
differential expression ofROMK isoforms along the nephron from TAL to OMCD in
rat12'65 have been widely reported to show ROMK2 and 3 expressed in TAL and
DCT, while principal cells in CCD express ROMK1 and 2. The OMCD cells only
express ROMK1.
ROMK expression and function is intricately regulated by a wide variety of factors,
including intracellular pjq19-29'88-156 and ^TP48'90'118, jncreasjng intracellular pH
and ADP activating the channel. A number of studies have also examined ROMK
gene expression in response to dietary K+ intake, but the findings have been
somewhat inconsistent. Nonetheless, the overview has been that ROMK is
upregulated with high K+ intake and downregulated with low K+ intake47. The
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regulation of individual ROMK isoforms by dietary K+ intake remains largely
unexplored, particularly in mouse, due at least in part to the lack of isoform-specific
antibodies.
Despite huge advances in our understanding of K+ homeostasis, a number of issues
remain unresolved. For example, although ROMK is regarded as the main exit portal
for K+ in the kidney, (type II) Bartter syndrome patients, with inactivating ROMK
mutations, and ROMK-/- mice are hypokalaemic and have a high rate of urinary K+
excretion. Thus, the precise pathways employed by the kidney to manage K+ balance
require further investigation. As ROMK was reported as a target of the WNK
pathway, the purpose of the present study was to examine the effects of fluctuations
in dietary K+ intake on mouse ROMK gene expression in the kidney, so extending
the study of these mechanisms driven by chronic K+ diet beyond WNK1 and WNK4
(Chapter 6) to examine this key channel, ROMK, and its conserved isoforms. We
found striking differences in mouse ROMK isoform distributions in keeping with the
literature available from studies in human and rat. However, we also found striking
differential regulation of these isoforms by high or low dietary K+ intake. Changes in
ROMK isoform expression with K+ depletion were paralleled by changes in cHKA
allowing the potential to facilitate H+ and NH4+ excretion and acid-base homeostasis
in K+ deficiency. These findings may have important implications for our
understanding of the role ofROMK isoforms in K+, H+, and acid-base balance.
7.2 Materials and Methods
This study utilised resources outlined in Chapter 6. Primers, probes and real-time
PCR assays are outlined in Tables 2.1-2.3.
7.3 Results
7.3.1 ROMK isoform distribution in mouse kidney
ROMK expression is reportedly regulated in parallel with K+-intake. However, real¬
time PCR, detecting all ROMK isoforms, indicated no significant change across K+-
diet groups, (8.5±8.3%, p=NS, Figure 7.1). Accordingly, we investigated individual
isoform expression using exon-specific ISH probes for major ROMK isoforms
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(Figure 7.2), R0MK1, 2, and 3 on adult mouse kidney (Figure 7.3). Serial sections
were probed for ROMK isoforms and NKCC2 or yENaC (TAL and CD markers
respectively). It is strikingly clear in medulla, ROMK1 is expressed in OMCD, (like
yENaC, Figure 7.3 {lower panels)) with limited cortical (CCD) extension, whilst
• 78
yENaC expression spans late DCT-OMCD, being strongest in cortex . In contrast,
ROMK2 expression overlaps that of NKCC2 in TAL and also yENaC in cortex
(including CCD) (Figure 7.3 (upper panels)). No clear expression of ROMK3 was
detected.
ROMK-T
Figure 7.1: ROMK expression in response to varied K+ intake. No significant changes
were observed in ROMK-T expression (representing combined expression of all isoforms) using
real-time PCR.
7.3.2 Expression of ROMK isoforms in response to changes in K+-
intake
Real-time PCR revealed upregulation of ROMK2 with HK by 47+17.6% (vs. NK,
p=0.008) but unchanged with LK. In contrast, ROMK1 was unchanged with HK but
strongly increased, 2.6+0.3-fold [2-3.2], with LK (vs. NK, p=0.0002). ISH studies
showed with LK ROMK1 extended further into CCD Figure 7.4(d) and image
analysis revealed a 2.2±0.3-fold [1.7-2.7] increase in renal ROMK1 expression (LK
vs. NK, p=0.0001; Figure 7.4(b)) but no significant differences with HK. In contrast,
HK induced a 76±33% [12-141] increase in ROMK2 expression (vs. NK, p=0.01;
Figure 7.4(c)) with no significant change on LK. Thus, the shift in ROMK2/ROMK1
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Figure 7.2: Schematic depiction of ROMK isoforms in mouse. The human and rat ROMK
genes produce alternatively spliced transcripts all sharing a core exon. The most
predominant isoforms in kidney are hROMK1-3(NM_000220, NM_153764 and NM_153765
respectively)124. In rat similarly rROMK1-3 isoforms are identified with rROMK1-2 being
homologues of hROMK1-2 respectively, but rROMK3 (AF081367) having no homology to
hROMK3. The exon-intron structure and alternative isoforms of mouse ROMK gene is less
well defined. For the purpose of these studies we identified mouse homologs of hROMKI
(exon 3), hROMK2 (exon 1) and rROMK3 (132bp, 86% homology and appropriately
positioned within the mouse ROMK gene locus to be a homolog of the unique alternate 5'
exon (termed exon 2 above) in rROMK3). There was no clearly identifiable mouse homolog
of hROMK3. Base-pair positions given in this figure refer to the mouse genome on contig
NT_039472.3 which spans the ROMK locus (chromosome 9 at 33.359-32.386Mb build 33.1).
7.3.3 Expression of cHKA in response to changes in K+-intake
Consistent with reports of upregulation of non-gastric H+/K+-ATPase in K+-deficient
states, cHKA expression was increased 4.1±0.7-fold [2.7-5.5] by LK (vs. NK:
p=0.0002; Figure 7.5(a)). ISH analysis clearly showed upregulated medullary
expression with LK, but usual analysis was impaired by high background.
Normalising for this allowed an estimate of at least 2.0±0.2-fold [1.6-2.45] (p=0.001)
increased medullary cHKA expression (LK vs. NK: Figure 7.5(b)), however the
limitations because of high background mean this is likely to be an underestimate.
7.4 Discussion
As part of our K+ study (outlined in Chapter 6) we looked at the expression of
ROMK and cHKA, genes known to play key roles in renal K+ handling, using
isoform-specific real-time PCR assays and ISH. Very few tools reliably
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differentiating isoforms of these genes are currently available especially when
quantifying changes and examining distribution. Moreover, this study allows
investigation of changes within kidney regions not easily accessible to micropuncture
techniques (e.g. OMCD, deep distal nephron arcades/CNT), and avoids dangers of
unequal RNA degradation, a concern associated with microdissection. Unfortunately,
there are no good, well validated, cell-line models for several nephron segments,
including OMCD and CNT. Thus, this study provided a unique opportunity to
examine the distribution and gene expression responses of ROMK and cHKA to
substantial variation in dietary K+ intake.
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Figure 7.3: Distribution of gene expression for ROMK1 and ROMK2 in mouse. Top and
bottom panels each show dark-field ISH studies for the genes indicated on 3 serial
transverse kidney sections. The expression pattern of NKCC2 and yENaC in the sections
flanking ROMK isoforms allows the distribution of TAL (NKCC2) and late DCT-CD (to inner
stripe/inner medulla junction: yENaC) to be compared. ROMK1 clearly has CD expression
matching yENaC but only weakly extending to cortex. ROMK2 matches NKCC2 but has
greater spread of cortical expression than NKCC2 and yENaC combined as it is expressed
in early DOT as well.
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Contrary to reports that ROMK expression is regulated in parallel with K+-intake, we
were unable to detect any significant change in total ROMK expression across the
treatment groups. Studies reporting changes in ROMK expression generally involve
dissection of cortical and medullary regions, or even individual nephron segment
dissection. Here we used a real-time PCR assay directed against a conserved ROMK
region and examined ROMK expression at the whole kidney level. Alternatively, the
discrepancy may be due to differences in experimental design, for example
differences in precise dietary K+ content or in the duration of treatment or possibly
the animal model, with most previously reported studies having involved rats.
To investigate the contributions of individual isoforms we identified the mouse
homologs of the major ROMK isoforms in kidney and examined their expression. By
ISH we identified differential distributions for mouse ROMK1 and ROMK2 in
keeping with the distributions described for the corresponding rat homologs. We
found ROMK1 expression in OMCD with limited cortical (CCD) extension and
ROMK2 expression in TAL and also in CCD. No clear expression of ROMK3 was
detected. Although the transcript region probed by ISH for ROMK2 (exonl; Figure
7.2) is also present in ROMK3, we also used a real-time PCR assay specific for
ROMK2 (transcripts with exon 1-core exon splicing) which detected abundant
ROMK2, whilst a ROMK3-specific probe (exon 2) was unable to detect ROMK3
expression in mouse kidney by ISH. Intriguingly, a remarkable pattern of differential
regulation of this key gene in K+ balance emerged as we found that K+-restriction
increases ROMK1 but not ROMK2 transcripts and that conversely high K+ diet
increases ROMK2 but not ROMK1 transcripts. These changes were substantial and
were determined by both real-time PCR and ISH. When merely examining total
ROMK expression these key expression changes are not evident as the striking
reciprocal variations in the expression level of these two conserved ROMK isoforms
will tend to cancel one another out in terms of their contributions to total ROMK
expression. Whilst other as yet unreported mouse ROMK isoforms may be
contributing to ROMK-T, ROMK1 and ROMK2 are the major conserved isoforms
recognised and we did not detect mouse ROMK3 expression.
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Figure 7.4: ROMK1 and ROMK2 expression in response to varied K+ intake. R0MK1
and 2 regulation by K+ diet examined by (a) isoform-specific real-time PCR assays
distinguishing ROMK1 and ROMK2 and (b and c) ISH (n=6). There is a striking reciprocal
regulation of these isoforms, with ROMK1 upregulation by low K+ and ROMK2 upregulation
by high K+. (d)Dark-field ISH studies for ROMK1 and 2 gene expression illustrating this
differential regulation and greater extent of ROMK1 expression in renal cortex with chronic low K+
diet. *p=0.0002; **p=0.008; #p=0.0001; ^=0.01.
Our findings identify that ROMK2 expression fits with an important role in
conventionally described regulation of K+-secretion: it is upregulated with HK and
strongly expressed where electrogenic (ENaC) Na+ transport is greatest (DCT2-
CNT-ICT-CCD). The importance of ROMK2/ENaC co-expression in DCT2-CNT-
Chapter 7. Distribution and regulation of ROMK gene expression in mouse. 133
WNK Kinases: Novel Regulators of Electrolyte Balance and Blood Pressure.
ICT is reflected in Na+-K+ balance not being significantly affected, even on altered
diets, by knock-out of aENaC in CD117. In contrast, ROMK1 (20 additional N-
terminal amino-acids and driven by a distinct promoter) is upregulated with LK, and
expressed in OMCD-deeper CCD (Figure 7.4): segments normally regarded as
having limited electrogenic Na+-reabsorption which, going distally, are increasingly
concerned with H+-secretion and K+-reabsorption rather than playing any significant
role in regulation ofNa+ balance. Interestingly, one study104 in rat reports, as we have
found in mouse, that LK increased ROMK1 in medulla. The ROMK1 changes
reported here would be missed looking at ROMK-T in cortex, or indeed in CCD with
higher ROMK2 expression changing reciprocally. Increased ROMK1 in long-term
K+-deficiency could assist in acid-base balance through apical K+-recycling and
electroneutral H+ secretion; (Figure 7.6) when a "lumen-positive" charge gradient
impedes alternative electrogenic routes (e.g. H+-ATPase). LK diet induces a gastric-
to-colonic H+/K+-ATPase isoform switch with upregulation of the latter (Figure 7.6)
reported in principal cells of OMCD (as well as intercalated cells) with lesser
changes in CCD23. LK diet thus appears to coordinate ROMK and H+/K+-ATPase
isoform switching. To understand the potential significance of this co-regulation it is
useful to consider the cytoplasmic face of active H+/K+-ATPase, where the pFl and
ADP/ATP ratio will rise with increasing H+/K+-ATPase activity; both these changes
are well known activators of adjacent ROMK, perhaps especially if coupled to an
ABC protein (e.g. CFTR)47'74. Such coupling may ensure ROMK1 K+-secretion is
effectively gated to occur when the H+/K+-ATPase pump is active. So ROMK1
thereby provides K+ efflux, in effect recycling K+ for H+/K+-ATPase to use in an
efficient coupling induced when tubular K+ will be deficient and the need for H+
secretion continues, particularly facilitating excretion of NH4+, production of which
is also induced in K+ deficiency.
It could be argued that an increase in ROMK1 expression on LK diet as we have
found may not necessarily imply a higher activity of the luminal K conductance in
the OMCD. ROMK channels are believed to be tetrameric (possibly forming homo
and/or heterotetramers)47. It is possible that a change in the ratio ROMK1/ROMKX
could result in a conductance with modified activity and regulation. However,
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R0MK1 is the only ROMK isoform expressed in OMCD and the upregulation
reported here by both real-time PCR and ISH is substantial and sustained over a long
period. We think it is unlikely that such gene expression regulation would not have
important implications on a functional level, especially when there is some indication




































Figure 7.5: cHKA expression in response to varied K+ intake. cHKA reabsorbs K+ from
renal tubular filtrate in exchange for H+. A striking, upregulation of cHKA was observed by
real-time PCR (4.1±0.7-fold [2.7-5.5]; n=6) and (b) by ISH (2.0+0.2-fold [1.6-2.45]; n=4) on
LK (vs. NK) diet. Background levels were high in this ISH study, meaning expression was
difficult to visualise and so images are not shown. Also as a consequence of high background,
values quoted are a conservative estimate and may underestimate true expression changes.
*p=0.0002; **p=0.001.
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Control of ROMK1 channel numbers and their apical trafficking represent two
separate levels of regulation. When co-expressed with active H+/K+-ATPase the
regulated withdrawal of ROMK1 from the apical membrane would increase K+-
reabsorption but may diminish H+-secretion. There has been great progress in
understanding ROMK trafficking47. With no ROMK isoform-specific antibodies or
knockouts, in vivo studies in CD, which have favoured CCD, usually reflect
segment-specific ROMK (i.e. CD which expresses ROMK2 and ROMK1). OMCD is
a relative "blind-spot" being difficult to study in vivo and without good OMCD cell-
lines. The pathways regulating ROMK export-retrieval in OMCD may involve:-
-7Q. OQ. 1 CO . .
protein kinase A-export ' ' (e.g. vasopressin-driven); tyrosine kmase-
import69,96'144 (e.g. driven via free radicals or medullary tonicity-EphA2) and
ROMK1-specific effects via a PKC site at. Serine-468. These signalling pathways may
thereby have important influence on K+ conservation and acid-base balance through
effects on ROMK1 conductance in K+ deficiency. Thus, for example, it is well
known vasopressin is required for efficient conservation of K+ and lack of
vasopressin leads, for several reasons, to a K+-wasting state.
Figure 7.6: Schematic depiction of potential ROMK1 function. An upregulation of
ROMK1 in a K+-deficient environment as observed in this study could facilitate apical K+
recycling to allow the efficient electroneutral secretion of H+ ions via the H+/K+-ATPase
pump.
This work uncovers features suggesting the ROMK gene is precisely regulated in an
isoform- and nephron segment-specific manner. This could have important
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implications for aspects of our understanding of K+ regulation and the role ofROMK
isoforms. The changes shown are substantial, chronically sustained over many days
and will be missed by tools not discriminating between ROMK isoforms. Whilst one
assessment concludes knockout of neither H+/K+-ATPase (colonic or gastric)
significantly impairs renal K+ conservation (although cHKA_/" mice are
hypokalaemic) no assessment has examined the role of cHKA in K+/acid-base
balance across the water loaded-dehydration spectrum nor in the maladaptive
perpetuation of alkalosis often seen in hypokalaemia. Clearly these findings merit
further investigation and may couple to the necessary changes in H+-secretion
required when NH3/NH44" production is upregulated in hypokalaemia134.
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Chapter 8 Differentiating the roles of
dietary K+ intake and aldosterone.
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8.1 Introduction
In health chronic K+ balance is tightly regulated and remains within normal limits
due to appropriate adjustment in renal handling so average K+ loss is matched to
intake. K+ intake and circulating aldosterone play major roles in renal K+ handling
and K+ balance. These two factors are not mutually exclusive as part of the response
to K+ load is mediated by changes in plasma aldosterone. Increased aldosterone
secretion from the adrenal gland stimulates both basolateral Na+/K+-ATPase and
apical Na+ channels, promoting K+ secretion111. This occurs mainly through
augmentation of the electrochemical driving force for K+ exit across the apical
membrane. However, aldosterone-independent mechanisms are also involved in K+
secretion. Hyperkalaemia reduces fluid and Na+ reabsorption, thereby increasing
distal fluid and Na+ delivery and promoting K+ secretion in the CNT and CCD15'40.
As described in Chapter 7, K+ loading also increases K+ secretion through induction
of ROMK. More recent evidence suggests a potential role for the maxi-K+ (BK)
channel which mediates flow-dependent K+ secretion in CCD150 and is activated by
high dietary K+101, but this remains to be clarified.
The studies described in chapters 6 and 7 of this thesis, show regulation of
expression within the WNK pathway and of ROMK isoforms in response to chronic
changes in dietary K+ intake. However, as aldosterone action is inextricably linked to
K+ homeostasis, it is difficult to assess if the changes seen in these studies are a
direct effect of dietary K+ intake, or if they are, even partially, indirect effects
occurring through stimulation of aldosterone secretion. To resolve this issue we
designed a study to attempt to differentiate between these two modes of regulation.
In this study we measured the direct effects of dietary K+ on gene expression by
challenging mice with varied dietary K+ intake while maintaining plasma aldosterone
constant. We also measured aldosterone induced gene expression changes by varying
aldosterone in mice maintained on the same normal K+ dietary intake.
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8.2 Materials and Methods
8.2.1 Animal Treatment
Groups of adult male C57BL/6J mice (n=5-7) were segregated into groups, housed in
mouse metabolic cages and fed a normal K+ diet. Following two days
acclimatization, bilateral Adx operations were performed on all mice under general
anaesthesia (day 0). Alzet® Mini-Osmotic Pumps (MP (Model 2004); preloaded with
aldosterone (at various doses) and dexamethasone (sufficient to deliver 50pg/kg/d)
were implanted subcutaneously to facilitate corticosteroid replacement. Groups were
given specific K+ diets in combination with corticosteroid replacement as outlined in
Table 8.1. Treatments lasted 2 weeks, commencing from the day of surgery, with
regular monitoring of food and water intake and bodyweight. 24hr urine collections
were made on the final two days of treatment to allow volume and electrolyte
composition measurements.
Table 8.1: Experimental groups in the dietary K+ and aldos terone study.
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*Vehicle: DMSO:Polyethylene Glycol (1:1)
8.3 Results
Mice were adrenalectomised and given group-specific treatments for 2 weeks, either
varying dietary K+-intake (LK/CTRL/HK) while holding plasma aldosterone
constant via MP infusion (15 pg/kg/d), or the opposite, varying plasma aldosterone
(0, 15, or 150 pg/kg/d) and holding dietary K+-intake constant (normal K+). All mice
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were given dexamethasone infusions (50 pg/kg/d) via MP to replace glucocorticoid
following Adx (Table 8.1).
8.3.1 Bodyweight, Food Intake and Fluid Balance
There was no significant difference in bodyweight between the groups throughout
the experiment (Table 8.2). In the initial stages of treatment (day 0-2), a dip in food
and water intake was observed immediately following Adx and MP implant surgery
(Figure 8.1(a) and (b)). The animals recovered quickly and there was no significant
difference in food intake across the treatment groups, throughout the experiment.
Table 8.2: Metabolic measurements in K*/Aldo Study.
CTRL Low K High K Low Aldo High Aldo
Initial
Bodyweight (g)
25.6±0.7 26.0+1.1 24.7+1.0 25.5+0.6 25.9+0.6
Final
Bodyweight (g)
26.0+0.6 25.1+1.0 24.9+0.8 24.8+0.4 25.0+0.6
Plasma K+
(mM)
3.6+0.2 3.0+0.1 3.9+0.1 5.8+0.6 2.8+0.3
Plasma Na+
(mM)
147.0+0.5 147.7+1.5 147.4+3.0 138.8+0.8 148.0+2.5
Plasma CI'
(mM)
110.6+1.2 105.2+1.4 111.8+1.8 111.0+2.5 104.8+1.4
Plasma
Creatinine (pM)
22.0+1.3 22.7+1.5 19.0+0.7 24.3+1.4 22.0+0.8
Aldosterone
(pmol/L)
1147.2+193.8 1366.7+366.8 1476.4+171.7 86.1+22.2 12469.7+2698.6
Renin Activity
(ng/ml/h)
3.3+0.6 6.1+1.1 4.7+1.3 9.3+3.9 2.7+0.8
Corticosterone
(nmol/L)
39.4+6.3 45.3+9.7 36.7+16.9 41.3+8.8 20.7+2.9
During the experiment, the LK group developed a higher fluid intake (Figure 8.1(b))
compared to the CTRL group, reaching significance on day 5 (p<0.05; ANOVAlsd)
and remaining significantly higher until day 13 (p<0.04; ANOVAlsd), with fluid
intake slightly lower in all groups on day 14. The HA group also developed a higher
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fluid intake (Figure 8.1(b)) compared to the CTRL group, reaching significance on
day 5 (p<0.003), remaining consistently higher for the rest of the experiment. The
HK group also showed a modest trend towards higher fluid intake but this only
reached significance compared to the CTRL group on day 4 (p<0.05; ANOVAlsd),
day 5 (p<0.05; ANOVAlsd), and day 9 (p<0.05). Fluid intake in the LA group was
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Figure 8.1: Effect of combined dietary K+ intake and aldosterone challenge on
metabolic measurements. Mice were treated (as outlined in Table 8.1) for 14 days, and
daily measurements of (a) food and (b) fluid intake. Urine output over 24hrs (c) was recorded
on the final two days of treatment. Urinary electrolyte excretion was measured over the final
two days of treatment. The mean values were taken and expressed as a ratio of creatinine
excretion (K/Cre, Na/Cre: d-e).
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Urine collections (24hr) were made on the last two days of treatment (day 13 and
14). Volume measurements (Figure 8.1(c)) revealed increased urine output in the HA
group on both days (HA vs. CTRL: 4.1 ±0.7 ml vs. 2.2±0.3 ml respectively, p<0.005
on day 13; 4.4±0.8 ml vs. 2.1 ±0.2 ml respectively, p<0.002 on day 14), consistent
with a high fluid intake. Similarly, the LK group also had increased urine output
compared to the CTRL group on both days, but this barely reached significance
(6.2±0.9 ml, p<0.03 (ANOVAlsd) and 5.1±0.9 ml, p<0.05 on days 13 and 14,
respectively). There was also a significant increase in urine output with HK on day
13 (5.7±2.1 ml, p<0.05), but there was no significant difference compared to the
CTRL group on day 14. Urine output in the LA group was not significantly different
from the CTRL group.
8.3.2 Urinary Electrolytes
Urine K+ and Na+ concentrations were measured in samples collected on the final
two days of treatment (Figure 8.1(d-e)). The mean measurements over the two days
were taken and expressed as a ratio over creatinine. K/Cre was significantly lower in
the LK group (96.1±0.37% decrease, p<0.0002) and significantly higher in the HK
group (3.3±0.35-fold increase, p<0.0002) compared to the CTRL group. There were
no differences in K/Cre or Na/Cre in the LA or HA groups compared to the CTRL
group. Unfortunately, Na/Cre measurements were unavailable for the LK and HK
groups1)
8.3.3 Plasma Measurements
LA induced a significant increase in plasma K+ (LA vs. CTRL: 5.8±0.6 mmol/L vs.
3.6±0.2 mmol/L respectively, p<0.002), accompanied by a decrease in plasma Na+
(LA vs. CTRL: 138.8±0.8 mmol/L vs. 147±0.5 mmol/L respectively, p<0.009; Table
8.2). HA induced a significant decrease in plasma CF (HA vs. CTRL: 104.8±1.4 vs.
110.6±1.2 respectively, p<0.04). The LK group also showed a significant but small
+ Certain electrolyte measurements are unavailable as they were beyond the accurate range of the
assaying technique. Some of these samples may be diluted and re-assayed. However, time constraints
toward the end of the PhD limited this option.
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decrease in plasma CI" (105.2±1.4, p<0.02) compared to the CTRL group, but was
still within the normal range. There were no significant changes in plasma creatinine.
As expected following infusion treatments, plasma aldosterone was significantly
elevated in the HA group (12,46912698.6 pmol/L, p<0.0002) and reduced (although
not significantly; 86.1122.2 pmol/L) in the LA group compared to the CTRL group
(1147.21193.8 pmol/L). There was no significant difference in plasma renin activity,
plasma renin concentration, or plasma corticosterone compared to the CTRL group.
Very low level plasma corticosterone (<104 nmol/L) was detected in all groups
despite Adx.
8.3.4 WNK Pathway Expression
Real-time PCR analysis indicated WNK1-S expression was downregulated by
33110.7% [11.6-53.6] with LA (p=0.03; ANOVAlsd), as was WNK1-T expression
(2018.9% [2.7-37.5] decrease, p=0.05; ANOVAlsd) compared to the CTRL group
(Figure 8.2). WNK1-S expression also showed a trend towards downregulation by
27111% [5.7-48.9] with LK compared to HK, however this change did not reach
significance. WNK4 was upregulated by 3419% [16.5-52.1] (p=0.04; ANOVAlsd)
across the dietary K+ spectrum. A downward trend in WNK4 expression was also
seen with LA compared to the CTRL group, but this small change did not reach
significance. HA had no significant effect on WNK expression in this study and
WNK1-L expression was unchanged across all treatment groups.
8.3.5 ROMK and cHKA Expression
ROMK-T expression was unchanged across the treatment groups. ROMK2
expression was downregulated by 2818.5% [11.7-44.9] with LK (p<0.05;
ANOVAlsd) compared to the CTRL group (Figure 8.3(a)), but was unchanged with
HK. In contrast, real-time PCR showed a 2.410.3-fold upregulation in ROMK1
expression by LK (p<0.0002) compared to the CTRL group (2.610.4-fold
upregulation compared to HK, p<0.0002). ROMK1 expression was also upregulated
by 26.7112.6% [1.9-51.3] with LA (p<0.04) compared to the CTRL group.
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cHKA expression (Figure 8.3(b)) was upregulated by 97±32.4% [33.6-160.7] as
dietary K+ content decreased from HK to LK (p<0.003). Similarly cHKA expression
was upregulated by 62.6±23.7% [16-109.1] as aldosterone level decreased from HA
to LA (p<0.09).
8.4 Discussion
In order to achieve K+ balance secretion must equal intake even when intake
increases several fold. This balance between urinary excretion and dietary intake
underscores the importance of the kidneys in maintaining K+ homeostasis. An
increase in dietary K+ intake promotes aldosterone secretion. However, both
aldosterone-dependent and -independent pathways contribute to stimulation of K+
secretion to balance the greater K+ intake. This in vivo study was designed to
differentiate between the effects of dietary K+ and aldosterone on the expression of
the WNK pathway, and a number of genes likely linked to it. Mice were given
treatments either varying dietary K+-intake while holding plasma aldosterone
constant (via Adx and MP infusion), or the opposite, varying plasma aldosterone
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Figure 8.2: WNK expression in response to varied K+ intake and aldosterone
challenge. Real-time PCR reveals WNK1-S and WNK1-T expression are significantly
downreguiated with LA compared to CTRL. WNK4 expression changes significantly across
the dietary K+spectrum. Downregulation of WNK1-S with LK (vs. HK) and WNK4 with LA (vs.
CTRL) were also suggested, but these changes did not reach significance. No significant
changes were observed in WNK1-L expression across the experimental groups.
*p<0.05 (ANOVALsd), **p<0.03 (ANOVAlsd), ***p<0.04 (ANOVALSD)
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Figure 8.3: ROMK and cHKA expression in response to varied K+ intake and
aldosterone challenge, (a) R0MK1 was strikingly upregulated with LK and modestly
upregulated with LA. ROMK2 expression was downregulated with LK compared to CTRL but
was unchanged with HK. Aldosterone had no effect on ROMK2 expression. No significant
changes were observed in ROMK-T expression across the experimental groups, (b)
Upregulation of cHKA was observed with both LK and LA.
*p<0.04 and **p<0.0002, ***p<0.05 (ANOVALSD)
#p<0.02, ##p<0.003, ###p<0.09
Real-time PCR analysis ofWNK expression reveals similar findings to our previous
study (Chapter 6). However, in this study expression in the control group has shifted,
so that basal expression is now closer to that seen previously with high K+. This may
be an effect of extended duration of treatment (four days longer), anaesthetic, Adx,
or dexamethasone treatment. In fact a recent in vitro study106 demonstrates increased
WNK1-S expression with dexamethasone treatment. Nonetheless, if the overall
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expression profile across the full dietary K+ range, from LK-CTRL-HK, is
considered, the changes seen are compatible, with WNK1-S and WNK4 expression
increasing from LK to HK. This WNK1-S change, however, does not reach
significance. A similar trend in WNK1-S expression is seen from low to high
aldosterone. Again, the CTRL group seems to set a higher baseline in this study with
a significant decrease in WNK1-S expression seen in the LA group, whereas in the
previous study WNK1-S increased from control to high aldosterone.
Supporting our findings in the previous study (Chapter 7), ROMK1 was strikingly
upregulated with LK. ROMK2 expression was downregulated with LK compared to
the CTRL group but was unchanged with HK. This result differs slightly from the
previous study where ROMK2 expression was upregulated with high K compared to
normal K+, but unchanged with low K+. Again, the basal expression level set by the
control group is higher. However, the same reciprocal trend is present, with ROMK2
expression rising from LK to HK, while ROMK1 expression rises from HK to LK.
cHKA expression was also upregulated with LK. This is consistent with our findings
in Chapter 8 and together with ROMK1 upregulation supports our theory that these
two genes may function side-by-side to promote H+ and NH4 secretion, while
conserving K+ in K+-deficient states.
Modest upregulation in ROMK1 expression was seen with LA. ROMK1 is most
abundant in OMCD, with expression barely reaching the cortex on a normal K+ diet.
A study by Wald et al.140 examining ROMK expression but not differentiating
between isoforms, reported that Adx decreased ROMK mRNA abundance in cortex
but increased transcript abundance in the medulla. K+-deficiency combined with Adx
in the same study reduced ROMK mRNA to control levels, suggesting that the
hyperkalaemia associated with Adx was the cause for the increased ROMK
expression in medulla. This upregulation of medullary ROMK could be due at least
in part to increased ROMK1 in OMCD, particularly since no change in ROMK2
expression was observed with LA in the present study. Aldosterone administration
by MP to adrenal intact rats has been shown to increase ROMK2 expression in whole
kidney8, however we saw no change in ROMK2 expression with HA in this study.
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This may be due to differences in study design (e.g. Adx with dexamethasone (50
pg/kg/day) and aldosterone infusion (150jag/kg/day) versus adrenal intact plus
aldosterone infusion (20 pg/kg/day)), technique (real-time PCR versus competitive
PCR) or this may be a species issue (mouse versus rat). Upregulation of cHKA was
also observed with LA, supporting the theory that cHKA and ROMK1 expression
may be coupled.
Clearly there are discrepancies between these findings and the changes observed in
the studies described in Chapters 6 and 7. As suggested above, these discrepancies
may be due to differences in experimental protocol. In an attempt to understand the
variation between the two studies, and also to try to discriminate the roles of dietary
K+ intake and aldosterone, linear regression analysis was performed, allowing case-
wise examination of continuous variables in individual mice (or cages). Analysis
across all the genes examined in this study and also those described in Chapters 6
and 7, consistently revealed that K+ was the most significant regulator of gene
expression (Table 8.3). Urinary K/Cre was the better indicator of K+ regulation, with
K+ intake also an important index.
Table 8.3: Regression analysis of gene expression.
Study K+Intake Urinary K/Cre Aldosterone
WNK1-S Dietary K+ + 75% (p<0.0004) + 75% (p<0.0004) + 30% (p=0.266; NS)
K+/Aldo + 15% (p=0.433; NS)
[+33% (p=0.119; NS,
minus CTRL]
+ 27% (p=0.134; NS)
[+51% (p<0.02),
minus CTRL]
+ 4.4% (p=0.812; NS)
[+ 16.2% (p=0.448; NS),
minus CTRL]
WNK4 Dietary K+ + 53% (p<0.03) + 56% (p<0.02) + 25% (p=0.346; NS)
K+/Aldo + 31% (p=0.088; NS) + 47% (p<0.05) + 3.2% (p=0.863; NS)
ROMK1 Dietary K+ - 51% (p<0.03) - 54% (p<0.02) -37% (p=0.159; NS)
K+/Aldo - 34% (p=0.065; NS) - 54% (p<0.002) - 17% (p=0.35; NS)
ROMK2 Dietary K+ + 66% (p<0.003) + 69% (p<0.002) + 53% (p<0.04)
K+/Aldo + 27% (p=0.143; NS) + 41% (p<0.02) - 6% (p=0.731; NS)
cHKA Dietary K+ -61% (p<0.008) - 64% (p<0.005) -42% (p=0.109; NS)
K+/Aldo - 38% (p<0.04) -46% (p<0.009) -27% (p=0.145; NS)
(NS, nonsignificant)
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R0MK1 and HKA expression negatively correlated with K+ and were not associated
with aldosterone level in either study (Table 8.3). ROMK2 expression also correlated
with K+ in the original dietary K+ study, but aldosterone also had a significant effect.
The K+ effect was weaker but still significant in the more recent study, whereas the
correlation with aldosterone disappeared. WNK4 expression was not significantly
affected by aldosterone level but correlated with K+ across both studies. WNK1-S
expression strongly correlated with K+ in the original study but this effect was not
clearly apparent in the study described in this chapter. As suggested earlier, we
wondered if the CTRL group was causing this discrepancy, so regression analysis
was repeated without this group. This revealed a significant correlation between
WNK1-S expression and K+.
This analysis indicates very little aldosterone regulation of the genes under
investigation in these experiments. In fact the only gene showing a significant
correlation with aldosterone is ROMK2 in the original dietary K+ study. This effect
is not unexpected as ROMK2 is an effector of aldosterone signalling albeit indirectly
via ENaC regulation. However, this aldosterone effect was not seen in the
K+/aldosterone study, possibly a consequence of the aldosterone dose given or
perhaps dexamethasone treatment. Thus, although further work is required to fully
discriminate between dietary K+ and aldosterone regulation, the evidence presented
here strongly suggests that K+ plays a more dominant role.
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In 2001, mutations in WNK1 and WNK4 were linked to Gordon syndrome ,
implicating these novel ser/thr kinases in the regulation of electrolyte balance and
BP. As mutations in WNK1 and WNK4 cause a broadly similar phenotype
(hypertension and hyperkalaemia with normal glomerular filtration), it seemed likely
that these novel proteins function in a common WNK pathway. Beyond this, nothing
was known of the function ofWNK1 or WNK4 when the studies of this thesis began,
with only limited information reported regarding their expression in human and
rat137,148,151^ fundamental objective of this PhD was to contribute to our
understanding of how WNK1 and WNK4 might function to regulate electrolyte
balance and BP.
9.1 The predominant WNK1 isoform in kidney is not a
kinase.
From an early stage, it was of great interest to us how intronic deletions in WNK1, a
widely expressed gene, could cause an autosomal dominant disease, with a pathology
seemingly targeting the kidney43'92. Identification and detailed expression analysis of
the nature of an alternative, abundant short WNK1 transcript in kidney showed that
rather than merely being a polyA-tail variant as originally suggested18'137'148'151, this
transcript is truncated at the 5'-end. In fact this predominant short kidney-specific
WNK1 transcript (WNK1-S) actually completely lacks a kinase domain. Two
months after our report describing WNK1-S expression109, another independent
study confirmed our findings, reporting an alternative promoter and an enhancer
element upstream of the novel 5'-exon24. We and others have also identified
additional WNK1 transcripts arising from a combination of alternative promoter
usage24 and splicing24;109;137;148.
9.1.1 Impact of WNK1-S Discovery
The breakthrough that WNK1 gene transcription in kidney differed from elsewhere,
and in kidney this WNK1 kinase gene was actually overwhelmingly expressing a
kinase-deficient product, demanded a revision of ideas as to how mutations of this
gene might cause autosomal dominant disease. At this time much of the research on
WNK1 was directed towards defining upstream kinases and downstream targets for
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this novel kinase138'152'155. The discovery of WNK1-S shifted the focus of WNK1
research and highlighted the possibility that the role ofWNK1 at least in kidney may
involve features beyond a simple kinase cascade. Studies exploring the physiological
role ofWNK1-S are still at the embryonic stage; however a specific disruption in the
expression of this isoform in kidney may be the mechanism behind the seemingly
kidney-restricted phenotype of Gordon syndrome despite the broad expression
profile of WNK1. The original study linking WNK1 to Gordon syndrome reported
i 4o
increased WNK1 expression in patient leucocytes . As the nature ofWNK1-S was
not known at this point, the technique used to quantify WNK1 expression did not
differentiate between WNK1 isoforms. So it is currently unknown whether one or
both isoforms are involved in this upregulation. Furthermore, WNK1 expression in
leucocytes may not be representative ofWNK1 expression in kidney, particularly as
WNK1-S may not be expressed in leucocytes. Indeed, Northern blot analysis of
leucocyte RNA revealed very little expression of either WNK1 isoform in the
original study148.
9.2 WNK Localisation
9.2.1 WNK1-L and WNK1-S have different distributions in kidney.
These studies also uncovered strikingly different renal distributions for WNK1-S and
WNK1-L. Low level widespread expression of WNK1-L is seen throughout the
kidney, whereas WNK1-S expression is highest in DCT-CNT (Figure 9.1). Thus, not
only are these isoforms structurally and functionally distinct, but they are also
differentially distributed. These studies localise WNK1-S to adjacent nephron
segments known to play important roles in the regulation of electrolyte balance and
BP (section 1.1.4), the very processes so clearly disrupted when WNK1 is mutated in
Gordon syndrome. Thus, this further suggests that WNK1-S may be the key isoform
affected by WNK1 mutations causing a NaCl/K+ and H+ imbalance and driving
hypertension. Moreover, antibodies capable of differentiating between the different
isoforms ofWNK1 are not available, so the techniques employed in these studies are
particularly informative. Indeed the antibody used in the original report describing
14o f
WNK1 distribution in kidney is directed against an epitope encoded by exon 12
which will limit detected WNK1 protein to a subset, as exon 12 is subject to
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alternative splicing in many tissues (including kidney) in all species
examined109'137'148'151. Also, contrary to our findings this study reports WNK1
expression in CCD and MCD (medullary collecting duct), segments of the nephron
where we see very little WNK1 expression compared to DCT-CNT by ISH with










Figure 9.1: Distribution of gene expression of key genes involved in Na+ and K+
balance in distal nephron. For aENaC/SGK expression, arrows represent regulated
expression by rising aldosterone (A).
9.2.2 Novel domains of WNK4 expression in TAL
Detailed localization studies, undertaken as part of this thesis, show that WNK4 is
highly expressed in DCT-CNT, consistent with earlier findings148, and supporting the
possibility that WNK4 may interact with transporters such as NCC and ROMK in
these nephron segments. However, contrary to reports by Wilson et al., we found
much lower WNK4 expression in CCD, with very limited detectable expression
extending into OMCD (Figure 9.1). A substantial novel domain ofWNK4 expression
was also identified in TAL (including macula densa). This finding questions the
physiological relevance of in vitro WNK4 interactions with transporters found
exclusively in this nephron segment.
9.2.3 Impact of WNK localisation on functional evidence
Reports of in vitro interactions between WNK4 and/or WNK1 and a number of renal
electrolyte transporters have been flooding into the literature implying a surprising
diversity of possible regulatory roles of these genes in electrolyte balance (Table
1.3). In particular, WNK4 interactions with transporters expressed in nephron
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segments ranging from proximal tubule (e.g. CFEX ) to more distal segments (e.g.
NCC in DCT149;161, ROMK in DCT2-CD56, and NKCC1 in OMCD52) have been
reported in vitro, as have effects on tight junction Claudin proteins, thereby also
indicating the potential of affecting distal nephron paracellular transport53'159.
However, the potential in vivo significance of these in vitro findings can only be
extrapolated if WNK4 co-localises along the nephron with the transporter in
question.
The discovery of substantial, previously unrecognized, WNK4 expression in TAL
and macula densa may have a major impact on WNK4 research which is currently
focused on more distal nephron segments (DCT-CD). This domain of WNK4
expression was missed by immunohistochemistry in the original study describing
WNK4 expression in kidney148. The reason for this remains to be clarified but
possibilities include shortcomings of the antisera perhaps because WNK4 protein in
TAL has different properties to WNK4 in other nephron segments. The prospect
WNK4 may regulate transport in TAL-DCT (including macula densa) is intriguing,
as upregulated NaCl reabsorption here would be expected to drive hyperkalaemia,
acidosis and low-renin hypertension: all features ofGordon syndrome.
9.2.3.1 Possible WNK4:ROMK interaction in TAL
WNK4 expressed in TAL may interact with ROMK which is also highly expressed
in this segment, and interestingly ROMK here facilitates NaCl reabsorption (via
NKCC2) and facilitates K+ reabsorption (via lumen positive charge driving
paracellular K+ absorption), so overactivity here may resemble the Gordon's
phenotype. A WNK4:ROMK interaction has been reported previously in vitro56 but
has only been considered in the context of the CCD, where ROMK acts simply to
allow K+ secretion and so inhibition of ROMK would result in K+ retention. ROMK
inhibition in TAL would prevent K+ recycling in this nephron segment, potentially
blocking NaCl reabsorption via NKCC2, resulting in increased distal Na+ delivery.
However, transgenic mice expressing a human Gordon syndrome mutant WNK4
(D564A) protein in TAL and DCT (at heterogeneous levels)160 did not have a
Gordon syndrome phenotype and ROMK localization appeared unaltered by co-
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localised mutant WNK4. The basis for absence of Gordon syndrome features
remains uncertain, but mutant WNK4 expression was transgenic cDNA-driven (via
the promoter of the human CLCNkb chloride channel gene) rather than genomic,
altering distribution (WNK4 localised to cytoplasm and not tight junctions in distal
tubules and to apical membranes in TAL) and curtailing native potential for
transcriptional diversity160. Thus this transgenic expression may have differed
significantly from equivalent native expression with WNK4 Gordon syndrome
mutations and this remains a likely explanation for the lack of phenotype in these
mice about which no further reports have been published.
9.2.3.2 Regulation of cation-chloride cotransport by WNK:SPAK complex.
WNK4 is reported to interact in vitro with SPAK35'113'114,139, another ser/thr kinase
structurally related to WNKs and widely expressed in transporting epithelia. This
kinase binds to several cation-chloride transporters, and is thought to be a scaffolding
protein involved in MAPK signalling (WNK kinases are distant homologs of MAP
kinases). This WNK4:SPAK complex regulates the activity of NKCC1 and KCC2 in
Xenopus oocytes35'36'113. Our studies highlight that expression of important elements
of the WNK pathway co-localise with two other key members of this cotransport
family of key importance in NaCl reabsorption and BP control: NKCC2 (TAL) and
NCC (DCT), targets for loop and thiazide diuretics, respectively. Moreover
increasing activity of either will limit K+ excretion (by lowering distal Na+ delivery)
whilst a decrease in their activity will promote diuresis, lower BP, and predispose to
hypokalaemia (as is the case with use of these diuretics).
A report, by Vitari et al., showed that WNK1 associates with SPAK, and that both
WNK1 and WNK4 phosphorylate and activate SPAK/OSR1, leading to
phosphorylation of NKCC1139. This is consistent with reports that both WNK1 and
WNK4 contain putative SPAK binding motifs consisting of the consensus: R/K-F-x-
90 • • •
V/I . Moriguchi et al. also show evidence that WNK1 interacts with SPAK (in
HEK293 cells) and report direct WNK1 phosphorylation of SPAK/OSR1. Additional
evidence suggests that low CP hypotonic stress increases WNK1 kinase activity,
activating SPAK/OSR1 and inducing phosphorylation of NCC, indicating that a
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WNK1:SPAK/0SR1 complex may mediate the hypotonic stress signalling pathway
to NCC and possibly other cation-chloride-coupled transporters to regulate
electrolyte balance97. NKCC2 is also subject to regulation by SPAK97. Thus, in
addition to NKCC1 regulation, a WNK1/WNK4:SPAK complex may regulate NCC
and NKCC2 in kidney.
9.2.3.2.1 WNK3 and SPAK
Furthermore, WNK3, a related member of the WNK kinase family, has recently been
cloned49 and shown to regulate a number of electrolyte transporters23'54'66'116
including NKCC2 and NCC. Kinase-active WNK3 activates, while kinase-inactive
WNK3 inhibits, NKCC2 and NCC in Xenopus oocytes (Figure 9.2), by altering their
surface expression116. WNK3 is structurally related to WNK1 and WNK4, sharing
homology across the kinase domain, autoinhibitory domain, an acidic region (site of
WNK4 Gordon syndrome mutations), and coiled coil regions49. Unlike WNK1-S and
WNK4, WNK3 is reportedly present in all nephron segments, with highest
expression in the proximal convoluted tubule and TAL, and lower levels of
expression in the DCT and CD116. Both WNK4 and WNK3 can regulate NCC, and
so it is tempting to speculate that WNK4 may also regulate NKCC2 (Figure 9.2). The
relative abundance of WNK3 compared to WNK4 and whether or not they are co-
expressed in the same cells is currently unknown. Certainly, initial studies suggest
levels of WNK3 expression are very low, detectable by RT-PCR but not Northern
hybridisation49.
9.2.3.3 WNK1 phosphorylates WNK4 relieving NCC inhibition.
Due to the recent discovery ofWNK1-S and possibly the lack of an antibody specific
to this isoform, the majority of WNK1 functional studies reported to date have
focused on WNK1-L. WNK1-L was reported to suppress WNK4-mediated inhibition
of NCC, thereby restoring cotransporter activity161, and was shown to physically
associate with WNK4 via their homologous N-terminal kinase domains. WNK4 has
to be phosphorylated to suppress its inhibition of NCC and WNK1-L is capable of
• .... . . .1A7
this WNK4 inhibition possibly facilitated by WNK1 tetramer formation . The
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kinase-deficient kidney-specific isoform, WNK1-S, would not be expected to inhibit
WNK4 as kinase activity is required.
(a)
Cell Shrinkage/ . NKCC1
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Figure 9.2: WNK kinases interact with SPAK. (a)Schematic depiction of the causal chain
in WNKSPAK interaction. (b)ln response to cell shrinkage (hypertonic stress) WNK3 has
been shown to interact with and activate SPAK, which phosphorylates both NKCC1 and
KCC2, leading to their activation and deactivation, respectively. Cell swelling induces the
opposite effect with deactivation of NKCC1 and activation of KCC2. WNK1 and WNK4 have
also been shown to interact with SPAK but the effect of this interaction is not yet fully
understood. We speculate that if may involve NCC and/or NKCC2, which have also been
shown to interact with SPAK.
9.2.3.4 WNK1-L scaffold facilitates ENaC Regulation by SGK.
Two recent papers by Xu et al. report that WNK1-L positively regulates ENaC
through SGK1153'154. ENaC p and y subunits are subject to C-terminal PY motif
ubiquitination which then leads to retrieval of the ubiquitin tagged ENaC channels
from the cell surface. In kidney this is mediated by the ubiquitin ligase Nedd4-2 and
this process is involved in regulation of cell surface ENaC channel density. Indeed
when the p or yENaC C-terminal PY motifs are mutated this leads to impaired
retrieval, increased ENaC conductance and the hypertensive disorder Liddle's
syndrome (Table 1.1 and Figure 1.6).
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It is known that phosphorylation of the ubiquitin E3 ligase Nedd4-2 by SGK1
reduces the interaction between Nedd4-2 and its substrates including ENaC, thus
increasing ENaC surface expression and consequently increasing Na+ current. Na+
transport via ENaC is regulated by insulin and mineralocorticoid hormones. Xu et al.
show that WNK1 interacts with SGK1 (not necessarily directly) and promotes SGK1
activation through increased phosphorylation of its activation loop (although WNK1
itself does not phosphorylate SGK1). They demonstrate that SGK1 activation by
WNK1 (not requiring WNK1 kinase activity) involves the kinases PI-3-kinase and
Akt. Expression of endogenous WNK1 is necessary for SGK1 activation by IGF-1.
WNK1 Thr58 has been shown to be an IGF-1-stimulated site ofAkt phosphorylation
(Figure 9.3). Xu et al. report that the N-terminus of WNK1, when phosphorylated on
Thr58, is capable of activating SGK1 and ENaC, independently ofWNK1 catalytic
activity. The authors propose that WNK1 and PDK1 (believed to phosphorylate
SGK1 within the activation loop) cooperate to activate SGK1 and that WNK1 may
form a scaffold to assemble a protein complex required for efficient SGK1
activation. They hypothesise that phosphorylation ofWNK1 on Thr58 may create a
binding site for such proteins or induce a conformational change in SGK1 that is
permissive for its activation. However, the relevance of these findings in kidney is
unclear, particularly as WNK1-L is not expressed at very high levels in any nephron
segment. Whilst these reports suggest a role and potential mechanism for WNK1-L
in the regulation of distal nephron electrogenic Na+ transport, they are largely
derived from in vitro studies, often in non-epithelial cells (e.g. Xenopus oocytes).
Moreover, their relation to the pathogenesis of Gordon syndrome remains unclear as





PDK—► SGK ► ENaC
>1-3 K -1 %
Akt —► WNK1
Figure 9.3: Proposed role of WNK1 in the regulation of SGK and ENaC.
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9.3 Regulation of the WNK pathway in vivo.
Based on these in vitro findings that WNK1 and WNK4 can affect the activity of key
Na+ and K+ transporters (especially ROMK and NCC) it was proposed this WNK
pathway worked as an in vivo molecular switch10'55'56, eliciting coordinated effects on
key ion transport pathways, to maintain homeostasis during physiological
perturbation. In the kidney, such a WNK molecular switch was proposed to react to
stimuli such as hypovolemia and hyperkalaemia, generating a response that may
complement aldosterone which is induced in these two very different states. To begin
to test this hypothesis, we focused on one side of this putative molecular switch,
principally examining the response of the WNK pathway to dietary K+ flux, but we
also examined the effect of allied variations in dietary Na+ and aldosterone. At the
time of these studies, there were no published reports ofWNK pathway regulation in
vivo, nor were there any functional roles described for WNK1-S, the predominant
WNK1 isoform in kidney.
We found significant transcriptional regulation of elements of the WNK pathway,
specifically upregulation ofWNK1-S and WNK4 with high K+ intake. A preliminary
look at the alleged volume side of the WNK molecular switch, examining WNK
expression in response to a wide (100-fold) range of chronic dietary NaCl intakes,
revealed a just significant trend to lower WNK1-S expression as dietary Na+ reduced
across the high to low spectrum. These coordinated WNK expression changes seem
functionally significant as merely heterozygous changes in WNK1 or WNK4 cause
substantial BP and electrolyte abnormalities13'42'148'165.
A preliminary investigation of the contribution of aldosterone to the changes seen in
WNK1-S expression across the dietary K+ spectrum suggested that aldosterone may
play a role in the regulation of WNK1-S expression in the HK group. In an
experiment designed to discriminate the roles of dietary K+ intake and circulating
aldosterone, linear regression analysis revealed strong correlations between K+ and
gene expression. In contrast correlations with aldosterone were much weaker, failing
to reach significance in most cases. Aldosterone signalling upregulated ENaC
activity, thereby increasing the lumen negative charge in DCT2-CD, and also
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upregulated Na+/K+-ATPase activity. Both of these effects enhance the
electrochemical driving force for K+ secretion via ROMK2. Intriguingly, ROMK2
expression correlated closely with circulating aldosterone level. Overall, however,
aldosterone had little or no effect on WNK pathway, ROMK1 or cHKA expression
in this analysis.
A recent study by Naray-Fejes-Toth and colleagues explored the hormonal regulation
of WNK1 expression in a mouse CCD cell-line (Ml cells) stably expressing MR106.
They concluded that aldosterone treatment at physiological concentrations increased
the expression of WNK1-S but not WNK1-L. WNK1-S expression was also
upregulated with dexamethasone treatment. Stable overexpression of WNK1-S
caused a significant increase in transepithelial Na+ transport via ENaC. The authors
propose that WNK1-S regulates the subcellular localisation but not the expression of
ENaC. However, as discussed previously, this WNK1 effect alone would promote
Na+ reabsorption but also reciprocal K+ secretion rather than the K+ retention
characteristic of Gordon syndrome.
9.3.1 WNK pathway molecular switch based on distal Na+ delivery.
Findings from our in vivo studies led us to propose a model whereby K+ loading
(such as with chronic high K+ diet) increased WNK1-S/WNK4 which inhibited NCC
and so enhanced distal Na+ delivery facilitating enhanced K+-excretion. Thus, an
increased K+ load evoked a WNK pathway response appropriately increasing K+
excretion. This model is based on hierarchical inhibitory regulation (triple negative)
down the regulatory chain WNK1-S-WNK1-L-WNK4-NCC, translating a rising K+
balance into a regulation of the site of NaCl reabsorption (Figure 6.6). Such
hierarchical inhibitory regulation is not unusual in kinase cascades and can facilitate
powerful amplification of physiological stimuli, and indeed often seems to generate a
decisive switch-like response32. In addition, such a hierarchy can also facilitate cross¬
talk between dominant stimuli (such as K+ balance here) and modifier stimuli acting
lower down the hierarchy - it is thus intriguing that in vivo the WNK pathway may
have these attributes. Moreover, this hypothesis was recently supported by another
independent study by Subramanya et al., showing (exactly as in Figure 6.6) that there
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seems to be a WNK1-S-WNK1-L-WNK4-NCC inhibitory hierarchy as studies in
Xenopus oocytes report WNK1-S downregulates NCC activity indirectly through the
suppression ofWNK1-L, relieving the inhibition ofWNK4. WNK1-S and WNK1-L
reportedly interact in a protein complex (a heteromultimer, most likely a
heterotetramer) with WNK1-S capable of inhibiting WNK1-L kinase activity in vitro
via multiple inhibitory sequences131. Additional support for WNK1-S inhibition of
WNK1-L is provided by a very recently published study showing firstly that WNK1-
L inhibits ROMK1 in Xenopus occytes and secondly that WNK1-S antagonises this
WNKl-L-mediated inhibition. This study also examined the effect of dietary K+
intake on WNK1-S expression in rat, reporting increasing WNK1-S expression with
• j # ZTO
increasing K , consistent with our findings (and the model in Figure 6.6) .
9.3.2 ROMK1 and cHKA coupling in K+, NH4+, and acid-base
balance.
Studies described in this thesis also uncover novel features of ROMK isoform
expression, including striking reciprocal regulation of ROMK1 and ROMK2 in
response to dietary K+ intake. This is the first report ofROMK isoform expression in
mouse and could have important implications for aspects of our understanding of K+
regulation and role of ROMK isoforms. In particular, upregulation of ROMK1 in K+
deficiency co-ordinates with changes in cHKA in a way which would allow fine
regulation of K+ and acid-base balance. Renal NH4+ production and excretion forms
a major component of renal acid-base homeostasis, particularly in response to
hypokalemia134, and occurs via a highly regulated pathway, whereby NH4+ is
delivered to multiple nephron sites where it substitutes for K+ ions and this facilitates
undisturbed homeostasis despite relative K+ deficiency. NH4+ is produced via the
metabolism of glutamine in the proximal tubular cells, secreted into the tubular fluid
via Na+/H+(NH4+) exchange129, and reabsorbed via NKCC2 (Na+/K+(NH4+)/2Cf)41
and K+/NH4+ antiport5-6 in TAL, where it accumulates in the medullary interstitium
and is finally secreted into the CNT-CD33.
For years, the mechanism of NH4+ secretion along the CD was thought to occur
through active H+ secretion in parallel with the non-ionic diffusion of NH3 down its
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33 "I-concentration gradient . Moreover the low permeability of CD epithelia to NH4
minimizes back diffusion of NH4+, promoting excretion in the urine. More recent
studies suggest that NH4+ transport across the basolateral membrane of MCD cells
may also occur by active transport of NH4+ via the Na+/K+(NH4+)-ATPase143. This
may be particularly relevant in hypokalaemic states when reduced medullary
interstitial K+ concentration augments Na+/NH4+ exchange rather than Na+/K+
exchange141'142. Furthermore, it has recently been proposed that NH4+ transport
across the apical membrane may occur actively in exchange for K+ via cHKA104.
This suggests that cHKA upregulation in K+ deficiency may occur to facilitate acid-
base balance, rather than primarily conserve K+. Thus, parallel upregulation of
ROMK1 with cHKA in OMCD, as we have seen in our studies, would allow
recycling of reabsorbed K+ back into the lumen via ROMK1, thus enabling H+
secretion via cHKA (Figure 7.6). This seems a particularly efficient coupling as
either increased pH or ADP/ATP ratio on the cytoplasmic face of active H+/K+-
ATPase would activate adjacent ROMK47 and both are likely to be present in the
vicinity of active H+/K+-ATPase pumps, but not otherwise, ensuring negligible
ROMK1 K+-secretion in excess of requirement for H+/K+-ATPase.
9.4 Integrated role of WNK molecular switch in renal
physiology.
Based on our findings we have proposed that the WNK molecular switch is based on
distal delivery ofNa+ to the aldosterone-sensitive nephron. Such a switch likely plays
a fundamental role in electrolyte balance, potentially explaining a long-standing
paradox in renal physiology. Aldosterone secretion from the adrenal glomerulosa is
stimulated in two very different physiological situations: (1) hyperkalaemia, in which
potassium is a direct stimulus for aldosterone secretion; and (2) hypovolemia, in
response to the activation of the renin-angiotensin system and angiotensin II action.
How the kidney differentiates between these two states to induce maximal K+
secretion in the first scenario, but maximal NaCl reabsorption in the second, in
response to the same aldosterone stimulus, is not very well understood, but clearly
the same aldosterone response pathway cannot deliver this sophisticated differential
response alone and a second independent or cross-talking response seems possible.
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9.4.1 Aldosterone as the sole regulator of renal electrolyte balance.
Aldosterone is firmly established as a powerful regulator of electrolyte balance.
However, it seems that the circulatory aldosterone level is not the sole factor
controlling the balance between Na+ reabsorption and K+ secretion in the distal
nephron. For example, during volume depletion, aldosterone secretion functions to
re-establish euvolemia by stimulating Na+ reabsorption in the principal cells of the
CNT and CD. This occurs through enhanced electrogenic Na+ transport apically via
ENaC and basolaterally via Na/K-ATPase in exchange for K+ secretion. This simple
mechanism is particularly effective in restoring fluid balance. However, as the sole
response to volume depletion, it would be disadvantageous as it would merely
replace the hypovolemic condition with potentially fatal hypokalaemia. Therefore the
kidney must have another mechanism to facilitate the uncoupling ofNa+ reabsorption
and K+ secretion in appropriate situations.
9.4.2 Two-compartment model of electrolyte homeostasis.
The WNK pathway seems well positioned to achieve this, primarily working in a
compartment proximal to, but complementing the aldosterone pathway. Effectively,
the WNK and aldosterone pathways would form a two-compartment model for the
regulation of electrolyte balance (Figure 9.4). According to our findings,
hyperkalaemia would induce increased inhibition of Na+ reabsorption in the upper
compartment via WNKs, driving Na distally. Aldosterone, secreted in response to
elevated K+, will stimulate Na reabsorption in the lower compartment in exchange
for K+ secretion. From our limited studies directed towards the volume side of the
switch we can attempt to predict what might happen in a high volume state. In this
scenario, increased inhibition by WNKs in the upper compartment will similarly
drive distal Na+ delivery (so increasing Na+ and volume balance will elicit an
appropriate response to augment NaCl excretion). However suppression of
aldosterone secretion in response to hypervolemia results in Na+ excretion in the
urine as Na+ reabsorption in the aldosterone-responsive DCT2-CD is downregulated.
Such a mechanism would re-establish euvolemia without disrupting K+ balance.
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Figure 9.4: Two compartment model of electrolyte balance in distal nephron.
Coordinated regulation of electrolyte balance via WNKs in an upper compartment and
aldosterone in a lower compartment allows appropriate Na+ reabsorption and K+ secretion
(a)under normal conditions and in the setting of (b)high plasma K+ (c)low volume and (d)
high volume. Regulation of electrolyte balance in response to K+ deficiency is shown in
Figure 9.5.
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Potentially, in K+ deficient states, a third compartment operating distal to this
aldosterone-sensitive region, would be induced, in which the coupled activity of
ROMK1 and cHKA would facilitate acid-base balance (Figure 9.5).
Low K+
Na+ H+
Figure 9.5: Three compartment model of electrolyte balance in K+ deficiency. The
coupled induction of ROMK1 and cHKA in K+ deficiency suggests that a third compartment
operating further distally, but working in concert with the two upper compartments, is
involved in K+ conservation and acid-base balance.
A loss of regulation via the WNK pathway, such as occurs in Gordon syndrome,
would result in unrestrained NaCl reabsorption in the upper compartment.
Consequently hypervolemic suppression of Ang II (and so relatively low
aldosterone) and reduced distal Na+ delivery would dissipate the electrochemical
driving force for K+ secretion in the aldosterone-sensitive lower compartment,
resulting in hypervolemia, hypertension and hyperkalaemia: Gordon syndrome's
cardinal features.
Supporting a key role for NCC in BP regulation, Majid and Navar identify NCC as
the major renal Na+ entry pathway in the distal nephron mediating arterial pressure-
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induced changes in sodium excretion. Also, Wang et al.i45 highlight decreased NCC
activity as an important mechanism to restore natriuresis, despite the continuous
presence of a high concentration of aldosterone in aldosterone-induced hypertension.
9.5 WNK1 and WNK4 Gordon syndrome phenotypes.
Although mutations in either WNK1 or WNK4 cause Gordon syndrome, the precise
clinical phenotypes caused by the individual mutations may not be identical. This
possibility is supported by current evidence indicating that WNK1 and WNK4 have
different nephron segment expression profiles and may regulate different electrolyte
transporters (at least in vitro). Moreover, only WNK4 has been reported to affect
paracellular electrolyte transport53'159. Indeed, even though only limited kindreds
have been reported since the association of WNK1 and WNK4 with Gordon
syndrome, a number of variables distinguishing the WNK1 and WNK4 phenotypes
have been documented.
Phenotypic analysis of a large French pedigree with the WNK1 deletion highlighted
notable differences compared to the clinical features resulting from the WNK4
(Q565E) mutation. The French WNK1 family had normal urine Ca2+ excretion,
9+ • •
compared to hypercalcuria (and low plasma Ca ) described in the Israeli WNK4
family87. Furthermore hypertension, when present, was much less severe than in the
Israeli family and did not develop until the fourth decade. Resolution of hypertension
86
during pregnancy has also been associated with the WNK4 (Q565E) mutation .
WNK1 and WNK4 are also expressed in extrarenal tissues, notably in tissues with
extensive epithelial systems18'52. It remains to be seen if any of these tissues prove to
be sites of minor phenotypic effects, previously unrecognised in Gordon syndrome.
Indeed WNK1-/- mice are embryonic lethal by mid-gestation highlighting the
systemic importance of WNK1165. In addition, Gordon syndrome is a dominant
disorder, with individuals bearing a Gordon syndrome mutation in one copy of
WNK1 or WNK4 suffering from the disease. More dramatic, perhaps lethal,
phenotypic effects could be anticipated in an individual homozygous for such a
mutation. Studies in Chapters 3 and 4 reveal extensive expression of WNK1 and
WNK4 before birth and show specific WNK1 splicing. Clearly it seems likely there
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are important indeed vital functional roles for these WNK genes in non-renal tissues
as well. If a clinical feature in a more accessible tissue is discovered, it may facilitate
the development of a simple, direct, non-invasive test for the diagnosis of Gordon
syndrome, as is already the case in Liddle syndrome diagnosis7.
9.6 Concluding remarks
The elucidation of the respective physiological roles of WNK1 and WNK4 is in its
infancy, and the various factors involved in the different pathophysiological features
of Gordon syndrome remain to be more clearly defined. Further investigation of this
pathway in vivo in different physiological settings, and the development of
transgenic models, will no doubt identify new branches of the WNK pathway as well
as verify existing in vitro models. Undoubtedly this is a pathway of major systemic
importance, and has potent effects through its actions in kidney. Unravelling the
mechanisms of the WNK pathway within kidney has the potential to advance our
understanding of the integrated physiology regulating electrolyte balance and BP,
and may even yield insights into the mechanisms involved in essential
hypertension107'135'166.
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WNK1, a Gene within a Novel Blood Pressure Control
Pathway, Tissue-Specifically Generates Radically Different
Isoforms with and without a Kinase Domain
MICHELLE O'REILLY,* ELAINE MARSHALL,* HELEN J.L. SPEIRS,* and
ROGER W. BROWN*
*Molecular Endocrinology, University of Edinburgh, Edinburgh, Scotland.
Abstract. WNK1 is a member of a novel serine/threonine
kinase family, With-No-K, (lysine). Intronic deletions in the
encoding gene cause Gordon syndrome, an autosomal dom¬
inant, hypertensive, hyperkalemic disorder particularly re¬
sponsive to thiazide diuretics, a first-line treatment in es¬
sential hypertension. To elucidate the novel WNK1 BP
control pathway active in distal nephron, WNK1 expression
in mouse was studied. It was found that WNK1 is highly
expressed in testis > heart, lung, kidney, placenta > skel¬
etal muscle, brain, and widely at low levels. Several WNK1
transcript classes are demonstrated, showing tissue-, devel¬
opmental-, and nephron-segment-specific expression. Im¬
portantly, in kidney, the most prominent transcripts are
Gordon syndrome (also known as pseudohypoaldosteronism
type 2, PHA 2; Online Mendelian Inheritance in Man 145260)
is a familial form of hypertension with an autosomal dominant
mode of inheritance (1). Patients have suppressed plasma renin
activity and present with symptoms of severe hypertension
(attributed to increased renal Na+ reabsorption), hyperkalemia
(despite normal glomerular filtration), and metabolic acidosis
as a result of reduced renal K+ and H+ excretion, respectively
(2). These features are chloride dependent and are particularly
well ameliorated by administration of thiazide diuretics (2-4).
In common with other chloride transport-related disorders
affecting BP, such as Bartter syndrome (5,6), it seemed possi¬
ble that the etiology lay in a direct mutation in a chloride
channel subunit or transporter (7).
However, mutations in human WNK1 and WNK4 genes
have recently been associated with Gordon syndrome (8).
The encoded proteins of these genes are described as mem¬
bers of a novel family of serine/threonine kinases known as
WNK (With No K, lysine) because of the atypical position¬
ing of a conserved lysine residue within the catalytic domain
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smaller than elsewhere, having the first four exons replaced
by an alternative 5'-exon, deleting the kinase domain, and
showing strong distal nephron expression, whereas larger
transcripts show low-level widespread distribution. Alterna¬
tive splicing of exons 11 and 12 is prominent—for example,
transcripts containing exon 11 are abundant in neural tissues,
testis, and secondary renal transcripts but are predominantly
absent in placenta. The transcriptional diversity generated
by these events would produce proteins greatly differing
in both structure and function. These findings help further
define and clarify the role of WNK1 and the thiazide-
responsive pathway relevant to essential hypertension in
which it participates.
(9). How they relate to ion transport abnormalities is of key
importance as this seems to represent a novel BP regulatory
pathway (10-12). Moreover, intriguingly, cases attributed
to WNK1 mutations in this autosomal dominant disorder are
due to intronic deletions and are not recognized as directly
affecting WNK1 coding sequence (8).
It is of great interest how such WNK1 mutations, in a
widely expressed gene, cause an autosomal dominant dis¬
ease, with a mechanism seemingly explicable by a distal
nephron-limited ion transport defect (2,13). One possibility
sees the intronic region involved in transcriptional regula¬
tion, and some preliminary evidence maintains this as a
reasonable explanation. Alternatively, this apparently "si¬
lent" mutation may alter the complement of spliced products
transcribed from the gene. Such silent mutations have been
shown to cause dominant diseases by altering splicing, e.g.,
in the fibrillin-1 gene, causing Marfan syndrome (14). Thus,
evidence relating to promoter use and alternative splicing of
WNK1, especially relating to kidney, is of interest.
The study presented here describes, in some detail, several
isoforms produced from the WNK1 gene, some of which show
strikingly different tissue-specific distributions, including one
showing abundant expression in kidney that is seen at low
level, if at all, in other tissues. Such modifications, generating
this transcriptional diversity, also produce predicted proteins of
very different structure and proposed function. The findings
reported thus help elucidate not only probable mechanisms by
which the WNK1 intronic deletions cause disease, but also
further clarify the novel WNK1 BP control pathway.
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Materials and Methods
Northern Blot Analysis
Total RNA was extracted in TRIzol Reagent (Invitrogen, Inchin-
nan, UK) and separated (15 p.g/lane) by denaturing (formamide/
formaldehyde) agarose electrophoresis (0.8%), and blotted onto Hy-
bond-N+ membrane (Amersham Biosciences, Little Chalfont, UK).
Blots were hybridized with PCR-amplified mouse WNK1 (mWNKl)
DNA fragments, radiolabeled with 32P-dCTP (Rediprime II Random
Prime Labeling System, Amersham Biosciences, UK), at 65°C over¬
night in hybridization buffer (0.5 M Na2P04-NaH,P04 pH 7.2/7%
SDS with 100 /rg/ml denatured salmon sperm and 20 p.g/ml yeast
tRNA). Washes were at 65°C with 50 mM Na2P04NaH2P04 pH
7.2/1% SDS. Blots were exposed to Kodak x-ray film (BioMax MS-1;
Sigma, Poole, UK) at —70°C. cDNA templates for Northern blot
probe production were PCR amplified with primers as detailed in
Table 1 and Figures 1 and 2.
RT-PCR
Promega Reverse Transcription System (random primed) (Pro-
mega, Southampton, UK) generated PCR templates (5 /jtl, diluted
1:20), used in standard PCR reactions, denaturing at 95°C for 3 min,
then incubating on ice, and adding 15 pmol each primer, 250 /rmol
dNTP, and 2 U Taq DNA Polymerase (Promega) to a final volume of
50 pi in IX PCR buffer. The PCR program used was as follows: 3
min at 95°C, then 35 to 40 cycles of 60 s at 95°C, 60 s at 60°C, 120 s
at 72°C, and finally 10 min at 72°C. For negative controls, template
was replaced with water. Products were visualized by agarose gel
electrophoresis and purified with QIAquick PCR Purification Kit
(Qiagen, Crawley, UK).
Production of Single-Stranded RNA Probes
RNA probes for in situ hybridization (ISH) analysis, produced
as described previously (15) to specific regions of mWNKl, used
a nested PCR method with primers, including 5' extensions con¬
taining phage polymerase consensus sites, with sense and antisense
primer pairs incorporating T3 (TCTAGATTAACCCTCACTA-
AAGGGA) and T7 (GGATCCTAATACGACTCACTATAGGG)
sites, respectively. The PCR program used was as follows: 5
cycles of 45 s at 95°C, 45 s at 55°C, 120 s at 72°C, followed by
30 cycles of 45 s at 95°C, 45 s at 69°C, and 120 s at 72°C, and
finally 10 min at 72°C. The required DNA-dependent RNA phage
polymerase (T3-sense, T7-antisense) was then used on these puri¬
fied PCR products to produce single-stranded 35S-UTP-labeled
RNA probes of the corresponding inserts for ISH, as described
elsewhere (15).
Table 1. Primer sequences
Primer Sequence (5'-3')a Orientation Position"
PI CTTGTCAGTGCTGAGTGGGAGTC Sense 1
P2 CAGATTTTGTTAACTTTCGATCCTGCAATTC Antisense 938
P3 GTTGTGAGCTGTGTGTGAAAGATAAGG Sense 8439
P4 CAGACCTCACTCAGAATGACTAAACC Antisense 9313
P5 GTATCCGACAAAACAAAGATGAAAGATATTCC Sense 1523
P6 CTGTATTCCCTGCTGCTGAGGATG Antisense 2382
P7 CTAGTATATCTGTGTTGTCTGATGGAACC Sense 2084
P8 GTCATTGTTCACCATAATTGTTGCTATCTC Antisense 3633
P9 AGAAACTACTAGTAGCAAAATCCCTGTC Sense Figure lc
P10 GCTTCACTCCCTCATTTATACAATCC Antisense Figure lc
Pll CCAAGGCAGTGGGAATGTCCAATG Sense 773
P12 CGTTTTCTCTTAATTAAGGACACCCTATC Antisense 1853
P13 GTCGCTTTCTCAAATTTGACATCGAAATC Sense 799
P14 CTTTGATAGCTTTAGCCATGGTCTTGTG Antisense 1825
P15 GCAGGATCGAAAGTTAACAAAATCTGAAAG Sense 903
P16 ACGTCTTAAGTGTTCCAGATGTCATTAG Antisense 1081
P17 GAAAATCAAAGTTTTAAGAAGCTGGTGTC Sense 1104
P18 TCTTGGCAAAAGAAGCCCGCTTTAGAG Antisense 1291
P19 ACCCCAGAGTTTATGGCTCCTGAG Sense 1303
P20 CACTCCACTGGTCACTCGAC Antisense 1464
P21 GTGGAGTGAAGCCAGCCAGTTTTG Sense 1457
P22 GAATATCTTTCATCTTTGTTTTGTCGGATAC Antisense 1553
P23 GACCTTTTGAACCATGCCTTTTTCCAG Sense 1587
P24 CTCAACCATTTCTTGAGCAACATCTTCTG Antisense 1773
P25 TCTAGATTAACCCTCACTAAAGGGACTTCCAGTTTCCCAGACAG Sense 2497
P26 GGATCCTAATACGACTCACTATAGGGTACAAAACATCTCCAGAGG Antisense 2956
P27 TCTAGATTAACCCTCACTAAAGGGAGCTTCCCATCTCGACTG Sense 2960
P28 GGATCCTAATACGACTCACTATAGGGCTCCAGAACTGCTTGCTG Antisense 3243
* Primer sequences are based on mouse WNK1 sequence (accession no. AY309076).
" Primer position refers to the position of the most 5' base according to the orientation of the primer.


















Figure 1. Schematic representation of WNK1 cDNA structure showing primer positions, (a and b) cDNA structure of WNK1 and
kidney-specific WNK1 containing exon 4A, respectively, with vertical bars representing splice junctions and dashed vertical bars indicating
3' polyadenylation sites A1 and A2. Numbers within rectangles refer to exon numbers. Primers are represented by arrows and are numbered
PI to P28. Additional primer details are given in Table 1. Horizontal dashed lines specify the cDNA region amplified by PCR with the
corresponding primer pairs, (c) cDNA sequence of exon 4A (accession no. AY319934). The predicted amino acid sequence also shown would
continue in frame across the splice site to exon 5.
ISH Analysis
ISH, as described previously (15,16), used cryostat sections (10
gm) cut from adult mouse kidney and mouse embryo samples (ges¬
tation day 16.5) mounted on silane-coated glass microscopic slides.
Slides were fixed in 4% paraformaldehyde, incubated with prehybrid-
ization buffer at 50°C, hybridized with denatured 35S-UTP-labeled
RNA probes (at a final concentration of approximately 10X106
cpm/ml in hybridization buffer at 50°C for approximately 16 h),
followed by washes in 2x SSC, treatment with RNase A, and further
washes to a maximum stringency of 0.1 X SSC at 60°C. After ethanol
series dehydration, slides were exposed to Kodak x-ray film (BioMax
MR-1; Sigma). Slides were then emulsion dipped and exposed in a
light-tight box for 3 to 5 wk before being developed.
Results
The mouse WNK1 gene (mWNKl) is large, spanning >100
kb, with a coding region showing 86% identity with human
WNK1 (hWNKl). mWNKl produces large transcripts (>10
kb) with cDNA encoded by 28 exons (Figure la), having a
predicted 2377 amino acid protein. Northern blot hybridization
with exons 6 to 9 revealed widespread distribution of these
large transcripts (Figure 2a) with high expression seen in testis
> heart, lung, kidney, placenta > skeletal muscle, brain, and
low-level expression elsewhere. Additional Northern blots
show placental transcripts are of similar size to the major
widely found isoform. In kidney, a smaller, more abundant
American Society of Nephrology. Unauthorized reproduction of this article is prohibited
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Figure 2. Northern blot analysis ofWNK1 expression. Hybridization
with a probe incorporating exons 6 to 9 (a) detects widespread
expression of large transcripts approximately 10.2 kb in size. In
addition, smaller and more prominent transcripts are detected in
kidney. This expression profile is also observed in (b) when hybrid¬
izing with the poly-A probe (refers to sequence located between the
two 3' polyadenylation signals Al and A2). (c) Probing with exon 1
fails to detect the smaller kidney-specific transcripts, (d) Northern blot
analysis reveals differential expression of individual exons in WNK1
isoforms in kidney (K) and testis (T). Hybridization with probes
against exons 2, 3, 4, 5, and 6 detect the large WNK1 isoform,
strongly in testis but weakly in kidney. The smaller and more abun¬
dant kidney-specific isoform is only detected by probes to exons 5 and
6. A probe to an alternative exon, 4A, detects the smaller kidney-
specific isoform only. Hybridization with a probe to exon 11 detects
the large WNK1 isoform in testis but signal is low for either isoform
in kidney. In contrast, hybridization with exon 12 readily detects both
the kidney-specific isoform and the large WNK1 testis isoform.
WNK1 expression was studied across a range of adult mouse tissues
and in placenta (E16.5). Probe templates were PCR amplified with the
following primer pairs: exons 6 to 9, P5/P6 (860 bp); poly-A, P3/P4
(875 bp); exon 1, P1/P2 (928 bp); exon 2, P15/P16 (180 bp); exon 3,
P17/P18 (187 bp); exon 4, P19/P20 (161 bp); exon 4A, P9/P10 (340
bp); exon 5, P21/P22 (96 bp); exon 6, P23/P24 (212 bp); exon 11,
P25/P26 (462 bp); and exon 12, P27/P28 (278 bp). For primer posi¬
tions and sequences, refer to Figure 1 and Table 1, respectively.
mWNKl transcript is seen differing by at least 1.5 to 2 kb
(Figure 2a). A 3'-polyadenylation (poly-A) site A1 (Figure 1) is
positioned approximately 800 bp downstream of the open
reading frame (ORF). To assess whether the use of an alter¬
native poly-A site could account for this size difference, we
isolated cDNA sequence encoding a second poly-A site ap¬
proximately 2400 bp downstream of the ORF (Figure 1, A2).
Northern blot hybridization with cDNA between these poly-A
sites revealed a similar expression profile to that described
above (Figure 2b). Both transcripts in kidney were detected
implying most WNK1 transcripts terminate at the second 3'
poly-A site (Figure 1, A2). Having excluded this possibility, an
exon 1 probe, overlapping the ORF (Figure 1), was designed
against the 5' region. Northern blot hybridization with exon 1
revealed a similar expression profile for the large mWNKl
transcript, but the smaller kidney-specific transcript remained
completely undetected, indicating it lacks exon 1 (Figure 2c).
To investigate whether this kidney-specific isoform lacked
further 5' exons, nested PCR was used to produce probes
against exons 2, 3, 4, 5, and 6 (Figure 1), ensuring amplifica¬
tion of mWNKl cDNA only (confirmed by sequencing) across
this highly conserved kinase domain region. Northern blot
analysis of kidney and testis RNA showed probes to exons 2,
3, and 4 only detect the large mWNKl transcript and not the
smaller kidney-specific isoform (Figure 2d). In contrast, exon
5 and 6 probes detect both mWNKl transcripts. Thus, the
smaller mWNKl transcript in kidney lacks exons 1 to 4.
Screening submitted expressed sequence tag (EST) databases
suggested an alternative exon preceding exon 5 in kidney,
positioned between exons 4 and 5 in the genomic sequence and
therefore termed exon 4A. Northern blot hybridization with
this exon only detects the smaller mWNKl transcript (Figure
2d), confirming inclusion of exon 4A in the kidney-specific
isoform (Figure lb).
ISH to exons 6 to 9 allowed detailed study of mWNKl
expression in mouse kidney. Figure 3 reveals clear WNK1
expression above background in distal nephron extending from
early distal convoluted tubule (DCT) into connecting tubule
and at lower level into cortical collecting duct (lower expres¬
sion in medullary rays; Figure 3). Strong expression in DCT
continues adjacent to glomeruli and is seen looping close to
their vascular pole (Figure 3 right panels) the site of the macula
densa. Additionally, lower expression, above background, is
distributed more extensively. This appears to have a different
origin from the higher expression seen in DCT (i.e., different
WNK1 transcripts; see below).
To investigate the distribution of the two kidney isoforms,
adult kidney sections were hybridized with exons 1, 4A, and
6 to 9 (Figure 4, top left panel). Probing with exon 1 detects
widespread signal at a low level (Figure 4a), whereas with
exon 4A, only strong punctate signal in cortex is detected
(Figure 4c). The expression pattern seen with exons 6 to 9
is thus a combination of that seen with exons 1 and 4A
(Figure 4e). These probes were also hybridized to embryo
tissue slices (E16.5) to examine developmental mWNKl
expression. Probing with exons 6 to 9 revealed a wide
mWNKl distribution, with high expression in tissues—for
example, placenta, nasal epithelium, lung, intestine, regions
of the brain, and developing renal cortex (Figure 4f). As
expected, the expression patterns revealed by probing with
exons 1 and 4A were subtypes of that seen for exons 6 to 9,
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Figure 3. In situ hybridization (ISH) of WNK1 in mouse kidney. The ISH study used a probe to WNK1 exons 6 to 9. Images are of
emulsion-dipped slides (eosin/cresyl violet counterstain; original magnification: left, X40; right, X200). View of renal cortex with a medullary
ray (MR) demarcated between the parallel lines and cortical labyrinth lateral to them. Below the dashed line is the outer medulla. Bright field
on top (black, strong expression), corresponding dark field view on bottom (white, expression). The very highest expression—showing black
on bright field—obscures light, and hence the strongest expressing tubules appear as black holes with ring outlines on dark field view (bottom
left). Short black arrows indicate glomeruli; a, examples of distal convoluted tubules (DCT) largely adjacent to glomeruli; b, example of
connecting tubules (CNT) in midcortical labyrinth arcades (adjacent to radial vessels); c, cortical collecting duct (CCD) in medullary rays; and
GA, glomerular arteriole, (left) Study with long exposure (5 wk) demonstrating wide range of expression level. Note regional expression at 3
levels: (7) widespread low level (low level white seen in darkfield), (2) higher in CCD (faint but distinct tubular outline seen on dark field,
pale gray on bright field); and (3) highest in DCT and CNT (darker gray-black on bright field and bright ring with black hole center when silver
grains confluent), (right) Three-week exposure: note the proximity of strongly expressing DCT to glomerulus and its vascular pole (between
arterioles) and stronger expression than in collecting duct.
m-■
with exon 1 widely expressed, particularly in placenta, lung,
kidney, intestine, thymus, and forebrain (Figure 4b),
whereas exon 4A revealed much lower expression, with
high signal detected in restricted regions (e.g., nasal epithe¬
lium, forebrain, thymus, and kidney; Figure 4d). Sense
control sections showed no specific hybridization (Figure 4).
EST sequences suggest that alternative splicing of mWNKl,
primarily concerning exons 11 and 12, takes place in some
tissues (Figure 1). To investigate this, we subjected kidney and
testis RNA to Northern blot analysis with probes specific for
each exon. Flybridization with exon 11 detects the large
mWNKl isoform in testis, but signal is greatly diminished for
either isoform in kidney (Figure 2d), suggesting exon 11 is
usually spliced out in both kidney mWNKl transcript classes.
In contrast, hybridization with exon 12 shows strong signal for
mWNKl in testis and for the smaller kidney-specific tran¬
script. The large mWNKl transcript in kidney is also detected
at a lower level (Figure 2d). To investigate tissue-specific and
developmental variations in these splicing events, we subjected
adult mouse kidney and fetal (E16.5) sections to ISH analysis.
The expression patterns seen when probing adult kidney sec¬
tions with either exon are similar to that described above for
exons 6 to 9, showing low-level, widespread expression
throughout the kidney, overlaid with strong punctate cortical
expression (Figure 4, g and i). However, developmental ex¬
pression studies that use these probes indicate that although
many fetal tissues express both exons similarly, striking tissue-
specific splicing occurs in some developing organs. For exam¬
ple, transcripts containing exon 11 are abundant in some neural
tissues but are rare or absent in placenta (Figure 4, h and j).
Sense-control sections showed no specific hybridization
(Figure 4).
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Figure 4. Analysis of WNK1 expression by in situ hybridization (ISH) of mouse adult kidney and fetal sections (E16.5). Cryostat sections were
subjected to ISH analysis; a range of probes against WNK1 were used. Left columns of top panels show local distribution within the kidney
(a, c, e, g, i, and k). Right columns of top panels show corresponding developmental expression patterns (b, d, f, h, j, and 1). Bottom panel shows
sense controls for both kidney (m and n) and fetal (o and p) sections. Probes were constructed against exon 1 (434 bp), exon 4A (280 bp), exons
6 to 9 (552 bp), exon 11 (460 bp), exon 12 (283 bp), and exon 4B (108 bp). Exposure times for detection of ISH signal were as follows: exon
1, (a and b) 1 d; exon 4A, (c) 1 d, (d) 4 d, (n) 1 wk; exon 6 to 9, (e and f) 1 d, (m) 3 d; exon 11, (g, h, and o) 3 d; exon 12, (i and j) 3 d; exon
4B, (k, 1, and p), 2.5 wk. For details of probe lengths and production, see Materials and Methods. B indicates brain; K, kidney; L, lung; and
P, placenta.
Reverse transcriptase-PCR (RT-PCR) studies across exons
11 and 12 confirm these splicing events (Figure 5a). Amplifi¬
cation in kidney by means of primers spanning the exon 7/8
splice site down to the exon 15/16 splice site shows two major
bands, corresponding in size to PCR products having either
exon 11, or both exons 11 and 12 spliced out (Figure 5b).
Additional RT-PCR studies that use alternative primers span¬
ning this region also show major bands, similarly representa¬
tive of these splice variants. However, it is difficult to interpret
the importance of additional large weak products occasionally
amplified by RT-PCR.
EST sequences also suggest that in addition to exons 4
and 4A, a third exon positioned between exons 4A and 5 in
the mouse genomic sequence and therefore termed 4B, may
precede exon 5 in some mWNKl transcripts (accession no.
AK052468). The EST evidence suggests that unlike the
kidney-specific transcripts described above containing exon
4A, which lack all known upstream exons, transcripts con¬
taining 4B splice directly from exon 4 to 4B to 5. ISH
analysis probing with exon 4B shows a similar pattern to
that seen previously in kidney, with high cortical expression
overlaying a low widespread distribution (Figure 4k). How-















Figure 5. Detection of WNK1 alternative splicing, (a) Ethidium bromide-stained agarose gel, showing reverse transcriptase-PCR-amplified
fragments in duplicate. These products were amplified with mWNKl primer pair P7 and P8, which span a region from the exon 7/8 splice site
down to the exon 15/16 splice site (lanes 3 and 4). A negative control is seen in lane 2. Lane 1 shows a 100-bp DNA ladder, (b) Schematic
depiction ofWNK1 alternative splicing involving exons 11 and 12. The major products seen correspond to(b) (iii) and (b) (iv). (c) Schematic
representation of the major predicted WNKl-derived proteins. mWNKl is 2377 amino acids in length and is particularly rich in serine,
glutamine, and proline, having 26 PXXP sites potentially recognized by SH3 domains. Black bars denote four putative coiled coil domains,
and a conserved WNK autoinhibitory domain is represented by horizontal stripes. Black arrowheads indicate the positions of all potential
phosphorylation sites; intriguingly none of which overlap with the region encoded by exons 11 and 12. Exon 11 encodes a leucine zipper
(LXXLL) motif. Kinase-deficient (KDP) WNK1 has a truncated N-terminus, lacking one coiled coil domain and deleting a major portion of
the kinase domain. This region is substituted with a highly cysteine-rich stretch of 30 amino acids.
ever, splicing events producing transcripts containing exon
4B appear to be rare, judged by the lower ISH signal
(requiring severalfold longer for clear detection). Further¬
more, signal detected on fetal sections was low and wide¬
spread, lacking the striking tissue-specific differences in
expression levels seen with probes to other exons (Figure 41),
and was only marginally higher than that seen for sense con¬
trols (Figure 4p).
As described above, Northern blot studies examining exon
11 expression detect very weak signal for both isoforms in
kidney, despite high expression in testis. In contrast, ISH
studies suggest exon 11 is expressed at levels comparable with
exon 12 in kidney. This discrepancy led to further Northern
blot analysis looking for evidence of further novel mWNKl
kidney transcripts containing exon 11. These studies revealed
at least two novel mWNKl transcripts in kidney and testis,
2454 Journal of the American Society of Nephrology
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Figure 6. Detection of smaller WNK1 transcripts in kidney and testis
by Northern blot (short exposure). Probes to exon 4A detect the
kidney-specific WNK1 transcript (B), but also reveal two additional
transcripts several kilobases smaller (C and D) in both kidney (K) and
testis (T). These transcripts are also seen when probing with exon 11,
which also detects the large WNK1 transcript (A) as expected.
evidently several kilobases smaller than the two isoforms de¬
scribed above (Figure 6). Intriguingly, transcripts of similar
size were detected in additional Northern blot analysis of exon
4A expression in both tissues (Figure 6).
Discussion
In this study, we show multiple WNK1 mRNA species are
expressed in both adult mouse and during development, with
some showing striking tissue-specific expression differences.
Large transcripts—greater than 10 kb in size—were seen by
Northern blot in virtually all tissues examined, with expression
highest in testis > heart, lung, kidney, placenta > skeletal
muscle, brain. Transcripts detected in testis appeared larger
than transcripts common to most other tissues, attributed to the
inclusion of exon 11 (462 bp). The major transcripts seen in
kidney, however, were smaller than elsewhere. This phenom¬
enon has been reported in previous studies (8) and appears to
be conserved between species. We have demonstrated that the
difference between these transcripts is not the result of the use
of an alternative 3' polyadenylation site, as previously sug-
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gested (8,9,17,18). Instead, we show that the first four exons in
the smaller, more prominent kidney transcripts are replaced by
an alternative exon, exon 4A (19). The sequence of this novel
exon and the resulting predicted amino acid sequence are
presented for the first time (Figure lc). ISH analysis revealed
strong punctate expression of these smaller transcripts re¬
stricted to cortex, localizing to distal nephron, whereas the
large transcripts showed uniform low-level expression
throughout the kidney. These expression patterns are combined
in that seen for exons 6 to 9, found in both transcript classes.
In addition to exons 4 and 4A, another novel exon, exon 4B,
was found to precede exon 5 in some WNK1 kidney tran¬
scripts; however, weak ISH signal suggests that this is a rare
splicing event.
Use of exon-specific primers identified two relatively abun¬
dant, alternatively spliced mWNKI mRNAs in kidney, corre¬
sponding in size to transcripts lacking either exon 11 or both
exon 11 and 12. Alternative splicing of these exons has also
been reported for hWNKl (17). Furthermore, the published rat
WNK1 sequence (accession no. NM_053794) corresponds to
the splice variant lacking both exons. Exon-specific ISH de¬
tected expression in kidney, with probes to both exons showing
a similar pattern to that described above for exons 6 to 9. In
contrast, Northern blot analysis showed that although exon 12
is usually included in the small abundant kidney isoform, exon
11 is largely absent in both kidney isoforms. Further studies
indicate the production of substantial levels of novel smaller
alternatively spliced transcripts from the WNKJ gene, with
Northern blot analysis implicating the inclusion of both exons
11 and 4A. These smaller transcripts are seen in kidney but
also in testis, a tissue in which exon 4A expression was
previously unsuspected because testis lacks obvious expression
of the much larger "kidney-specific" 4A transcript. Preliminary
investigations suggest that these transcripts differ from this
largely kidney-specific 4A transcript, described above, being
much smaller in size. However, RT-PCR in testis easily am¬
plifies a product from exon 4A to exon 11, suggesting these
smaller transcripts contain this region.
This study was the first to assess WNK1 expression in
development by means of ISH analysis, demonstrating that
WNK1 is widely expressed in the mouse embryo (E16.5), in
both epithelial tissues (e.g., developing renal cortex, intestine,
lung, nasal epithelia, and placenta) and in nonepithelial tissues
(e.g., regions of the CNS). Again, there are tissue-specific
differences in the pattern of transcripts expressed in developing
organs, with transcripts containing exon 1 showing high wide¬
spread but nonuniform expression and exon 4A- containing
transcripts showing high expression only in restricted sites.
Exon-specific ISH also showed striking tissue-specific differ¬
ences in expression of exons 11 and 12—for example, tran¬
scripts containing exon 11 are abundant in some neural tissues
but are very low or absent in placenta.
It is appropriate to suggest that WNK1 regulates ion trans¬
port through the kinase domain. However, the major WNK1
transcript in kidney lacks this functional entity as a result of the
replacement of exons 1 to 4 with exon 4A (Figure 5c). Addi¬
tionally, a coiled coil motif predicted just N-terminal to the
J Am Soc Nephrol 14: 2447-2456, 2003 WNK1 Isoforms and Their Expression 2455
kinase domain is lost, possibly disrupting interactions with
molecular targets. This implies that the remainder of the
WNK1 protein must contribute functionally to the WNK1
regulatory pathway. Exons 11 and 12 are of key interest
because splicing of this region is conserved between species, is
clearly tissue specific, and would produce a repertoire of
proteins likely to be coexpressed in the same tissues and
probably the same cells (Figure 4). The predicted amino acid
sequence encoded by these exons is proline rich (approximate¬
ly 15%), and analysis suggests a potential transmembrane span
flanked by a flexible conformation. This region also shows
homology to a number of extracellular matrix proteins (e.g.,
mucins, glycosaminoglycans, and sialoproteins). Clearly, this
is of interest in the context of proteins that may play a role in
tight junction regulation. Conversely, when this stretch of
amino acids is removed, these features disappear. The resulting
juxtaposed sequence is predicted to form an exposed loop
region with homology to proteins that tend to bind ligands
and/or act as transcription factors. Intriguingly, although
WNK1 contains numerous potential phosphorylation sites, no
such site occurs within the exon 11 to 12 region, implying that
signaling through protein kinase pathways acting on WNK1 is
not affected by such splicing events. Clearly, experimental
studies are required to fully investigate these possibilities.
Also of interest is the addition of thirty amino acids to the
N-terminus of kinase-deficient (KDP) WNK1, contributed by
exon 4A. This exon may have no major functional effect other
than deleting the kinase domain. However, this sequence is
strikingly cysteine rich. Within a cluster of six likely very
reactive cysteine residues, at least three have a high predictive
index for forming either disulfide bonds or bonds with other
molecules (e.g., metal-containing moieties). Moreover, the N-
terminal positioning of this cysteine cluster may promote this
region as a potential point of anchorage to other structures.
Furthermore, the novel small bands seen by Northern blot
clearly indicate the production of WNK1 transcripts lacking
several kilobases compared with the kidney-specific 4A band.
Therefore, it is very likely that additional changes in WNK1
protein structure exist that have profound effects on WNK1
function.
The transcriptional modifications described above would
greatly influence the potential complement of proteins pro¬
duced from the WNK1 gene and may have evolved to regulate
WNK1 function. KDP-WNK1 proteins may act to inhibit other
WNK1 proteins, having "active" kinase domains, via interac¬
tions through the remaining coiled-coil motifs (Figure 5c). This
is supported by the recent report of a WNK1 autoinhibitory
domain, positioned between residues 515 to 569 in the rat
sequence, which is conserved between species and also within
the WNK family (Figure 5c). Preliminary evidence was also
reported for WNK1 tetramer formation via the coiled-coil
motif C-terminal to the autoinhibitory domain (Figure 5c) (20).
This work provides a number of insights into the cause of
Gordon syndrome. We have examined WNK1 expression in
some detail, further elucidating kidney-specific and distal-
nephron-specific WNK1 transcripts. Our findings imply the
use of alternative promoters, one initiating transcription in
exon 1 and the second giving rise to transcripts having exon 4A
in place of exons 1 to 4. It is therefore reasonable to suggest
that cis elements within intron 1 affect the second promoter
regulating such 4A transcripts. Dominant negative regulation
would imply that intronic deletions causing Gordon syndrome
lead to abnormally high expression of KDP-WNK 1 transcripts
in kidney, in turn causing excessive inhibition of "normal"
WNK1 function. Alternatively, the intron 1 deletions could
interrupt splicing enhancer or silencer sequences, thereby
affecting the inclusion or exclusion of exons and disrupting
the complement of alternatively spliced WNK1 transcripts.
A similar effect is seen in Marfan syndrome, another auto¬
somal dominant disorder affecting connective tissue, where
a silent mutation results in exon skipping (14). In ataxia-
telangiectasia, an intronic deletion in the ATM gene results
in aberrant inclusion of a cryptic exon (21).
The pathway disrupted in Gordon syndrome involving
WNK I is regarded as different from other signaling pathways
known to regulate BP. The findings presented here reveal the
central importance of the transcriptional control of this gene in
generating a complement of kidney-specific, WNK 1-derived
proteins. The correct balance within this complement of pro¬
teins must mediate the effects on ion transport that constitute
this novel BP regulatory pathway. Clearly the regulation of
alternative promoter use and splicing is likely to participate in
the control of BP by WNKl-derived proteins.
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Basic Science Articles
Dietary Electrolyte-Driven Responses in the Renal WNK
Kinase Pathway In Vivo
Michelle O'Reilly/ Elaine Marshall/ Thomas MacGillivray/ Manish Mittal/ Wei Xue/
Chris J. Kenyon/ and Roger W. Brown*
*Endocrinology, Centre for Cardiovascular Science, Queen's Medical Research Institute, and fWellcome Trust Clinical
Research Facility, Western General Hospital, Edinburgh, United Kingdom
WNK1 and WNK4 are unusual serine/threonine kinases with atypical positioning of the catalytic active-site lysine (WNK:
With-No-K[lysine]). Mutations in these WNK kinase genes can cause familial hyperkalemic hypertension (FHHt), an auto¬
somal dominant, hypertensive, hyperkalemic disorder, implicating this novel WNK pathway in normal regulation of BP and
electrolyte balance. Full-length (WNK1-L) and short (WNK1-S) kinase-deficient WNK1 isoforms previously have been
identified. Importantly, WNK1-S is overwhelmingly predominant in kidney. Recent Xenopus oocyte studies implicate WNK4
in inhibition of both thiazide-sensitive co-transporter-mediated Na+ reabsorption and K+ secretion via renal outermedullary
K+ channel and now suggest that WNK4 is inhibited by WNK1-L, itself inhibited by WNK1-S. This study examined WNK
pathway gene expression in mouse kidney and its regulation in vivo. Expression of WNK1-S and WNK4 is strongest in distal
tubule, dropping sharply in collecting duct and with WNK4 also expressed in thick ascending limb and the macula densa.
These nephron segments that express WNK1-S and WNK4 mRNA have major influence on long-term NaCl reabsorption, BP,
K+, and acid-base balance, processes that all are disrupted in FHHt. In vivo, this novel WNK pathway responds with
significant upregulation of WNK1-S and WNK4 with high K+ intake and reduction in WNK1-S on chronic lowering of K+ or
Na+ intake. A two-compartment distal nephron model explains these in vivo findings and the pathophysiology of FHHt well,
with WNK and classic aldosterone pathways responding to drivers from K+ balance, extracellular volume, and aldosterone
and cross-talk through distal Na+ delivery regulating electrolyte balance and BP.
J Am Soc Nephrol 17: 2402-2413, 2006. doi: 10.1681/ASN.2005111197
The role of WNK1 and WNK4 in control of electrolytebalance and BP first became apparent with their mutationbeing associated with familial hyperkalemic hypertension
(FHHt; also known as Gordon syndrome and pseudohypoaldo-
steronism type 2), a human autosomal dominant disorder that
features hypertension, hyperkalemia, and acidosis that usually are
hyperresponsive to thiazide diuretics (1,2). FHHt can be caused by
intronic deletions in WNK1 or missense mutations in WNK4 (3).
Mutations in either cause a broadly similar phenotype, suggesting
that WNK1 and WNK4 function in a common pathway. Unlike
mostmonogenic disorders that affect BP, which feature reciprocal
Na+ and K+ (and/or H+) imbalances and share a relationship to
the aldosterone pathway (4), FHHt features concurrent NaCl and
K+(and/or H+) retention (1,3/5). This unusual characteristic indi¬
cates the existence of a novel "WNK pathway" functioning in
normal physiology, which may allow the "independent of aldo¬
sterone" regulation of K and Na balance (and extracellular vol¬
ume) by the kidney, ultimately also maintaining BP within the
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normal range. The BP-regulatory role of this WNK pathway is
conserved in evolution as WNK1 + /— mice are hypotensive (6).
Previously, we and others demonstrated that a 5'-truncated
kinase-deficient isoform (WNK1-S) predominates in kidney (7),
this being conserved between human and mouse (7-9). Iso-
form-specific probes distinguished ubiquitous low-level ex¬
pression of full-length WNKl-long (WNK1-L) from abundant
WNK1-S expression in distal nephron. Recent Xenopus oocyte
studies implicate WNK4 in inhibition of NaCl reabsorption by
thiazide-sensitive Na+Cl~ co-transporter (NCC) (10,11) and/or
K+ transport via renal outer medullary K+ (ROMK) (12), while
WNK1-L may in turn inhibit WNK4 (11). Furthermore, very
recent in vitro reports show that WNK1-S, the predominant
isoform in kidney, may participate in regulation of electrolyte
transport. In Xenopus oocyte studies, WNK1-S acted as a dom¬
inant negative regulator of WNK1-L (13) (thereby WNK1-S
would relieve repression of WNK4). In cultures of mouse cor¬
tical collecting duct (CCD) cells, aldosterone induces WNK1-S
expression, and this may mediate an increased epithelial Na
channel (ENaC) conductance (14).
This evidence suggests that this WNK pathway plays a func¬
tional role in normal physiology to control electrolyte ho¬
meostasis and BP. The full renal response that maintains nor¬
mal BP or compensates for altered electrolyte intake involves a
substantial component that takes many hours per day to de¬
velop fully and is accompanied by significant persistent
ISSN: 1046-6673/1709-2402
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Table 1. Primer and probe sequences for assays by design3

















a-L, full length; -S, short; -T, total.
changes in nephron ultrastructure and gene expression. These
current studies progress from valuable insights of Xenopus
oocyte work to investigate the physiologic role of the WNK
pathway in vivo in mice, localizing it within the nephron and
tracking WNK mRNA expression changes in response to
chronic variations in dietary electrolyte intake and aldosterone
status. This leads to a working model of the distal nephron,




All procedures were carried out under provisions of ethically ap¬
proved licenses and involved adult, 25- to 30-g, male C57BL/6 mice
(Charles River, Margate, UK). Modified electrolyte feeds for mice were
obtained from Special Diet Services (Witham, UK).
RNA Extraction
At conclusion of treatments of mice, both kidneys were removed
under terminal anesthetic, immediately frozen on dry ice, and stored at
—80°C. Frozen kidneys were fragmented and immediately homoge¬
nized in TRIzol Reagent (Invitrogen, Paisley, UK), and total RNA was
extracted following the manufacturer's guidelines.
Real-Time PCR
Assays used ABI PRISM 7900 relative quantification real-time meth¬
ods (Applied Biosystems, Foster City, CA). PCR was performed in
384-well plates (AB Gene) and used 10-/J.1 reactions that contained 5.0
pi of TaqMan Master Mix (Applied Biosystems), 200 nM of each
primer, 5 nM of probe, and 4.5 pi of template (1:40 dilution of cDNA
synthesized as described previously [7]). PCR conditions involved 95°C
for 10 min, then 40 cycles of 95°C for 15 s and 60°C for 60 s. Standard
template dilution curves enabled target gene quantification and nor¬
malization to tire endogenous control TATA-Box Binding Protein
(TBP). All group values were calibrated to their control groups.
Validation studies using mouse renal RNA established TBP as an
excellent control for these studies, showing less variation than 18S,
actin, and several other reputed housekeeping genes and excellent
reproducibility against an exogenous control gene. Previous literature
(15) reinforces TBP as a particularly good renal endogenous control
gene. Real-time PCR assays used tire ABI Assays-on-Demand (TBP:
Mm00446973_ml) or Assays-by-Design services (all other assays, see
Table 1).
In Situ Hybridization Analysis
RNA probes for in situ hybridization (ISH) were produced to specific
gene regions using nested PCR methods (7,16). For primer sequences, see
Table 2. ISH used renal cryostat sections (10 pm) from each mouse
mounted on silane-coated glass slides, then fixed, hybridized, RNase A
treated, washed, and ethanol-dehydrated as described previously
(7,16,17). Slides were exposed to Kodak x-ray film (BioMax MR-1; Sigma,
Poole, UK), dipped in NTB-2 photographic emulsion (Anachem Ltd.,
Bedfordshire, UK), exposed (within light-tight box) for up to 4 wk, and
developed. Cresyl violet/eosin counterstaining with bright and dark-field
illumination was used routinely to visualize and localize silver-grain dis¬
tribution in emulsion-dipped slides. In counterstained slides, blue dark-
field views (dark-field view in blue-filtered light) also were used to limit/
eradicate counterstain dark-field artifacts. Serial sections allowed co-
localizations and tracing of nephron structures beyond the plane of
individual sections.
Image Analysis
Digital image analysis was performed using custom-written applica¬
tions within the Image Processing Toolkit MATLABR version 7 (The
Mathworks, Inc., Natick, MA) environment on 16-bit grayscale TIFF
Table 2. Primer sequences for PCR construct probes used in ISH3









"Primer sequences for WNK1 are detailed in reference (7). For additional information, contact the corresponding author.
>-ENaC, y subunit of epithelial Na channel; NCC, thiazide-sensitive Na+Cl~ co-transporter; NKCC2, Na+K+2C1~ co-
transporter type 2.
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Figure 1. Schematic representation ofWNK cDNA structure showing
5' -exon composition and probe positions. The cDNA structures of the
5'-regions of kinase-intact full-length WNK1 (WNK1-L; containing
exons 1 through 4), kinase-deficientWNK1 short (WNKl-S; contain¬
ing exon 4a in place of exons 1 through 4), and WNK4 are illustrated
with vertical bars representing exon:exon boundaries. Numbers
within rectangles refer to exon numbers. Black boxes specify the
cDNA region probed by in situ hybridization (ISH). Double-headed
arrows indicate the exon:exon boundary crossed by probes used in
real-time PCR studies. Horizontal dashed lines indicate further exons
that were not included in this illustration.
images, having an intensity range from 0 (black) to 65535 (white). This
allows semiquantitative image analysis of ISH autoradiographic films
and dipped emulsion slides, measuring areas and grayscale intensities
(or silver grain densities) as an index of expression level. Measured
grayscale levels are converted to equivalent dpm of bound radioactive
probe by calibrating from co-exposed radioactive microscales (Amer-
sham, Little Chalfont, UK) that are designed specifically for this pur¬
pose. Alignment of consecutive sections involved systematic rotation
and linear displacement of one image relative to the next to calculate
their nonnalized cross-correlation and interatively proceeding to the
optimal alignment, where this value is a maximum. The aligned images
can be displayed as different red and green channels of a single over¬
laid merged image. Autoradiographic films were scanned on a high-
resolution flatbed scanner. Any damaged or inadequate sections were
excluded. The software greatly facilitated selection of regions (typically
complex shapes) showing expression that was highly significantly
above background levels. Background was low, with sense-section
backgrounds having a grayscale level that was not significantly differ¬
ent from zero.
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Figure 2. WNK kinase gene expression in kidney. ISH for the genes
indicated in mouse kidney. (A and B) Serial transverse sections,
dark-field views. (C and D) Two-color dark-field views for paired
serial sagittal sections, merging showing co-localization (yellow shift).
(E) Two-color merge views of D (at higher magnification). WNK1-T
expression (E) encompasses the striking distal nephron cortical ex¬
pression ofWNKl-S (B) and additional widespread expression near
background levels of WNK1-L. Note: comparing (A)+(B), major
coincidence of expression of WNKl-S and WNK4 in cortex, but
WNKl-S proportionately very limited in medullary rays and absent
inmedulla; (E) strongWNKl-S cortical (labyrinth) expression is seen
beyond thiazide-sensitive Na+Cl~ co-transporter (NCC) overlap
(distal convoluted tubule [DCT]), representing particularly extension
into connecting tubule (CNT; NCC being DCT restricted).
Figure 3. Nephron structure. Several distal nephrons that drain
into one cortical collecting duct (CCD) are shown. Distal
nephron begins in the renal medulla in thick ascending limb of
the loop of Henle (TAL; numbered), which ascends into cortical
medullary rays and enters the cortical labyrinth, contacting its
glomerulus (specialized macula densa cells at contact point)
then shortly beyond this enters DCT, CNT, and finally initial/
cortical collecting tubule (ICT/CCT), which re-enters medul¬
lary rays as CCD and re-descends into medulla. Nephrons of
superficial glomeruli (e.g., TALI) typically have a simple struc¬
ture, with a short usually unbranched CNT. In contrast, in most
species, nephrons of mid-cortical (e.g., TAL2) and some jux-
tamedullary glomeruli (TAL3 + 4) commonly drain through
well-developed branched arcades of CNT. A considerably
higher proportion of nephrons form arcades in mouse than in
human. Arcades are arranged around vascular axes, with CNT
being close to arcuate and especially intralobular vessels. The
dashed boxes and lettering delimit regional views relevant to
panels of Figure 4 (red letters) and Figure 5 (gray letters).
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Figure 4. WNK4 gene expression in mouse kidney. ISH studies are shown in bright-field, dark-field, and blue dark-field (see In Situ
Hybridization Analysis). Throughout a through g, similar regions of view are illustrated in Figure 3 (red labeled [A through G] boxes), (a)
WNK4 expression in TAL(T) in medullary ray, crossing boundary (dashed line) to contact glomeruli (*) in cortical labyrinth, (b) Substantial
expression in segment of macula densa (MD) and higher still in DCT (D), also seen in c. U, proximal tubule emerging from urinary pole of
glomerulus, (d)WNK4 expression in TAL emerging frommedulla, throughMD segment, DCT, and CNT. DCT convolutions (dashed arrow)
and a segment ofTAL (red dashed outline) fall outside the plane of section, (e) ExtensiveWNK4 expression throughout awell-developed deep
cortical arcade. Vascular axis (arcuate artery [AA] and vein [AV] and intralobular artery [LA]) and associated glomeruli are seen in left panel.
Note extensive EXIT loops adjacent to glomerulus (*) in left panel. Dashed arrow indicates connections of EXIT convolutions (out of section
plane), (f) Superficial cortexwith loops of DCT and ICT/CCT passing near renal capsule. Although both segments have WNK4 expression,
note that the level is strikingly higher in EXIT. Dashed line indicates renal capsule, (g) Views of ISH studies for the genes indicated in inner
stripe of renal outer medulla (having TAL and outer medullary CD [OMCD] as largest tubules). Note that the relative density of
WNK4-positive tubules is greater than that for the y subunit of epithelial Na channel (y-ENaC; an OMCDmarker) but similar to Na+K+2C1_
co-transporter type 2 (NKCC2; a TAL marker). Dashed red line indicates boundary of outer and innermedulla (I). Magnifications: X50 in g,
top (dark-field view); X100 in G, bottom (blue dark-field view).
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Statistical Analyses
Data are expressed as mean ± SEM, P < 0.05 was considered signif¬
icant, and group comparisons were analyzed by one-way ANOVA and
Neuman-Keuls post hoc testing, unless otherwise stated. Least signifi¬
cant difference post hoc test for planned comparisons (ANOVAISD) was
used when Neuman-Keuls testing was borderline nonsignificant. Rou¬
tine changes are expressed as %change (mean ± SEM) relative to
control values. Larger scale changes are expressed as fold change
(mean ± SEM), relative to control values, and 95% confidence intervals
are quoted.
Results
Renal WNK1 and WNK4 Gene Expression
Renal WNK1 and WNK4 mRNA expression is illustrated in
Figures 1 through 5, with WNK structure and probe positions
shown in Figure 1, an overview shown in Figure 2, the struc-
Figure 5. WNK1-S gene expression in mouse kidney. ISH stud¬
ies: in bright-field view in a (top) and b, in blue dark-field view
in A (bottom), and in dark-field view in c. Note that WNK1-S
gene expression is present in late TAL (T) including at the
macula densa (MD) but rises to much higher levels in DCT (D)
and CNT (C), reducing somewhat by CCT. *Glomerulus;
dashed line indicates position of renal capsule; U, proximal
tubule emerging from urinary pole of glomerulus (see also
Figure 3, gray-labeled boxes).
tures involved (and their abbreviations) in superficial and deep
distal nephrons in Figure 3, and key expression details in
Figures 4 and 5. Both WNK1-S and WNK1-L are expressed in
kidney (Figure 2, B, D, and E). WNK1-L shows near back¬
ground seemingly ubiquitous expression. The great preponder¬
ance of WNK1 expression is due to WNK1-S and limited to
renal cortex (Figure 2B). High levels of WNK1-S in distal tu¬
bules (Figure 2, D and E) fall off sharply distally from connect¬
ing tubule (CNT) to cortical collecting tubule (CCT) to CCD
(Figure 5C; see Figure 3) (7) and proximally dropping 10-fold at
the thick ascending limb of the loop of Henle (TAL)-distal
convoluted tubule (DCT) junction (Figure 5, A and B) with
expression (including the macula densa) extinguishing in the
cortical TAL. Hence, WNK1-S has only a limited weak exten¬
sion into medullary rays. WNK4 expression levels are lower
than WNK1 (more than threefold longer exposures for WNK4
than for WNK11-S/-TJ in Figures 2, 4, and 5). WNK4 expression
also is strongest in distal tubule structures (DCT/CNT) but
extends beyond distal tubule, at reduced levels, more proxi¬
mally into TAL, including macula densa and medullary TAL
(Figure 4, A, B, D, and G) and more distally at low expression
levels (compared with DCT) in collecting duct (CD; Figure 4F).
Thus, substantial WNK4 expression extends into medullary
rays and outer (but not inner) medulla (Figures 2A and 4G)
involving much too high a proportion of tubules to be due to
outer medullary CD alone (ENaC y-subunit versus WNK4; Fig¬
ure 4G) rather resembling the density of medullary TAL tu¬
bules (shown by Na ' K + 2Cl~ co-transporter type 2 [NKCC2];
Figure 4G).
Effects of Chronic Variation in Dietary K+ In Vivo
Body Weight, Food Intake, and Fluid Balance. Mice were
given group treatments of varying dietary K+ intake (low K+
[LK], normal K+ [NK], and high K+ [HK]; see Table 3 and
Figure 6, A through C). The LK group showed borderline lower
weight that became significant versus HK (but not NK) at the
end (25.6 ± 0.6 versus 27.3 ± 0.6 g, respectively; P = 0.03), but
mice seemed healthy throughout. Both HK and LK groups
developed a higher fluid intake and urinary output compared
with the NK group (HK versus NK significant at conclusion:
>3.4-fold higher intake [P < 0.05] and >4.9-fold higher output
[P < 0.01]).
Urinary Electrolytes. Mice were allowed a period of 3 d
(days 1 through 3) to acclimate to metabolic cages. After this,
during the initial 3 d of active treatment with specific diets
(days 4 through 6), K/Cre and Cl/Cre rose 6.8-fold and 4.9-
fold, respectively, with HK; remained unchanged with NK; and
K/Cre showed a dramatic 24.4-fold decrease with LK. After
days 5 to 6, group K/Cre ratios did not change significantly,
indicating reestablishment of appropriate electrolyte balance.
The HK and LK groups demonstrated a >17-fold increase and
a >14-fold decrease, respectively, in K/Na by day 6 (Figure 6,
D through F).
Plasma Measurements. As expected, HK induced a small
but significant increase in plasma K+ within the normal range.
Plasma aldosterone was elevated with HK but was unchanged
with LK (see Table 3).
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Table 3. Metabolic measurements3
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Low K Normal K High K
Initial body weight (g) 29.7 ± 0.7 28.8 ± 0.5 29.8 ± 0.6
Final body weight (g) 25.6 ± 0.5 26.9 ± 0.3 27.3 ± 0.6
Plasma K+ (mM)b 4.13 ± 0.22 4.08 ± 0.22 4.85 ± 0.2
Plasma Na+ (mM)c 145.4 ± 0.4 146 ± 0.6 144.3 ± 0.7
Plasma Cl~ (mM)d 114.4 ± 1.54 112 ± 1 114.5 ± 1.05
Plasma creatinine (/xM)e 13.8 ± 2.24 14.4 ± 1.21 12.5 ± 1.44
Aldosterone (nM) 0.834 ± 0.297 0.793 ± 0.207 1.879 ± 0.387
Renin activity (ng/ml per h) 4.38 ± 1.12 4.45 ± 0.83 5.71 ± 0.34
Corticosterone (nmol/L) 345.8 ± 48.8 342 ± 58.2 300 ± 42.6
""Plasma concentrations of Na+, K+, CP, and creatinine were measured on commercial clinical chemistry analyzers and
remained within the normal range for all groups. Plasma renin activity (PRA), aldosterone, corticosterone, and plasma
electrolyte measurements were performed in samples that were removed on cardiac puncture during terminal anaesthetic.
Blood samples were centrifuged, and plasma was removed, put on ice, and rapidly stored at —20°C. Aliquots of plasma for
assay of PRA were thawed, and buffer stabilizing renin activity was added immediately. PRA (40) and corticosterone (41)
were assayed as previously described (40,41). PRA and corticosterone did not change significantly. Aldosterone levels were
measured using a radioimmunoassay kit (Coat-a-Count aldosterone; DPC, Los Angeles, CA). Values are means ± SEM.
Normal plasma ranges for bK+, 3.0 to 8.3 mmol/L (35), but carefully taken having a narrower range probably nearer 3.8 to
6.8 mmol/L (36-38); cNa+/ 139 to 157 mmol/L; dCl~, 104 to 119 mmol/L (39); Creatinine, 5 to 67 pjnol/L (35).
WNK Expression Responses to Dietary K+ and Na4
Challenges
For investigation of the effect of varied dietary K+ intake on
WNK expression, mice were fed diets with a specific K+ con¬
tent (NK, LK, or HK) for 10 d. Specific real-time PCR assays
indicated that renal WNK1-S was downregulated by 20 ± 9.3%
with LK (P = 0.04) and upregulated by 30 ± 10.4% with HK
(P = 0.01; a 50 ± 10.2% rise from LK to HK), as was totalWNK1
(WNK1-T: 24 ± 7% increase; P = 0.0009) compared with NK
(Figure 7A).WNK4 was upregulated with HK (48 ± 24.2%; P =
0.01) but unchanged with LK.
In regions with clear WNK1-S expression (Figure 7B), ISH
analysis showed upregulation in cortex by HK (versus NK:
2.1 ± 0.6-fold; 95% confidence interval 1 to 3.3; P = 0.003).
WNK1-S distribution remained cortical without striking
change. Over kidney regions with clear WNK4 expression,
there was a 2.3 ± 0.6-fold (1.1 to 3.5) upregulation in expression
with HK (P = 0.02; Figure 7C); in contrast, the LK diet did not
affect WNK4 mRNA significantly.
For testing whether varied dietary Na+ induces similar WNK
expression changes, mice were fed diets with a specific Na+
content (normal Na+ [control], low Na+ [LNa], or high Na+
[HNa]) for 6 d. WNK1-S showed a borderline significant down-
regulation, by 39 ± 16% of control levels, between HNa and
LNa-diet (P = 0.049, ANOVA, SD; Figure 8). Although WNK4
in particular showed a trend to similar changes, no other sig¬
nificant changes in WNK expression were observed across the
treatment groups.
WNK Expression and Aldosterone Challenge
For examination of the effect of aldosterone levels on WNK
expression, mice were given excess aldosterone via minipump
(150 p.g aldosterone/kg per d [18]) or adrenalectomized (sup¬
plemented with 0.9% saline drinking water) to abolish aldoste¬
rone production. Real-time PCR showed that aldosterone treat¬
ment induced a 32 ± 6.7% (18.9 to 45.2) WNK1-S upregulation
(P = 0.0002) without affecting WNK1-L or WNK4 expression
(Figure 9). Adrenalectomy had no significant effect on WNK
expression, but WNK1-S rose significantly across the adrena¬
lectomy-aldosterone excess range (43 ± 7.6%; P = 0.0002).
Discussion
In beginning to understand the WNK pathway, Xenopus oo¬
cyte studies provided invaluable evidence of WNK pathway
regulation of key mediators of distal nephron electrolyte trans¬
port. This study is one of the first to investigate this pathway in
vivo in a much more physiologically relevant system, the
mouse, reporting detailed nephron segment localization and
WNK expression responses to dietary electrolyte challenges.
The relevant aspects of human physiology and their disorders
are very well modeled in mice, particularly mechanisms of
electrolyte handling and associated effects on long-term BP
control (19,20). Very few tools that reliably differentiate WNK
isoforms are currently available to quantify expression changes
and examine distribution simultaneously. Moreover, this study
allows examination of changes within kidney regions that are
not easily accessible to micropuncture techniques and have no
good, well-validated, cell-line models (e.g., outer medullary
CD, deep distal nephron arcades/CNT) and avoids dangers of
unequal RNA degradation, a concern that is associated with
microdissection.
Here we report strongest WNK1 and WNK4 expression in
the distal tubule (DCT, CNT) with WNK1-S dropping to much
lower levels by CD, whereas WNK4 extends somewhat dimin¬
ished into TAL and CD. WNK1-L has widespread, low-level,
near-background expression. Figure 10 puts the distribution of
WNK pathway expression in context.
WNK4 expression in TAL and macula densa (discussed fur-
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figure 6. Effect of dietary K+ intake on metabolic measurements. The K+ diet study involved adult male C57BL/6 mice, housed
in pairs in mouse metabolic cages (Techniplast). After 3 d of acclimation, groups (n = 6) of mice commenced specific diets: (2)
Normal (0.33%) K+ feed (NK; control group), (2) low (0.006%) K+ feed (LK), and (3) high-KCl (3.3% K+, 4.4% Cl_) feed (HK).
Batch analysis confirmed that diets were well matched for Na+ (0.28 ± 0.05%; all diets) and CP content (0.7 ± 0.12%; NK and
LK). Mice took the specified diets for 10 d, and daily measurements of food intake (A), fluid intake (B), and urine output (C) were
recorded. Urinary electrolyte excretion was measured daily, reflected changes in dietary electrolyte intake, and was expressed as
a ratio of creatinine or Na+ excretion (Cl/Cre, K/Cre, K/Na [D through F]). A transient decrease in food intake was observed in





















ther below) has not been recognized before and may indicate
different WNK4 isoforms or posttranslational modifications in
TAL (3). These are common in transport pathways (e.g., NKCC2
in TAL), whereas additional bands on WNK4 immunoblots
suggest varied posttranslational modification (3). A study of
transgenic mice that express a FHHt-WNK4 cDNA in TAL-
CNT (and intercalated cells) reported that mutant-WNK4 pro¬
tein was absent from tight junctions and apically localized in
TAL (21). The lack of FHHt phenotype in these FHHt-WNK4
mice leaves some uncertainty. This may relate to transgenic
WNK4 expression being driven from a cDNA and so lacking
normal in vivo regulation and potential for transcriptional di¬
versity of the WNK4 genomic locus.
Our studies challenged mice with varied dietary K+ and Na+
intake and aldosterone. All three classes of treatment showed
notable WNK pathway gene expression responses in vivo to
these physiologic determinants of electrolyte balance and BP.
Changes with varied dietary K+ intake were particularly clear.
WNK1-S expression rose on HK and fell on LK diet, correlating
significantly with K+ intake, while ISH findings revealed the
importance of upregulation of this isoform with HK diet, in
strongly expressing segments (DCT-CNT). HK intake also in¬
creased WNK4 expression. These coordinatedWNK expression
changes seem functionally significant as merely heterozygous
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Figure 8. WNK expression in response to varied Na+ intake. The
Na+ diet study involved adult male C57BL/6J mice, housed in
pairs in mouse metabolic cages (Techniplast). Animals were al¬
lowed 1 wk to acclimate, after which they commenced specific
dietary Na+ treatments that lasted 7 d: (1) low Na+ (0.03%) feed
group (LNa), (2) normal/control Na+ (0.3%) feed group (NNa), or
(3) high Na+ (3%) feed group (HNa). WNK1-S showed a margin¬
ally significant* downregulation (by ANOVAlsq) between HNa
and LNa diet. No other significant changes in WNK expression
were observed across the treatment groups. *P = 0.049.
Figure 7. WNK expression in response to varied K+ intake. (A)
Real-time PCR results from renal RNA from groups of mice
(n «= 6) with variations in dietary K+. WNK1-S expression is
significantly downregulated with LK, whereas WNK1-S and
WNK4 are upregulated with HK. No significant changes were
observed in WNK1-L expression across the experimental
groups. (B and C) 1SH analysis for WNK1-S and WNK4 de¬
tected any major shifts in distribution and level of WNK ex¬
pression with K+ intake at the regional level, undiluted by any
widespread, invariant low-level expression, (i) Representative
sections and (ii) densitometric analysis from ISH studies.
WNK1-S (B) and WNK4 (C) have different expression profiles
with WNK1-S expression restricted to the cortex, and WNK4
restricted to cortex and outer medulla. WNK1-S and WNK4
expression both are upregulated with HK. *P = 0.009; **P =
0.04; ***P = 0.01; *P = 0.003; **P = 0.02.
WNK1-S was significantly upregulated with chronic aldoste¬
rone excess. There were no significant changes in WNK1-L or
WNK4 across the aldosterone-adrenalectomy range. With vari¬
ations in Na+ intake, a fall in WNK1-S expression just reached
significance comparing HNa and LNa groups. It is intriguing
that this could represent a WNK pathway response to reduc¬
tions in extracellular fluid volume as Na+ intake falls.
Thus, K+ intake, plasma aldosterone, and dietary Na+ in¬
take/extracellular volume seem to be possible in vivo regulators
of theWNK pathway. K+ intake seems to be a relatively robust
regulator, whereas in some circumstances, the role of aldoste¬
rone may be counterbalanced or secondary to another regula¬
tor. Thus, similar WNK1-S expression accompanies very differ¬
ent aldosterone elevations (2.3-fold [HK] and 11.2-fold
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Figure 9. WNK expression in response to variations in aldosterone.
The aldosterone study involved adult male C57BL/6 mice,
housed in pairs in normal cages. Mice that had food and fluid
intake and BPmonitoringwere given (n = 6) subcutaneous (Alzet)
minipump (MP) treatments for 6 d: (1) Adrenalectomy (ADX):
Bilateral adrenalectomy, 0.3% Na1 feed, 0.9% saline drinking wa¬
ter, saline-only MP; (2) control (CTRL): Normal 0.3% Na+ feed,
saline-only MP; and (3) aldosterone excess (ALDO 150): 150 p.g
aldosterone/kg per d (18) by MP, 0.3% Na ! feed. Plasma renin
activity and aldosterone measurements allowed confirmation of
adequacy of treatments. WNK1-S expression was upregulated by
chronic aldosterone treatment (150 p.g/kg per d, 6 d) but was
unchanged in the absence of aldosterone after adrenalectomy. No
changes in WNK1-L or WNK4 were observed across the experi¬
mental groups. *P = 0.0002; **P = 0.02.
lectomized levels (Figure 9). Aldosterone-independent regula¬
tion of WNK1-S expression clearly is present across LK-HK
dietary groups, with individual WNK1-S expression correlating
with K+ intake (P < 0.001) but not significantly with aldoste¬
rone. Moreover, reduced WNK1-S with LNa intake (lowering
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Figure 10. Distribution of gene expression of key genes involved
in Na+ and K+ balance in distal nephron. Structure illustrated
in Figure 3. mTAL, cTAL, medullary and cortical TAL; CNT/
ARC, connecting tubule/arcade; CCD/OMCD/IMCD, corti¬
cal/outer medullary/inner medullary CD. cr/3-yENaC, a(3y sub-
units of ENaC; ROMK, renal outer medullary K channel;
WNK1-S/-L/-T, WNK1 short (kinase deficient), long (kinase
intact), and total; sgkl, serum and glucocorticoid kinase 1. For
aENaC/sgk expression, arrows represent regulated expression
by rising aldosterone (A).
volume, stimulating secondary hyperaldosteronism) and in¬
creased WNK1-S with aldosterone (raising volume, primary
hyperaldosteronism) implies that WNK1-S responds more to
extracellular volume than aldosterone and suggests falling
WNK1-S as a potential response to conserve volume. Further
investigation is required to define fully the in vivo regulatory
roles of K+ intake, aldosterone, and volume acting on the WNK
pathway, but integrating these findings into a more functional
context is of interest. One attempt to do so is outlined in Figure
11 and discussed further next.
How do these results expand understanding of this novel
WNK pathway? The FHHt phenotype and usual hyperre-
sponsiveness to thiazide diuretics highlight the importance
of DCT in electrolyte balance and BP control (1,5,22). The
work above provides some of the first clues as to the role in
vivo of WNK1-S, the predominant WNK1 isoform in kidney,
and intriguingly shows that strongest WNK1-S and WNK4
expression co-localizes in DCT-CNT, where they may con¬
tribute to a mechanism that regulates K+ homeostasis and
BP. Xenopus oocyte work suggests that WNK4 may inhibit
NCC in DCT, and WNK1-L prevents this inhibition (10,11).
In a preliminary presentation of this work (see Acknowledg¬
ments), we proposed the hypothesis that both WNK1-S and
WNK4 can limit NCC transport (Figure 11A). Xenopus oocyte
work reported since supports a similar mechanism (13). We
propose, especially in DCT-CNT, that WNK1-S could bind
and counterbalance WNK1-L effects, so shielding WNK4
from inhibition. Although WNK1-S is kinase deficient, it
retains domains (coiled-coils) that likely facilitate multimer-
ic/tetrameric WNK1 assembly (23,24). Alternatively,
WNK1-S could interact directly with a WNK-binding site on
WNK4 or another regulatory kinase to repress NCC.
Figure 11 incorporates this WNK pathway in a two-com¬
partment model. In the upper co-transport compartment,
increased WNK1-S or WNK4 (as in our in vivo studies)


























Figure 11. Potential WNK pathway and two-compartment
model of distal nephron Na+/K+ handling. (A) The WNK
pathway is suggested to regulate the extent of NaCl reab¬
sorption in (early) DCT in the manner of the alleged molec¬
ular switch proposed in explaining familial hyperkalemic
hypertension (FHHt). A high K+ intake switches to lower
Na+ reabsorption via NCC in DCT, so distal Na+ delivery
rises, allowing K+ to be cleared. (B) Two-compartment
model, (i) Normally, Na reabsorption is partitioned between
an upper co-transport compartment (under WNK pathway
repression), driving NaCl reabsorption and a lower electro-
genic compartment (stimulated by aldosterone and Na * de¬
livery), where Na" reabsorption via ENaC generates a lu¬
men-negative charge facilitating K+ secretion, (ii) In
hypovolemia, both compartments upregulate Na reabsorp¬
tion, minimizing urinary NaCl loss and facilitating K+ secre¬
tion. (iii) In high K intake, the mechanism above delivers
increased Na and aldosterone, which strongly drive Na+
reabsorption and K+ secretion, (iv) In FHHt, there is consti¬
tutive overreabsorption of NaCl, causing hypervolemia and
hypertension with low renin, which limits the distal delivery
to the electrogenic compartment without renin suppression
and blunted aldosterone, promoting limited K secretion and
hyperkalemia. WNK pathway regulation of NCC and the
extent of Na+ delivery to the distal electrogenic compart¬
ment and inappropriate restriction of this in FHHt fits well
with reported features of FHHt, including thiazide-sensitiv-
ity and NaCl dependence.
ing Na+ delivery to the lower electrogenic compartment
(from late DCT distally), where ENaC reabsorbs Na+, facil¬
itating K+ secretion (19) (itself augmented by high distal
flow-mediated Maxi-K channel activation). The two com¬
partments will normally overlap in late DCT. LNa diet/
hypovolemia and HK diet both will stimulate aldosterone,
activating the lower compartment. The in vivo studies above
indicate that LNa diet/hypovolemia also will stimulate the
upper compartment (Figure llB[ii]), producing appropriate
Na+ retention, whereas HK diet will repress it, producing
appropriate K+ secretion (Figure llB[iii]). The upper co-
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transport compartment thus interconverts the same aldoste¬
rone response between Na+ retention and K+ excretion. We
propose that the molecular switch that is alleged to explain
FHHt (12) is based on distal delivery of Na + . This hypothesis
is supported by careful ultrastructural studies showing that
HK diet (25), NCC—/— Gitelman mice, and high-dosage
thiazide diuretics (19) all predispose to extensive hypertro¬
phy and increased Na+/K+-ATPase (25) in early CNT (indi¬
cating higher Na+ delivery) and predispose to greater K+
clearance and reduced BP (19). In WNK1 + /— mice, global
WNK1 reduction would repress NaCl reabsorption (in DCT,
unopposed WNK4) and promote lower extracellular volume,
in keeping with their lower BP.
FHHt jams the switch in the opposite direction (Figure
llB[iv]), inappropriately engaging a response (reducing dis¬
tal Na ' delivery and K ' secretion) that these studies suggest
is normal when body K and/or Na/extracellular volume fall
and require conservation. Although aldosterone level is low
to normal, its contribution to FHHt pathophysiology and
hypertension should not be underestimated (26). Both aldo-
sterone-dependent and -independent mechanisms contribute
to K+ secretion (19,27); blunting of both seems likely in
FHHt. Thus, distal Na+ delivery is blunted and hypervole¬
mic suppression of renin will restrain circulating aldoste¬
rone, blunting the aldosterone response to levels that are
inadequate to restore normokalemia despite hyperkalemic
drive (28). Thus, FHHt causes hypertension and hyperkale¬
mia.
In vitro evidence suggests the WNK pathway also may
directly (i) reduce surface ROMK (12), (ii) promote ENaC
conductance (14), and (iii) increase paracellular Cl~ flux
(29,30) (depleting electrogenic lumen-negative charge). Al¬
though the pathway in Figure 11 seems not to require these
effects, these processes could impair K+ secretion, promote
Na+ reabsorption, or both if they contributed significantly.
Effect (ii) depends on WNK1-S and was demonstrated in
CCD cells; it is unresolved if it extends to late DCT-CNT,
where the expression of WNK1-S and ENaC and the poten¬
tial physiologic influence all are stronger. The roles and
significance in vivo, and in FHHt, of effects (i) through (iii)
are not yet clear.
It is intriguing that we have found previously unexpected
gene expression of WNK4 in TAL and macula densa. WNK4
potentially could influence TAL NaCl transport via regula¬
tion of ROMK, NKCC2, CLC-Kb, or Barttin, because inacti-
vation of any causes severe NaCl wasting in Bartter's syn¬
dromes. ROMK surface localization was unaffected in
transgenic mice that expressed FHHt-mutant WNK4 protein,
which was apically distributed in TAL (21). In vitro, WNK4
can interact directly or with other kinases (e.g., OSR1, SPAK,
other WNK), to regulate proteins of key importance in TAL-
DCT transport, including NCC (11,12), ROMK (12), and, it
seems, NKCC2 (31,32). Hence, WNK4 might influence
NKCC2 co-transport and expand the co-transport compart¬
ment (Figure 11) to more powerful proportions. Overactivity
of TAL-DCT NaCl reabsorption seems compatible with
FHHt. Certainly, increased BP is reported with activating
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mutation of CLC-Kb (T481S) (33). Moreover, considering
phenotypes of Gitelman plus Bartter syndromes (DCT+TAL
salt-wasting hypokalemic alkalosis), it seems that the inverse
of these may encompass hyperkalemia, acidosis, and low-
renin hypertension, all FHHt features. Other WNK4-FHHt
features (e.g., degree of thiazide sensitivity, hypercalcuria
[34]) might depend on the spectrum of overactivation within
DCT-TAL. Clearly, this makes WNK4 expression in TAL of
interest, but much needs to be clarified before a role in
physiology or FHHt pathophysiology could be attributed.
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